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OUTLINE OF THE THESIS
Colorectal cancer is one of the most common causes of cancer-related death in the 
Western world. Recurrence after apparently curative resection of the primary tumor 
occurs in up to 50% of the patients, mainly depending on stage of the primary tumor. 
Colorectal cancer may relapse in the liver (40-50%), lung (25-30%) and at later 
stages in bone, brain, and other organs. Approximately 50% of the patients 
presenting with colorectal cancer will also suffer from disseminated disease, 
predominantly to the liver.
For liver metastases, surgery is the gold standard for curative treatment, with 5-year 
survival rates up to 50%. However, eligibility for surgical treatment of liver 
metastases requires strict criteria. Foremost, the clinical condition of the patient and 
the extend of the disease must allow surgery (e.g. from a simple wedge resection to 
an extended hemihepatectomy). Furthermore, eligibility depends on the possibility to 
completely resect all metastases while maintaining adequate liver reserve. This 
indicates a crucial role for anatomical imaging modalities to assess the number and 
location of the metastases in relation to vital structures, such as the hepatic and 
portal veins, and bile duct. In addition, to achieve the chance for curation and thus an 
increase in survival, irresectable extrahepatic disease should be absent or there 
should be a possibility for a complete tumour clearance.
In most centers, patients who underwent resection of the primary colorectal tumour 
are followed with serial measurements of carcinoembryonic antigen (CEA) levels, 
colonoscopy and abdominal ultrasound or computed tomography (CT). If isolated 
hepatic metastases are suspected, patients are screened with a CT scan of chest 
and abdomen to assess resectability and identify extrahepatic disease. Despite the 
extensive work-up before surgical treatment for these metastases, a significant 
number of patients prove to have unresectable disease during laparotomy. During 
follow-up, up to 75% of patients develop new sites of recurrent cancer after initial 
curative resection. This indicates that these patients must have had unidentified 
(extra)hepatic disease prior to surgery. Apparently, conventional diagnostic 
modalities miss a significant percentage of occult, mainly extrahepatic disease, which 
become visible during laparotomy or even at later stages after resection of liver 
metastases. Therefore, a better imaging work-up is warranted to improve staging, 
and ultimately avoid futile surgery. Patient care may also improve, since this will
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enable palliative treatments, such as chemotherapy, to be started early and before 
larger volume disease develops.
This urges the need for improved staging initiated research incorporating functional 
imaging, such as positron emission tomography (PET) and magnetic resonance 
imaging (MRI) in the pre-operative diagnostic work-up. PET with [18F]-2-deoxy-2- 
fluoro-D-glucose (FDG) has emerged as one of the more promising diagnostic 
modalities in recurrent colorectal cancer. Several studies show the impact of 
additional FDG-PET scanning in clinical management in up to 30% of the patients. 
An increasing number of centers have PET facilities installed on site, making this 
technique the fastest growing diagnostic modality at present.
In this thesis, data in the literature on clinical value, the effectiveness and the 
consequences of FDG-PET in the diagnostic work-up of patients with colorectal liver 
metastases were studied.
An overview of the role of PET in diagnosis and treatment of colorectal recurrent 
disease and especially of liver metastases is presented in chapter 1. This chapter 
provides a review of the available literature focusing on potential indications, 
limitations, and pitfalls of FDG-PET and fusion possibilities with CT.
The initial interest in staging patients with colorectal liver metastases further 
increased after the observation that the literature was relatively scarce and warranted 
a systematic research of the available data. As randomized clinical trials are absent, 
data to perform a traditional, systematic meta-analysis were missing. To compare, 
weight, and summarize data from the different studies, an alternative approach was 
designed and described in chapter 2.
Chapter 3 describes an evaluation of preoperative and intra-operative imaging in a 
subgroup of patients with colorectal liver metastases, who were selected for liver 
surgery by both preoperative CT of chest and abdomen and preoperative FDG-PET. 
To assess the accuracy of these modalities, multiphase CT, FDG-PET and intra­
operative ultrasound were compared to postoperative histopathological data.
The role of FDG-PET in the selection of patients with colorectal liver metastases and 
the effect on disease-free and overall survival after hepatic surgery for colorectal liver 
metastases was studied in chapter 4. For this purpose, we identified and compared 
two homogeneous groups of patients with colorectal liver metastases who were
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selected for hepatic surgery of liver metastases, either with or without additional 
FDG-PET.
In chapter 5, the predictive value of quantitative pretreatment FDG uptake for patient 
prognosis in metastatic colorectal carcinoma was investigated. If the degree of FDG 
uptake in liver metastases of colorectal carcinoma is of prognostic significance, this 
diagnostic modality could be an important adjunct to traditional staging. It could also 
improve appropriate selection of candidates for aggressive therapies and treatment 
combinations and could be useful as an early indicator of tumor chemosensitivity, 
which could refine therapeutic strategies.
Previous studies generally aimed to assess accuracy were prone to selection bias 
and may lead to overestimation of the additional value of FDG-PET. In the 
prospective randomized trial presented in chapter 6, the value of the addition of FDG- 
PET to conventional CT-based diagnostic imaging in patients considered eligible for 
hepatic surgery of colorectal liver metastases is investigated. Outcome measures in 
this study were the number of futile laparotomies, and disease-free and overall 
survival.
Several studies indicated that FDG-PET is cost-effective in colorectal metastatic 
disease when added to conventional work-up. To increase the level of evidence 
about the value of adding FDG-PET to the conventional diagnostic work-up, a cost- 
effectiveness analysis alongside the randomized controlled multi-centre clinical study 
was conducted. Chapter 7 describes the cost-effectiveness from a healthcare 
perspective of the conventional work-up versus conventional work-up supplemented 
with an additional FDG-PET.
As many previous contra-indications for surgery in patients with colorectal cancer 
liver metastases have now been abandoned (such as multiple lesions, bilobar or 
synchronous disease), an increasing number of patients is eligible for invasive 
treatment. This inherently results in a larger patient group that is more likely to 
develop recurrent disease after surgery. Health-related quality of life (HRQoL) is an 
important issue in this context and data on HRQoL after hepatic resection are scarce 
in current literature. Chapter 8 investigates the impact of surgery in patients with 
colorectal liver metastases and the different treatment modalities on HRQoL.
Chapter 9 provides a general discussion and concluding remarks.
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Introduction
Controversies in the Management of Colorectal Liver 
Metastases: the role of PET and PET/CT
Bastiaan Wiering, Wouter V. Vogel, Theo J.M. Ruers, Wim J.G. Oyen
Digestive Surgery, 2009; 25: 413-20
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Chapter 1
Abstract
Positron emission tomography (PET) using [F-18]-2-deoxy-2-fluoro-D-glucose (FDG) 
has emerged as a promising diagnostic modality in recurrent colorectal cancer. Data 
in the literature show that the addition of FDG-PET changes patient management in 
up to 30% of patients with potentially resectable liver metastases, mainly by detecting 
previously unknown extrahepatic disease. Furthermore, FDG-PET is useful in the 
follow-up of patients who underwent surgical procedures of the liver, since it is 
sensitive in detecting residual or relapse malignancy in scarred liver tissue following 
both resection and local ablative techniques. For follow-up during systemic therapy, 
early FDG-PET appears predictive for response to therapy.
FDG-PET, Computerized Tomography and Magnetic Resonance Imaging are 
complimentary techniques in staging and restaging patients with advanced colorectal 
cancer. A combination of FDG-PET and CT scanning characteristics seems 
promising, and integrated PET/CT is becoming more widely available, although the 
exact clinical value and efficacy is not yet fully established. In addition, assessment 
of these modalities in joint reading sessions with radiologist, nuclear medicine 
physician, medical and surgical oncologists significantly impacts upon patient 
management.
This review evaluates the potential of FDG-PET and combined PET/CT in patients 
with colorectal liver metastases and discusses potential future possibilities.
16
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INTRODUCTION
Colorectal cancer is one of the most common causes of cancer-related death in the 
Western world. Recurrence in apparently curatively treated patients appears in up to 
50% of patients. Relapse may occur in the abdomen, the liver being the most 
predominant site in 40-50% of patients, the lungs in 25-30% and bone or brain, 
mostly at later stages of the disease.
For liver metastases, surgery is the only curative treatment, thereby increasing 5- 
year survival to up to almost 50%. Eligibility for surgical treatment requires strict 
criteria. Besides an adequate clinical condition, all liver lesions have to be completely 
resectable, thus emphasizing the need for accurate imaging modalities for staging. 
The number of lesions, and their vicinity to vital structures, e.g. vascular structures 
such as liver veins, is of the upmost importance. Also, extrahepatic disease should 
be absent or eliminated, advocating whole body imaging for staging. Therefore, early 
detection of any recurrent colorectal carcinoma has become more important in the 
past decade, as the treatment options for localized disease have improved 
significantly. However, aggressive locoregional interventions (e.g. partial liver 
resections, radiofrequency ablation (RFA) of liver metastases, resections of 
pulmonary metastases) are still considered futile in the presence of additional 
metastases elsewhere1. For these patients, detection of tumor sites throughout the 
body is needed with high sensitivity and specificity.
With regard to increasingly extensive hepatic surgery, accurate information about the 
local extent of the tumor deposits is also necessary. Tumor visualization is 
traditionally performed using anatomical imaging techniques such as ultrasound 
(US), computed tomography (CT), and magnetic resonance imaging (MRI). 
Functional imaging is of additional value, as anatomic imaging has limitations when 
used in a single modality setting.
Visualization of metabolism with [F-18]fluoro-deoxy-glucose positron emission 
tomography (FDG-PET) is a valuable tool for detection of primary and recurrent 
colorectal cancer2-4. Tumor sites may be detected throughout the body with high 
contrast resolution, unaffected by distorted anatomy due to e.g. prior surgical 
interventions. However, exact localization and demarcation of lesions with PET is 
less accurate due to its relatively low spatial resolution, and lack of anatomical 
reference. The added value of simultaneous FDG-PET and CT has been 
demonstrated5.
The theoretical benefit of the joint potential of CT (anatomical reference) and FDG- 
PET (sensitive tumor detection) have led to the practice of fusion of the images, and 
subsequently to an integrated PET/CT imaging device. Although promising6-8, the
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technique is relatively new. Availability is still limited, but is rapidly expanding. 
Furthermore, PET/CT image fusion may suffer from artefacts, and the exact clinical 
value has not yet been fully established. Therefore, the role of PET/CT image fusion 
must be weighed carefully against other available modalities.
Mechanism of FDG accumulation
Unlike most conventional diagnostic modalities such as CT and ultrasonography, 
which require anatomic alterations for detecting malignant deposits, FDG-PET 
provides information on localization and growth of tumor based on increased 
metabolism and glucose uptake of malignant cells. Upon intravenous administration, 
FDG is delivered to and transported into cells analogous to glucose. After conversion 
of FDG to FDG-6-phosphate by hexokinase, the metabolite cannot be processed via 
the citric acid cycle, in effect trapping it intracellularly. The uptake of glucose in most 
normal celtypes is regulated by insulin levels, and can thus be reduced by fasting 
prior to imaging. In malignant cells, glucose and thus FDG is taken up predominantly 
through the Glut-1 transporter, which is independent of the presence insulin. Thus, 
FDG-PET allows a whole-body survey, depicting metabolic activity of malignant 
tissues, thereby providing substantial additional information to conventional anatomic 
based imaging.
Principle of PET
Disintegration of positron-emitting radioactive nuclei will result in the forming of a 
positron (p+), which annihilates with a nearby electron (p-). The mass of the merged 
particles is converted into two discrete photons of 511 keV, emitted in a 180-degree 
angle. PET cameras, set in a ring-like structure, are designed as blocks of separate 
crystal detectors and photomultipliers. An event is registered if two opposing 
detectors are activated at (almost) the same time by the 511 keV photons 
(‘coincidence’), which provides a line of response. Processing and reconstructing the 
acquired lines of response provides the PET image.
PREOPERATIVE FDG-PET
Ruers et al. demonstrated that FDG-PET as a standalone modality improves 
diagnostic work-up in patients with liver metastasis when added to conventional 
diagnostic imaging9. Furthermore, it has an impact on and improves therapeutic 
management10-13. Integrated PET/CT can provide further value especially in the 
postoperatively distorted liver with scar tissue and artificial materials, where
18
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sensitivity and specificity are relatively low for both CT and MRI14, 15. Fernandez et al. 
showed an improved survival after preoperative staging with FDG-PET compared to 
previous studies16. Even decreased SUV (standardized uptake value) could offer 
some insight in the distribution of the tumor, suggesting more disease than 
anticipated after FDG-PET17.
Extrahepatic metastases
Whole body imaging as a standard procedure is a major benefit of FDG-PET, thus 
providing information on extrahepatic metastases, with a direct impact on patient 
management. Lai et al. demonstrated that 29% of patients with liver metastases 
appeared inoperable because FDG-PET detected extrahepatic metastases18. In 
recurrent colorectal carcinoma, most extrahepatic distant metastases will be 
pulmonary. Detection of these metastases is of particular importance as surgical 
intervention is still a possibility in some patients, combining hepatic surgery with 
resection of a limited number of pulmonary lesions19, 20. Both CT and FDG-PET have 
demonstrated high sensitivity for pulmonary lesions, but PET may be useful in 
differentiating benign from malignant lesions21. An example is provided in figure 1.
Figure 1. Image fusion of contrast enhanced CT and FDG-PET. Shown are transverse slices of the 
pulmonary region from PET (left), CT (middle), and PET/CT. PET shows 2 lesions in the mediastinum, 
where interpretation of the CT only showed no suspect nodes, whereas combined images clearly 
show two suspect lesions. This case indicates the value of combined PET/CT.
In detection of other extrahepatic distant metastases, such as bone metastases, 
FDG-PET has also demonstrated added value22. In unexpected extrahepatic lesions 
detected by PET, exact localization may be very hard without correlative anatomical 
imaging as provided by PET/CT. The same applies to the identification of unexpected 
second primaries, which may occur in approximately 1% of cases23. Abdominal 
lymph node metastases from colorectal carcinoma tend to be small. Many involved 
lymph nodes are below 1 cm in diameter, thus explaining the poor sensitivity of CT. A 
number of these small deposits can be detected by FDG-PET, albeit with a poor 
sensitivity of 29%, but with a high specificity of 88%24 Problems arise when a hotspot
19
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on FDG-PET may correlate with several anatomical structures including activity 
excreted in the urinary tract, blood vessels and bowel polyps, or be the result of 
physiological bowel uptake. In these cases, PET/CT could adequately identify a 
lesion, and settle the diagnosis. Again an example is given in figure 2.
Figure 2. Image fusion of contrast enhanced CT and FDG-PET. Shown are transverse slices of the 
pulmonary region from PET (left), CT (middle), and PET/CT. PET shows 1 abdominal, whereas the CT 
showed no indication of malignant disease. The PET/CT image illustrates the need for correlation with 
anatomical imaging.
FDG-PET IN FOLLOW-UP OF SURGERY AND SYSTEMIC THERAPY 
Recurrent Liver metastases
Several studies reported that recurrent liver metastases after earlier hepatic resection 
can be resected curatively in 15-30% of these patients25, 26, so evaluation of this 
patient subset with conventional and functional imaging seems appropriate. Sobhani 
et al. reported that FDG-PET detects recurrent disease after a shorter time than 
conventional imaging and recurrences were more frequently curatively resected27. 
Furthermore, PET/CT showed a significant impact on clinical management of 
patients with recurrent liver metastases28.
After local ablative therapy
After local cryo- or radiofrequency ablative therapy, PET may detect recurrence of 
liver metastasis well before abnormalities are visualized by CT29, 30. Nevertheless, 
correlation with CT is often needed for more exact localization31. Conversely, CT may 
be false-positive at the rim of the lesions because of hyperperfusion after RFA 
(radiofrequency ablation), while FDG-PET remains reliable32. MRI using 
enhancement with manganese containing contrast may further improve detection of 
liver metastases and provide additional information on the nature of postoperative 
liver lesions33. FDG-PET is not affected by scar tissue and artificial materials. For the 
detection of liver metastasis after hepatectomy a sensitivity of 100% and specificity of
20
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89% was demonstrated for PET/CT, while the specificity of contrast enhanced CT 
dropped to 50% for this specific patient subgroup34. For the evaluation of liver 
metastases, combined PET/CT appears to be the technique of choice.
Recurrent extrahepatic disease
As with extrahepatic disease at the time that the first hepatic metastases surface, the 
accuracy of PET for extrahepatic disease is higher than CT35, so combining these 
modalities could further improve the detection of these deposits for patients in the 
follow-up after liver resection.
Postoperative elevated CEA with normal conventional diagnostics
Most centers apply a follow-up scheme that includes CEA (carcinoembryonic 
antigen) combined with a conventional diagnostic follow-up. In several cases CEA is 
elevated, even though a patient may have normal conventional imaging. In this 
situation there is a 90 percent chance of tumor being present, and a small group of 
patients will be elegible for curative surgery36. Flamen and Valk reported true-positive 
PET findings in patients with raised CEA but normal conventional imaging37, 38. 
Flanagan presented data that PET showed recurrent disease, when CEA was 
elevated, in 89% of patients, where CT scans could not demonstrate any tumor, 
suggesting a major benefit in using PET scans to evaluate these patients39.
Role in systemic therapy
FDG-PET is on its way to becoming a monitoring-tool for the response in 
chemotherapy in metastasized colorectal cancer. Findlay showed that 4-5 weeks 
after start of chemotherapy (5-fluorouracil with or without interferon-a) FDG uptake 
differentiated responders and non-responders, both in a patient based and in a lesion 
based analysis40. Furthermore, Dimitrakopoulou et al. reported similar findings in 
patients treated with 5-fluorouracil, folonic acid and oxaliplatin (FOLFOX regimen)41, 
where even the pretreatment FDG-PET was predictive for response. Also, therapy 
induced chances in tumor can be depicted by FDG-PET42, impacting on patient 
management.
Lesion characterization
Differentiation of benign from malignant disease remains a challenge, regardless the 
type of lesion visualized by imaging. Both CT and FDG-PET can contribute to the 
final diagnosis, but a combination of both modalities delivers a strong diagnostic 
tool43, 44 as would combining this information with MR imaging. Given this asset, 
PET/CT or in the near future PET/MRI, is a very good option when atypical lesions
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need to be characterized at the highest possible level of accuracy, especially in 
cases where a definitive diagnosis through histological biopsy cannot be obtained, 
e.g. due to the risk for seeding metastases in the puncture tract of the biopsy 
needle45, 46.
MULTIMODALITY IMAGE FUSION 
Visual fusion
When considering the combination of PET and CT, different methods of fusion are 
available. Without integrated scanners the most common approach is ‘visual fusion’, 
where two scans are read side-by-side for comparison and correlation. Discrepancies 
between PET and CT or MRI can thus be resolved in many cases, especially when 
clinical information and imaging results are exchanged in joint reading sessions with 
radiologists, nuclear medicine physicians, clinical and surgical oncologists. This 
significantly impacts upon patient management. When further uncertainties persist, 
integration of the images can prove to be of additional value. However, before 
attempting to integrate PET and CT or MRI images, some specific issues must be 
considered47.
Scanning characteristics
CT and PET depict different and complementary information. CT demonstrates 
anatomy with high spatial resolution, but with low contrast resolution especially for 
soft tissues. On the other hand, PET visualizes pathological sites with high contrast 
resolution, but spatial resolution is limited to 4-7 mm, and normal anatomical 
structures are poorly visualized. Due to these characteristics, discrepancies may 
exist between CT and PET images. Benign lesions may appear unequivocal on CT 
but may be negative on FDG-PET (e.g. cysts, haemangioma, scar tissue), while 
intensely FDG-positive lesions may be imperceptible on CT (e.g. local recurrence, 
liver metastasis). These characteristics complicate visual recognition and correlation. 
Furthermore, positional differences may exist between PET and CT because of 
repositioning and/or accidental or voluntary motion. Organs may be displaced or 
changed in size and shape (e.g. bowel motion, gastric emptying, differences in 
bladder filling between PET and CT scanning). The main problem is respiratory 
mismatch, for PET is acquired during free breathing due to the length of the scanning 
procedure (20-60 min), resulting in slightly blurred images in the upper abdomen and 
lower pulmonary regions. For correlation purposes, CT acquisition may be adapted to 
match PET-imaging by scanning during either free breathing or timed unforced
22
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expiration, depending on the type of imaging equipment48. Failure to do this 
adequately will result in localization errors, as the diaphragm (including lower lung 
fields and upper abdominal organs such as the liver) will be relatively displaced.
Software fusion
When separate CT and PET images are available these may be integrated using 
specialized software. Identical positioning is a prerequisite and breathing instructions 
to avert artefacts due to breathing motions needs to be employed. Interval scans 
must be short, in order to avoid discrepancies due to disease progression (or 
regression) during the interval. Such a procedure is relatively lengthy, logistically 
complex, and it has a serious risk of registration errors. Some authors do report 
adequate results using software fusion, even in the region of the liver49, but others 
disagree50. In some areas such as the bladder region, and possibly also gut area and 
upper abdomen, software fusion is a challenge with relatively limited accuracy in 
image registration.
Hardware fusion
A hybrid scanner consists of separate CT and PET scanners placed in line, which 
acquire scans consecutively without the need for repositioning the patient. Fusion of 
images obtained by these two modalities is often referred to as ‘hardware fusion’, 
although this term ought to be reserved for situations where multiple images are 
acquired by a single detector system at the same time.
PET/CT fusion as currently available, reduces (but not fully eliminates) many of the 
abovementioned positioning problems, such as bladder filling and bowel motion, but 
the need for an adequate breathing protocol remains. In some cases a patient is not 
able to comply with breathing instructions. This problem is important when 
considering the liver, as the result may be misplacement of liver lesions in the lung or 
vice versa, although in a low percentage of scans51.
When using a hybrid PET/CT scanner, CT images can be used for attenuation 
correction of the PET images. Although convenient, as the total scanning time can be 
reduced by ±35%, any artefact in the CT images may cause secondary artefacts in 
the PET images. Examples of such artefacts are false-positive hotspots related to 
attenuating metal such as prosthesis or clips52 and hotspots related to X-ray 
contrast53. Also, abdominal discrepancies between the PET images and the CT 
images are reported, resulting from bowel movement54.
PET and CT integration can provide synergistic benefit regardless of the technique 
applied. Hybrid PET/CT is more expensive than software fusion, but it delivers a fast, 
logistically easy and more reliable image correlation. A definitive advantage of hybrid
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PET/CT is that both visual fusion and software fusion may be impossible or 
inadequate when demanded ad hoc, especially in case of above-mentioned 
unexpected findings55.
Interpretation
While fused PET/CT images do appear straightforward, above-mentioned 
characteristics indicate that interpretation of the images requires specific expertise 
and careful reading. The benefits of integrated PET/CT not only depends on accurate 
integration of images, but also on the integration of expert opinions. Therefore, joint 
reading sessions are a necessity, taking place with radiologists and nuclear medicine 
physicians with the appropriate clinical input from clinical oncologists and/or 
surgeons.
Integration of PET and MRI
The combination of PET and CT is not the only possibility, nor is it a perfect solution. 
On theoretical grounds it is preferable to combine PET with (functional) MRI, for 
better soft tissue evaluation with a relatively low radiation burden. An excellent 
example of the application of PET/MRI fusion is accurate delineation of malignant 
lesions in the liver, to allow optimally guided locoregional therapeutic intervention56. It 
is expected that integrated PET/MRI scanners will become clinically available in the 
next few years.
Economic Evaluation
Despite the increased sensitivity and specificity demonstrated by FDG-PET and 
PET/CT, the additional contribution of this diagnostic modality has yet to be 
determined. Several evaluation studies have examined the FDG-PET scan in a 
number of diagnostic scenarios through modeling. These studies showed that FDG- 
PET is cost-effective in colorectal metastatic disease when added to the conventional 
work-up. However, these studies were based on assumptions and were unable to 
demonstrate how these diagnostic scenarios influenced clinical management and 
clinical outcomes 57-59.
FUTURE DEVELOPMENTS
The true clinical value of FDG-PET, and the added value of the application of 
PET/CT scanners, should ideally be clarified by prospective clinical trials. However, a 
true comparison between separately acquired PET and CT images, visual fusion,
24
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software fusion, and integrated PET/CT images can hardly be achieved, as this 
implies the acquisition of multiple scans with a high cumulative radiation burden to 
the patient. As a result of the rather limited scientific evidence, the current choices for 
implementation of FDG-PET in diagnostic strategies appear rather random, and large 
variations exist among institutes. This also applies to the application of hybrid 
PET/CT. However, scientific evidence about the diagnostic values of PET and 
PET/CT is rapidly increasing.
New PET tracers
Besides visualization of glucose metabolism with FDG-PET scanning may be applied 
for in vivo non-invasive evaluation of other tissue characteristics using tracers other 
than FDG. Studies using O-15-water for flow determination are reported. DNA 
synthesis activity may be quantitatively assessed using [F-18]fluoro-deoxy-L- 
thymidine (FLT) as a reflection of cell proliferation and tumor growth60, 61, which 
seems promising in differentiation with inflammatory lesions62. The exact clinical 
applicability of these and other tracers is currently under investigation, but at present 
more uncertain than the utility of FDG-PET.
Other PET radiopharmaceuticals depict specific receptors on the tumor cell 
membrane, which is not only important for staging patients with tumors that express 
a particular receptor, but also for characterization of these tumors’ receptor status in 
vivo. For example, somatostatin derivatives radiolabeled with F-18, Y-86 or Ga-68 
are extensively studied in patients with neuro-endocrine tumors63-65.
CONCLUSIONS
Evidence is growing that PET, and more specifically the combination of PET and CT, 
are valuable tools in the diagnostic strategy for detection of hepatic metastatic 
colorectal carcinoma, especially in the field of staging before surgical (re-) 
interventions. This has an impact on diagnosis and choice of therapy. Although 
unbiased supporting literature is currently limited, hardware integrated PET/CT using 
a hybrid scanner does seem to be able to improve diagnostic accuracy over 
correlated stand-alone PET and CT in several specific cases. As software image 
fusion is prone to error, this technique should be used with caution and should be 
reserved for specific applications. The largest benefit from integration of PET and CT 
images depends on the integration of knowledge. This implies joint consensus 
reading by a multidisciplinary team. This will be of even greater importance when 
new PET tracers and new MRI applications enter the clinical field.
25
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With the increasing availability of integrated PET/CT scanners, it is to be expected 
that clinical use and experience will rapidly expand. However, a critical review of 
indications and added value of these techniques are a prerequisite for rational 
application and maximum diagnostic yield.
26
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Abstract
Background. Fluor-18-deoxyglucose-positron emission tomography (FDG-PET) has 
emerged as a promising diagnostic modality in recurrent colorectal carcinoma. 
Wholebody FDG-PET may be an accurate diagnostic modality to determine whether 
patients with recurrent hepatic disease are suitable candidates for curative resection. 
Reports on the use of FDG-PET in patients with recurrent colorectal carcinoma are 
scarce, especially those on colorectal liver metastases. To assess the usefulness of 
this emerging modality for the selection of patients to undergo resection for colorectal 
liver metastases, a systematic (meta)-analysis of the current literature was 
conducted. In the absence of randomized controlled clinical trials, a traditional meta­
analysis could not be performed.
Methods. An alternative strategy was designed to evaluate the current literature. 
After a literature search, an index score was devised to evaluate the articles with 
regard to the impact of FDG-PET in patients with colorectal liver metastases. The 
index scored articles on several items and, as such, could be considered an objective 
approach for the assessment of diagnostic, nonrandomized clinical trials.
Results. The proposed index proved to be an independent instrument for judging 
several research questions and was used systematically to address the sensitivity, 
specificity, and clinical impact of FDG-PET in patients with colorectal liver 
metastases. For FDG-PET, the pooled sensitivity and specificity results were 88.0% 
and 96.1%, respectively, for hepatic disease and 91.5% and 95.4%, respectively, for 
extrahepatic disease. For the 6 articles that reported the highest scores on the index, 
the sensitivity and specificity of FDG-PET for hepatic metastatic disease were 79.9% 
and 92.3%, respectively, and 91.2% and 98.4%, respectively, for extrahepatic 
disease, respectively. For computed tomography, the pooled sensitivity and 
specificity results were 82.7% and 84.1%, respectively, for hepatic lesions and 60.9% 
and 91.1%, respectively, for extrahepatic lesions. The percentage change in clinical 
management due to FDG-PET was 31.6% (range, 20.0 -58.0% ) in the articles that 
scored above the mean and reported this item. For the 6 highest scoring studies, the 
percentage change in clinical management was 25.0% (range, 20.0 -32.0% ). 
Conclusions. Despite apparent omissions in the literature, the combined sensitivity 
and specificity of FDG-PET clearly indicated that FDG-PET has added value in the 
diagnostic workup of patients with colorectal liver metastases. FDG-PET can be 
considered a useful tool in preoperative staging and produced superior results 
compared with conventional diagnostic modalities, especially for excluding or 
detecting extrahepatic disease.
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Colorectal carcinoma ranks second as the cause of death due to cancer in the 
Western world, with a 5-year survival rate of 55%. Liver metastases are the main 
cause of death in this patient group. Approximately 20% of patients already have 
hepatic metastases at the time the primary tumor is detected, and another 25% will 
develop metastatic lesions in the years after they undergo resection of their primary 
tumor. For selected patients who have recurrent disease that is confined to the liver, 
surgical resection of the metastases is the treatment of choice, with a 5-year survival 
rate of > 40% reported in the recent literature1-3.
The selection of patients for surgical resection of colorectal liver metastases, 
however, still poses a significant clinical problem4,5. First, significant numbers of 
patients (15-25%) who are scheduled for surgical resection have unresectable 
disease identified at the time of laparotomy. Second, after they undergo liver 
resection, 60% of patients will develop recurrent tumor within 3 years either in the 
liver or in extrahepatic areas. These findings strongly support the need for more 
effective preoperative imaging to improve staging and to avoid futile surgery.
Positron emission tomography (PET) using fluor-18-deoxyglucose (FDG) has 
emerged as a promising diagnostic modality in recurrent colorectal carcinoma. 
Whole-body FDG-PET may prove to be an accurate diagnostic technique for 
determining whether patients with recurrent disease in the liver are suitable 
candidates for curative resection. In contrast, with conventional diagnostic modalities, 
such as computed tomography (CT) scanning and magnetic resonance imaging, 
FDG-PET does not require anatomic alterations for the detection of malignancy but 
provides images based on the increased glucose uptake and the altered metabolism 
of the tumor.
Reports on the use of FDG-PET in patients with recurrent colorectal carcinoma are 
scarce, especially from patients with colorectal liver metastases. Furthermore, 
randomized, controlled clinical trials are not available. To assess the usefulness of 
this emerging modality for the selection of patients undergoing hepatic resection for 
colorectal metastases, a systematic (meta)-analysis of the current literature was 
conducted. Data on liver metastases were extracted from all reports of FDG-PET in 
patients with colorectal carcinoma and were analyzed with a systematic approach.
INTRODUCTION
35
Chapter 2
MATERIALS AND METHODS 
Search Strategy
A systematic literature search for articles concerning recurrent colorectal liver 
metastases and PET imaging was performed using the Medline data base and 
EMBASE up to January 2004. Through the Medline and EMBASE data bases, 5 
search strategies with the following Medical Subject Heading items were used: 1) 
diagnostic imaging (FDG, fluorodeoxygly-, fluorodeoxyglucose-F-18-, tomography-X- 
ray-, tomography emission computed, magnetic resonance imaging, and all 
subheadings thereof), 2) PET-scan (positr- near emissio-, positron-emiss-, PET, and 
all subheadings), 3) metastases (metasta-, recur-, reappear-, recidiv-, relaps- or 
recrudes- near cancer-, carcinom-, malign-, tumor-, tumour- or neoplasm-, neoplasm- 
metastasis, neoplasm-recurrence-local, recurrence-, bile-duct-obstruction- 
extrahepatic, and bile-ducts-extrahepatic with all subheadings), 4) liver metastases 
(Search Strategy 3 near liver- or hepat- or extrahepat- or bile- or bilia-), and 5) 
matching strategies (see Table 1). In total, 363 articles were identified in this first 
search. A second search was conducted using the up-dated strategy published by 
Mijnhout et al.6, 7 The results of these search strategies were combined.
Articles were included in this review only when they included either a description of 
the impact on clinical management by FDG-PET or a description of FDG-PET 
imaging results in patients with recurrent colorectal carcinoma. Systematic review 
articles that mentioned PET alongside CT or other diagnostic modalities were 
excluded, because the individual articles were included in our review8-12.
Analysis of the Literature
Because randomized clinical trails are missing, data with which to perform a 
traditional, systematic meta-analysis could not be obtained. To compare, weight, and 
summarize data from the different studies, an alternative approach was designed 
using the stepwise process described below (Table 2).
First, a panel of experts (a hepatic surgeon, a nuclear medicine physician, a 
methodologist, and a radiologist) constructed a concept study containing all items 
that should be included and weighted in an ideal study design. Table 2 shows that 
this team of experts selected 5 different domains, each containing several items. 
There was consensus that these domains and items ideally should be reported in the 
individual studies.
Second, every item in a domain was weighted (5, very significant; 4, significant; 3, 
average; 2, mildly significant; 1, not significant) by each individual member of the
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expert team, after which, a consensus was achieved on the final weight factor of 
each item (Table 2).
In a third step, all articles were screened for the presence of the selected items. 
When an item was not available, no points were awarded. In articles in which an item 
was covered partially, 0.5 points were assigned. When the item was present and 
reported adequately, 1 point was awarded. The awarded points for each item were 
multiplied by the weight factor (1-5) to achieve the final value per item, and the total 
number of points per domain was calculated. Each of the 5 domains contributed 20% 
to the total score. In Figure 1, the scores for each domain and the total score for each 
article are presented as standard deviations from the mean.
The method described above can be considered a conceivable approach for the 
assessment of diagnostic, nonrandomized clinical trials to determine the impact of 
FDG-PET in oncology, in line with the Standards for Reporting Studies of Diagnostic 
Accuracy (STARD) statement13, 14 for diagnostic trails, the Consolidated Standards of 
Reporting Trials (CONSORT)15 statement for randomized trials, and the 
Methodological Index for Non-Randomized Studies16 for nonrandomized surgical 
clinical trials. We used the STARD initiative as a starting point and adopted it 
specifically to suit our objective of addressing the impact of FDG-PET in patients with 
potentially resectable colorectal liver metastases. Like with any new trial design that 
has no definitive gold standard, it is feasible that the proposed list has internal flaws. 
To validate the approach used, the results from the systematic assessment were 
compared with the results from a search for the best articles by two surgeons who 
were not aware of the items on the list.
The objective of this proposed approach was to conceive a method by which most 
critical research questions on FDG-PET and hepatic colorectal metastases could be 
addressed in a systematic and semiquantitative manner. Using this approach, the 
following questions were addressed: 1) How do the descriptive statistics (sensitivity 
and specificity) for FDG-PET compare with those for CT in the assessment of both 
hepatic and extrahepatic metastatic involvement? 2) Does FDG-PET have a 
significant impact on changes in the management of these types of metastases? 3) 
Which domain of research is lacking in the literature?
Not all studies were designed specifically for the analysis of hepatic recurrences of 
colorectal carcinoma. Therefore, a low total score does not automatically indicate that 
a study was poor, because the score merely recognizes the study's contribution to 
the evaluation of FDG-PET in colorectal liver metastases.
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Statistical Analysis
All statistical analyses were performed using the SPSS version 11.0 software 
package (SPSS Inc., Chicago, IL). To demonstrate a correlation between different 
aspects of the study and the validity of the proposed domain list, a Pearson 
correlation test was used. Furthermore, pooled sensitivity and specificity results were 
calculated from the true-negative results, true-positive results, false-negative results, 
and false-positive results that were reported in the different articles. Pooled sensitivity 
and specificity were determined after correcting for the variable number of patients 
per study.
RESULTS
The search strategies identified 32 studies, which were included in this systematic 
analysis17-49. An overview describing the content of each article can be found in Table 
3. All selected articles were scored according to the weighting procedure, as shown 
in Table 2. By using this approach, it was possible to determine the weight for each 
domain and the total weight of for different articles. Although large variations were 
observed between the different articles, there was remarkable consistency in the 
domain scores and in the final total scores for the both lower scoring and higher 
scoring articles. At least six articles consistently showed high scores for all of the 
domains, whereas six other studies consistently scored low for the different domains.
Both the results of the weighted evaluation and the total scores are summarized in 
Figure 1, which presents the score as a deviation from the mean for each article.
The proposed list appeared to be valid, because 5 of the 6 articles also were 
selected by the surgeons who were blinded to the items identified on the list (k  = 
0.839). The 6 articles that had scores > 10 points above the mean and, therefore, are 
regarded as the best studies that evaluated the research questions addressed in this 
systematic review.
Descriptive Statistics
To use the designed domain list as a separate instrument for analysis, the list should 
be independent from the main endpoints: the sensitivity and specificity of CT 
scanning and PET imaging and the change in clinical management that is attributable 
to FDG-PET. For this reason, the total score of the domain list was compared with 
the presence of sensitivity and specificity data in each article from a Pearson 
correlation test. The correlations of the total score with sensitivity and specificity for
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liver metastases of FDG-PET and CT were 0.21 and 0.05, respectively. For 
extrahepatic disease, these values were 0.13 for FDG-PET and 0.01 for CT. This 
indicates that the sensitivity and specificity are not correlated with the total scores of 
the domain list, underlining the fact that the proposed list is not dependent on the 
outcomes of sensitivity and specificity, thus securing the domain list as an 
independent measuring tool.
Change in clinical management was another endpoint of interest, because it shows 
the clinical implications of FDG-PET imaging in patients with liver metastases. No 
significant correlation (r) was found between the total score and the reported change 
in management (r = - 0.20), supporting the use of the proposed domain list as an 
independent tool for assessing the different studies.
Sensitivity and Specificity
Lesion-based sensitivity and specificity were calculated for the different diagnostic 
modalities as derived from the different studies. The results presented here may 
differ from the sensitivities and specificities provided in the articles because of the 
lesion-based nature of the current analysis. Figure 2 shows the sensitivity and 
specificity according to each individual article. The pooled overall scores (Figure 2, 
Combined) were derived directly from the combined true-negative, true-positive, 
false-negative, and false-positive results from all studies. If FDG-PET was 
inconclusive in the lesion-based analysis, then the results were considered false 
positive. For hepatic lesions, the pooled sensitivity and specificity results from FDG- 
PET were 88.0% and 96.1%, respectively, with 95% confidence intervals (95% CIs) 
of 88.-98.0 and 70.4-104.3, respectively. For extrahepatic lesions, the pooled 
sensitivity and specificity results from FDG-PET were 91.5% and 95.4%, respectively 
(95% CIs, 84.3-96.2 and 71.4-98.4, respectively). When the same analyses were 
performed for CT scanning, a sensitivity of 82.7% (95% CI, 64.2-88.6) and a 
specificity of 84.1% (95% CI, 68.2-97.0) were found for hepatic lesions. For 
extrahepatic lesions, the sensitivity and specificity results were 60.9% and 91.1%, 
respectively (95% CIs, 44.4-68.9 and 66.0-92.8, respectively). Compared with CT, 
sensitivity for the detection of extrahepatic disease was superior for FDG-PET, 
emphasizing the utility of FDG-PET for the detection of extrahepatic disease.
When the same pooling procedure was applied only to the 6 highest scoring articles, 
the analysis showed similar results for FDG-PET, as illustrated in Table 4. For 
hepatic disease, FDG-PET had a sensitivity of 79.9% and a specificity of 92.3%; for 
extrahepatic disease, these values were 91.2% and 98.4%, respectively. For CT, the 
sensitivity and specificity results were 85.8% and 88.3%, respectively, for hepatic 
disease and 55.3% and 95.6%, respectively, for extrahepatic disease. Again, this
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illustrates the added value of FDG-PET imaging compared with CT scanning for the 
detection of extrahepatic disease in patients who have hepatic metastases from 
colorectal carcinoma.
Weighted Change in Clinical Management
Among the studies that reported scores below the mean according to the proposed 
index score, only 5 of 14 studies listed a change in management on a patient basis, 
with a mean percentage change of 35.7% (range, 20.0-58.0%) (Figure 3). In contrast, 
13 of 17 studies that scored above the mean mentioned the change in clinical 
management. In those series, a percentage change in clinical management of 31.6% 
(range, 20.8-43.0%) was reported. After correcting for the number of patients in each 
study, the change in clinical management was 32.9% for the studies that scored 
below the mean and 30.8% for the studies that scored above the mean.
Five of the 6 highest scoring articles focused on the percentage change in clinical 
management and reported a mean change of 25.0% (range, 20.0-32.0%), which is 
lower compared with the percentage change in clinical management reported in all 
other articles. After correcting for the number of patients with liver metastases in the 
individual studies, the mean change in management that was observed in those 5 
articles was 25.4%.
Omissions in the Literature
Because there were no randomized trials in the literature on the subject, the scoring 
list that was used shows the reported items systematically, thereby identifying 
omissions (Figure 1). All articles failed to report some of the items that are useful in 
the assessment of the research questions discussed above. Items such as the 
handling of excluded patients and descriptive statistics, and, more specifically, the 
95% CIs, the workup of patients for resection, technical aspects and patient 
preparation for both PET and CT, means and intervals of postoperative follow-up, 
and the impact of PET on the clinical management of this patient group all are 
described poorly or inadequately in some of the articles, although all of these items 
may have a significant impact on the outcome of the study.
DISCUSSION
In the current review, we identified several gaps in the literature that addresses the 
use of FDG-PET in patients with recurrent colorectal carcinoma and, more 
specifically, in patients with liver metastases. Most apparent was the lack of one or
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more randomized clinical trials, which complicates a systematic meta-analysis. 
Combining the six highest scoring articles may be considered as a surrogate for a 
randomized trial, because it can provide the most accurate overview of the current 
data from the literature.
Furthermore, most studies failed to report a number of items, making it difficult to 
present an appropriate interpretation of the results. Data regarding comorbidity (e.g., 
diabetes) and patient-selection criteria were not always described appropriately and 
even were absent, although both items may have had a significant impact on both 
the imaging results and the study outcome. The same holds true for the 
characteristics of the primary tumors, because a higher stage results in a greater 
likelihood of metastatic disease and has a subsequent impact on the diagnostic 
workup of these patients. The different items that may have a significant impact and 
that are described inadequately in the literature should be addressed in future 
research.
Despite the apparent omissions in the literature of the results from imaging recurrent 
and metastatic colorectal carcinoma, these studies demonstrate the potential utility of 
FDG-PET in this specific patient group. Most publications (18 of 32 studies) 
demonstrated the general usefulness of FDG-PET for recurrent colorectal carcinoma, 
although they did not specifically address hepatic involvement.
Overall, the pooled sensitivity and specificity for FDG-PET compared favorably with 
the pooled results from CT scanning, clearly indicating that the FDG-PET diagnostic 
technique is appropriate in this clinical setting, especially for the assessment of 
extrahepatic disease. For extrahepatic lesions, the pooled sensitivity and specificity 
results for FDG-PET were 91.5% and 95.4%, respectively, compared with 60.9% and 
91.1% for CT scanning. Furthermore, the data showed a 25% change in clinical 
management after FDG-PET, indicating that this imaging modality has a significant 
impact on the treatment of patients with colorectal liver metastases. This is attributed 
mostly to the detection of extrahepatic disease with FDG-PET, which generally 
precludes liver resection, as discussed above. The presence of extrahepatic disease 
may be more important than the detection of additional hepatic lesions by FDG-PET. 
Such additional lesions detected by FDG-PET seldom turn resectable disease into 
unresectable disease and, therefore, hardly effect clinical management22, 36, 37,40.
The current systematic analysis emphasizes the importance of joint interpretation of 
FDG-PET results and CT scan images. Future developments in technology may 
enhance further the joint interpretation of multiple diagnostic modalities. This may be 
accomplished by using combined PET and CT scanners or by fusing software to 
combine different diagnostic techniques. At the least, multidisciplinary oncologic 
meetings should be held at which several clinical and nonclinical specialist can
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perform a joint assessment of all data to review clinical information and diagnostic 
imaging on a patient-by-patient basis. Only in this way can we guarantee the optimal 
translation of imaging results into clinical management decisions.
Our proposed index may serve as a tool to distinguish poor studies from more 
appropriate diagnostic studies in the literature and also may serve as a guideline for 
reporting this type of study. Obviously, when evaluating trials and trial design without 
a gold standard, it is possible that the proposed approach may have internal flaws. 
However, the validity of our approach was tested by searching for the top five articles 
in the field of study, and those articles coincided with the highest rated articles 
according to the proposed index. Moreover, the proposed index may be used as a 
separate instrument for analysis, independent from other endpoints.
In conclusion, despite the apparent omissions in the literature, the pooled results 
clearly indicate that FDG-PET is useful in the diagnostic workup of patients with 
potentially resectable hepatic metastases from colorectal carcinoma. Most evident is 
the detection of extrahepatic disease, in which the FDG-PET demonstrated superior 
sensitivity and specificity compared with CT scanning. A clear influence of FDG-PET 
on clinical management was observed in the majority of studies.
Nevertheless, randomized, controlled clinical trials should be performed to 
investigate the role played by FDG-PET scanning in patients with colorectal liver 
metastases and its actual impact (e.g., on survival parameters). An additional 
assessment of the cost-effectiveness of FDG-PET may serve to strengthen its role 
further.
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Table 1. Search Strategies
Search Strategy I
1. Explode “tomography-X-ray-+”/all subheadings in MIME, MJME; or explode “tomography-emission-computed-+’7all 
subheadings in MIME, MJME; or explode <emagnetic-resonance-imaging-+”/all subheadings in MIME, MJME (414,785 
records)
2. “ Fludeoxyglucose-F-18”/all subheadings in MIME, MJME (8176 records)
3. Explode “bile-duct-obstruction-extrahepatic”/all subheadings in MIME, MJME; or explode “bile-ducts-extrahepatic’7all 
subheadings in MIME, MJME (19,559 records)
4. Explode “neoplasm-recurrence-local ”/al I subheadings in MIME, MJME; or explode “recurrence-”/all subheadings in 
MIME, MJME (205,571 records)
5. Explode “ neoplas m~metastasis”/al I subheadings in MIME, MJME (123,300 records)
6. Fluorodeoxygl* (3305 records)
7. (Metasta* or recurr* or reappear* or recidiv* or relaps* or recrudes*) near (cancer* or carcinom* or malign* or tumor* or 
tumour* or neoplas*) (276,686 records)
8. Strategy I-7, or I-5, or I-4, or I-3 (461,092 records)
9. Strategy I-6, or I-2, or I-1 (415,891 records)
10. PET* (259,611 records)
11. Positron-emiss* (747 records)
12. Positr* near emissio* (21,386 records)
13. Strategy I-12, or I-11, or I-10 (26,7521 records)
14. Strategy I-8 near (liver* or hepat* or extrahepat* or bile* or bilia*) (33,772 records)
15. Strategies I-9 and I-13 (32,398 records)
16. Strategies I-14 and I-15 (244 records)
17. FDG (6593 records)
18. Strategy I-17, or I-6, or I-2, or I-1 (416,353 records)
19. Strategies I-18 and I-13 (32,732 records)
20. Strategies I-14 and I-19 (253 records)
Search Strategy II
1. Explode “tomography-X-ray-+”/all subheadings in MIME, MJME; or explode “tomography-emission-computed-+’7all 
subheadings in MIME, MJME; or explode “magnetic-resonance-imaging-+”/all subheadings in MIME, MJME (248,884 
records)
2. “ Fludeoxyglucose-F-18”/all subheadings in MIME, MJME (4525 records)
3. Explode “bile-duct-obstruction-extrahepatic’Vall subheadings in MIME, MJME; or explode “bile-ducts-extrahepatic’Vall 
subheadings in MIME, MJME (14,860 records)
4. Explode “neoplasm-recurrence-local ”/all subheadings in MIME, MJME; or explode “recurrence-”/all subheadings in 
MIME, MJME (135,546 records)
5. Explode “neoplasm~metastasis”/alI subheadings in MIME, MJME (90,666 records)
6. Fluorodeoxygl* (1792 records)
7. (Metasta* or recurr* or reappear* or recidiv* or relaps* or recrudes*) near (cancer* or carcinom* or malign* or tumor* or 
tumour* or neoplas*) (182,550 records)
8. Strategy II-7, or II-5, or II-4, or II-3 (307,154 records)
9. Strategy II-6, or II-2, or II-1 (249,509 records)
10. PET* (167,845 records)
11. Positron-emiss* (444 records)
12. Positr* near emissio* (12,063 records)
13. Strategy II-12, or II-11, or II-10 (172,504 records)
14. Strategy II-8 near (liver* or hepat* or extrahepat* or bile* or bilia*) (22,625 records)
15. Strategies II-9 and II-13 (18,421 records)
16. Strategies II-14 and II-15 (134 records)
MIME: minor Medical Subject Headings (MeSH) headings; MJME: major MeSH headings;
PET: positron emission tomography; FDG: Fluor-18-deoxyglucose.
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Table 2. List of Domains and Items
Domain Classification Weight factor 
(quantity)a
1. Patien t popu lation
1.1 P a tien t charac te ris tics
C le a r descrip tion  o f po p u la tio n 's  age  and gender
1.2 Loca liza tion  an d  s tage  p rim a ry  CRC
Loca liza tion : co lon  vs. rectum  o r  co lon se g m e n t m entioned  AN D  
S tage: I-IV  o r pTN M  
O ne o f th e  above 
N one o f th e  above
1.3 C o m orb id ity /d iabe tes
D iabe tes is in te rfe ring  w ith  the  co rrec t asse ssm e n t o f the 
F D G -P E T  im ages
1.4 S am p le  s ize ; no. o f live rs /to ta l pa tien ts  
>  35 pa tien ts  w ith  hepatic  m etastases
< 35 pa tien ts  w ith  hepatic  m etastases 
Not m entioned
1.5 M a nagem en t dec is ion  a fte r  norm a l d iagnos tic  w o rkup  (see 
2.6, be low )
A fte r norm a l w o rkup , dec is ion  to  o pe ra te  w a s  taken
1.6 E xc luded  pa tien ts
No. o f exc luded  pa tie n ts  and  how  th e y  w e re  cons ide red  in the 
ana lys is
2. S tu d y  design
2.1 R esearch  question
A  c le a r and dec is ive  question  shou ld  be sta ted  o f the  s tudy ob jective
2 .2  Inc lus ion  criteria
An e xa c t sum m ation  o f all inc lus ion  a nd  exc lus ion  crite ria  
T he  p a tien t g roup  ch a ra c te ris tics  in genera l 
N one given
2.3  D esign 
Prospective  
R etrospective  
Not described
2.4  R andom iza tion
S tudy  des ign  invo lved  a random iza tion  o f P ET used in d iagnostic  
w orkup
2.5  S tu d y  period
D escribed  beg inn ing  and end ing  o f s tudy
2 .6  B linding
B lind ing P ET resu lts  be fo re  above -m e n tio n e d  dec is ion  (see 1.5)
3. S tatis tics
3.1 D escrip tive  s ta tistics
C le a r descrip tion  o f s ta tis tics  and  ra tiona le  used
3.2  S e n s itiv ity /sp e c ific ity  o f P ET (O R  fa lse -p o s itive /p o s itive  p red ictive  
va lue ) liver
R esu lts  o f P ET o f hepatic  m etastases
3 .3  S e n s itiv ity /sp e c ific ity  o f C T /M R I (O R  fa lse -pos itive /pos itive  
p red ic tive  va lue ) liver
R esu lts  o f C T  o r MRI o f hepa tic  m etastases
3 .4  S e n s itiv ity /sp e c ific ity  o f P ET (O R  fa lse -p o s itive /p o s itive  p red ictive  
va lue ) extrahepa tic
R esu lts  o f P ET o f e x trahepa tic  m etastases
3 .5  S e n s itiv ity /sp e c ific ity  o f C T /M R I (O R  fa lse -pos itive /pos itive  
p red ic tive  va lue ) extrahepa tic
R esu lts  o f C T  o r MRI o f ex tra h e p a tic  m etastases
3 .6  C o n fid e n ce  interva l
M ethod used to  describe  95 %  o r 90%  m argin  e rro r
4. P reo p era tive  te c h n o lo g ie s  and im age interpretation
0.5
0.0
1.0
0.5
0.0
1.0
0.5
0.0
1.0
0.5
0.0
0/1
0/1
0/1
0/1
3
2
1.0
4
5
4
4
4
4
5
5
3
4
5
5
5
3
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4.1 P reopera tive  fo llo w -u p  1 
A  c le a r ou tline  th a t s ta tes  fo llo w -u p  o f p rim ary  tum or, w ith  se t tim e  0/1
Interva ls
4 .2  S u rg ica l w o rku p  5 
C T-chest, abdom en /M R I co lonoscopy  1.0
C hes t X -ray, u ltrasound  0.5
Not g iven 0.0
4 .3  In te rva l C T  and P ET 4
< 4 w ks  1.0
< 8 w ks  0.5 
Not g iven 0.0
4 .4  In te rva l d iagnos tics  and  su rge ry 4 
<4 w ks  1.0
< 8 w ks  0.5 
Not g iven 0.0
4 .5  T e ch n ica l spec ifica tions  and  p a tien t p repa ra tion  PE T  4 
Both 1.0
O ne o f tw o  0.5
N one 0.0
4 .6  T e ch n ica l spec ifica tions  and  p a tien t p repa ra tion  C T  4 
Both 1.0
O ne o f tw o  0.5
N one 0.0
4 .7  D efin ition  o f p os itive  and negative  P E T  fin d in g s  4 
S ca ling  o f P ET find ing  1.0
D escrip tive  o r S U V  m e a su rem en t 0.5
Not g iven 0.0
4 .8  No. o f rev iew ers  (PET) 3 
T w o  o r m ore  1.0
O ne 0.5
Not g iven 0.0
4 .9  D isease  d is tribu tion  4 
C le a r descrip tion  o f o rg a n s  invo lved  in m etasta tic  tu m o r 0/1
4 .10  Les ions  s tud ied  3 
Lesion -by-les ion  s tudy and descrip tion  o f a ttribu tion  to  d iffe ren t 0/1
O utcom es
5. Final confirm ation
5.1 P reopera tive  u ltrasound 3 
P reopera tive  u ltrasound  to  ve rify  the  fin d in g s  in p re o pe ra tive  0/1
d iagnos tic  w orkup
5.2  C on firm a tion  by h is topa tho logy  o r c lin ica l fo llo w -u p  5 
C lin ica l fo llo w -u p  > 12 m os 1.0
C lin ica l fo llo w -u p  > 6 m os and < less than 12 m os 0.5
Not g iven and no h is to p a th o lo g y  0.0
5 .3  P os tope ra tive  fo llo w -u p  I 4 
Frequency o f s tanda rd  fo llo w -u p  w ith  in te rva ls  o f 3 m os 1.0
Frequency o f s tanda rd  fo llo w -u p  w ith  in te rva ls  o f 6 m os 0.5
Not g iven 0.0
5 .4  P os tope ra tive  fo llo w -u p  II 4 
D iagnos tic  m eans o f fo llow -up ; C T -chest, abdom en /M R I 1.0
co lonoscopy
D iagnos tic  m eans o f fo llow -up ; ch e s t X -ray, u ltrasound  0.5
Not g iven 0.0
5 .5  Lost to  fo llo w -u p  5 
No. o f p a tien ts  and  cons ide ra tion  o f a ttribu tion  to  ou tcom e
Both 1.0
O ne o f tw o  0.5
N one 0.0
5 .6  C h ange  in m anagem en t 5 
C lin ica l im p lica tion  o f P E T  used in th is  se tting  0/1
CRC: colorectal carcinoma; pTNM: pathologic tumor, lymph node, metastasis classification: 
FDG-PET: fluor-18-deoxyglucose-positron emission tomography;
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Table 3. Study Scores
Study Sampling* Design study Score
Beets et al., 1994 [18] 15/35 Prospective 5.9
Schiepers et al., 1995 [39] 73/76 — 3.3
Vitola et al., 1996 [45] 24/24 Prospective 4.5
Lai et al., 1996 [32] 34/34 Prospective 10.3
Ogunbiyi et al., 1997 [35] 23/58 Retrospective 2.3
Delbecke et al., 1997 [20] 52/52 — 5.7
Flanagan et al., 1998 [25] 22/22 Retrospective -5.1
Delbecke et al., 1998 [21] 53/110 Prospective 0.0
Yasuda et al., 1998 [47] 8/8 Retrospective -17.2
Flamen et al., 1999 [23] 45/103 Retrospective -1.7
Fong et al., 1999 [26] 40/40 Prospective 11.0
Valk et al., 1999 [44] 57/115 Prospective 28.7
Boykin et al., 1999 [19] 14/14 Retrospective -25.2
Imdahl et al., 2000 [29] 28/71 Prospective 14.1
Whiteford et al., 2000 [46] 35/105 Retrospective -3.8
Zhuang et al., 2000 [48] 28/28 Retrospective -20.1
Staib et al., 2000 [41] 3/100 Prospective 9.7
Imbriaco et al., 2000 [28] Not mentioned Retrospective -11.0
Iwata et al., 2000 [30] 8/78 — -21.7
Strasberg et al., 2001 [49] 43/43 Prospective - 7.9
Flamen et al., 2001 [24] 15/50 Retrospective 4.4
Topal et al., 2001 [43] 91/91 Prospective 2.2
Hung et al., 2001 [27] 2/32 Retrospective -5.5
Arulampalam et al., 2001 [17] 15/42 Prospective 3.0
Johnson et al., 2001 [31] 26/41 Retrospective -1.9
Ruers et al., 2002 [37] 51/51 Prospective 20.1
Lonneux et al., 2002 [34] 33/68 Retrospective —
Rydzewski et al., 2002 [38] 47/47 Retrospective -6.7
Rohren et al., 2002 [36] 23/23 Retrospective - 3.1
Langenhoff et al., 2002 [33] 23/23 Prospective 13.7
Simo et al., 2002 [40] 31/145 Retrospective - 9.7
Desai et al., 2003 [22] 25/114 Prospective 1.7
* S am p ling : the  n um ber o f pa tien ts  w ith  live r m e tas tases  d iv ided  by the  to ta l pa tie n ts  in th e  study.
CT: computed tomography; MRI: magnetic resonance imaging; SUV: standardized uptake value.
a Classification: 0.0, not mentioned; 0.5, partly mentioned; 1.0, adequately described. 
b Weight factor: 1, not significant; 2, mildly significant; 3, average; 4, significant; 5, very significant.
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Table 4. Sensitivity and Specificity by Diagnostic Modality for the Six Studies with the Highest Scores
FDG-PET hepatic lesions FDG-PET extrahepatic lesions CT hepatic lesions CT extrahepatic lesions
Study Sensitivity Specificity Sensitivity Specificity Sensitivity Specificity Sensitivity Specificity
Lai et al.: 
1996[32]
0.93 0.44 0.92 0.95 1.00 0.14 - -
Fong et al., 
1999[26]
0.71 0.93 0.85 0.91 0.88 1.00 0.30 0.81
Valk et al., 
1999[44]
0.95 1.00 0.92 0.99 0.84 0.95 0.61 0.96
Imdahl et al., 
2000[29]
0.84 0.86 0.86 0.88 -
Ruers et al., 
2002[37]
0.65 ■ 0.95 0.97 0.80 0.65 0.94
Langenhoff et al. 
2002[33]
, 1.00 0.98 -
Combined
studies
0.80 0.92 0.91 0.98 0.86 0.88 0.55 0.96
FDG-PET: fluor-18-deoxyglucose-positron emission tomography; CT: computed tomography.
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Figure 2. The sensitivity and specificity (Sens/spec) of diagnostic modalities for the detection of colorectal liver métastasés are charted for 
each study and for all outcomes (COMBINED). PET: positron emission tomography; CT: computed tomography.
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Figure 3. The changes in the clinical management (%) of colorectal liver metastases are charted on a 
patient basis for each study and for all studies combined.
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Abstract
Background. Selection of patients for hepatic resection of colorectal liver metastases 
is still limited. After conventional work up by computed tomography (CT) scan, 60% 
of patients will develop recurrent disease in the early years after resection. The aim 
of the present study was to evaluate whether an additional fluorine-18-deoxyglucose 
positron emission tomography (FDG-PET) improves patient selection and therefore 
adds value to select patients for curative liver resection.
Methods. Data from 203 patients selected for surgical treatment of colorectal liver 
metastases between 1995 and 2003 were collected in a prospective database. 
Group A consisted of 100 consecutive patients selected for hepatic surgery by 
conventional diagnostic imaging (CT chest and abdomen) only. Group B consisted of 
103 consecutive patients selected for hepatic surgery by conventional diagnostic 
methods plus an additional FDG-PET.
Results. The number of patients with futile surgery, in which further treatment was 
considered inappropriate at laparotomy, was 28.0% in group A and 19.4% in group 
B. The reason for unresectable disease differed between groups. In group A, 10/100 
(10.0%) patients showed extrahepatic abdominal disease versus 2/103 patients 
(1.9%) in group B (P = .017). In all other cases, resection was not performed 
because liver disease proved too extensive at laparotomy. For patients ultimately 
undergoing surgical treatment of the metastases, survival was comparable between 
groups. Overall survival at 3 years was 57.1% in group A versus 60.1% in group B. 
Disease-free survival at 3 years was 23.0% in group A and 31.4% in group B. 
Conclusions. In patients with colorectal liver metastases, FDG-PET may reduce the 
number of negative laparotomies. However, the effect size on the selection of these 
patients seems not sufficient enough to affect the overall and disease-free survival 
after treatment.
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Colorectal cancer is one of the most common causes of cancer-related death in the 
Western world. After apparently curative resection of the primary tumor, recurrence 
of the disease is observed in up to 60% of patients. The liver is often the first site of 
metastatic disease and may be the only site of spread in as many as 30% 1-3 of 
patients. Surgery is the only possible curative treatment in a subset of patients with 
colorectal liver metastases. Eligibility for hepatic surgery of colorectal metastases 
depends on (1) the absence of extra hepatic tumour, and (2) the technical ability to 
completely resect all hepatic metastases.
Preoperative workup for resection of colorectal liver metastases is generally focused 
on imaging of the number and location of liver lesions by contrast-enhanced 
computed tomography (CT) or magnetic resonance imaging (MRI) of the liver and the 
exclusion of extrahepatic disease by abdominal and chest CT. Still, within 1 year, up 
to 50%4-7 of patients with potentially curative resection of liver metastases show 
recurrent disease at other sites of the liver or at extrahepatic sites. This suggests that 
these common modalities of diagnostic imaging frequently overlook minimal 
metastatic disease, which becomes apparent shortly after resection of the liver 
metastases.
Recently, fluorine-18-deoxyglucose positron emission tomography (FDG-PET) has 
been introduced as an additional staging modality in patients with colorectal liver 
metastases. FDG-PET is a sensitive imaging modality for the detection of tumour 
tissue based on the increased utilisation of glucose by tumour cells. Being a 
functional imaging modality, FDG-PET may be of value in the detection of additional 
liver lesions or extrahepatic disease. Moreover, FDG-PET may be helpful in 
determining the nature of liver lesions detected by CT. Several studies showed the 
impact of FDG-PET in clinical decision making in patients with suspected colorectal 
recurrence8-16. Most of these studies concern recurrent colorectal cancer in general. 
Data on the specific impact of FDG-PET for selection of patients for hepatic surgery 
are, however, more limited17-20. Moreover, direct comparison between patients 
selected for hepatic surgery with or without FDG-PET are still lacking.
In the present study, we investigated the effect of FDG-PET on disease-free and 
overall survival after hepatic surgery for colorectal liver metastases. For this purpose, 
we identified two homogeneous groups of patients with colorectal liver metastases 
who were selected for hepatic surgery of liver metastases, either with or without 
additional FDG-PET.
INTRODUCTION
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MATERIALS AND METHODS 
Protocol and Patient Groups
Between January 1995 and November 2003, a consecutive series of 203 patients 
was identified from our prospective colorectal liver metastases database who 
underwent laparotomy for intended resection of colorectal liver metastases. During 
the study protocol, all patients underwent a standardised diagnostic protocol 
consisting of conventional diagnostic imaging (CDM) by CT of liver, abdomen and 
chest; and colon visualisation, either with colonoscopy or barium enema. From 
January 1999, an FDG-PET was added to the standard diagnostic protocol. After 
diagnostic workup, patients were selected for hepatic surgery only when (1) 
preoperative imaging showed no extrahepatic disease (except for the presence of s 2 
resectable lung metastases, n = 5) and when (2) all liver lesions could be resected or 
treated adequately by local tumour ablation or a combination of both. Ultimately, two 
groups of patients could be identified: one group of 100 consecutive patients 
(January 1995 to December 1998) selected for hepatic surgery by standard CDM 
only (group A) and a second group consisting of 103 patients (January 1999 to 
November 2003) selected for hepatic surgery by CDM and additionally FDG-PET 
(group B).
Patient Characteristics
For comparison of both groups, patient and tumour characteristics were analysed 
according to the prognostic scoring system of Fong et al.21 Five prognostic variables 
were assigned one point each: disease-free interval of 12 months or more after 
resection of the primary tumour, number of tumours > 1, size of tumour > 5 cm, node­
positive primary tumour, and carcinoembryonic antigen (CEA) > 200 ng/ml. The total 
score ranging from 0 to 5 proved to be highly prognostic for long-term outcome and 
could be used to compare groups of patients for baseline prognostic variables21.
CT Scanning
Between 1995 and December 1998, CT examinations of the abdomen and chest 
were performed with a one-slice CT scanner with 8-mm slices (Siemens, Erlangen, 
Germany); from 1999, examinations were performed with a spiral CT scanner 
(Somaton Volume Zoom, Siemens, Erlangen, Germany). All patients received diluted 
ionic oral contrast 1 h before CT examination. The liver was scanned before and after 
intravenous injection of iohexol nonionic contrast material (Omnipaque, iodine 350 
mg/ml; Nycomed, Princeton, NJ, USA). By use of an Envision CT injector (Medrad, 
Pittsburgh, PA, USA) at a rate of 4 ml/s, intravenous contrast was injected through a
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18-gauge catheter placed in an antecubital vein. A total of 100 ml of contrast material 
was injected. The liver was scanned in the venous phase 70 s after the start of the 
injection. Both nonenhanced and enhanced helical sequences were performed at 
120 kV and 150-300 mAs. Contiguous reconstructed sections (pitch 1:1) were 
obtained with 7-mm collimation. All examination results were stored on a optical disc 
for further review and were analysed by two reviewers, both radiologist with an 
expertise in hepatic imaging.
FDG-PET
All FDG-PET studies were performed with a dedicated PET scanner (initially ECAT- 
ART, later 2001 ECAT-EXACT; Siemens/CTI, Knoxville, TN, USA) at the Radboud 
University Nijmegen Medical Centre. Patients had to fast for at least 6 h before the 
study. Immediately before the procedure, the patients were hydrated with 500 ml of 
water. One hour after intravenous injection of 200-260 MBq of FDG and 20 mg of 
furosemide, emission images of the area between the proximal femora and the base 
of the skull were acquired in 10-min-per-bed position in a series of seven to eight 
positions. The images were corrected for attenuation and reconstructed using the 
ordered-subsets expectation maximisation (OSEM) algorithm. The reconstructed 
images were displayed in coronal, transverse and sagittal planes. Patients with 
diabetes mellitus were not excluded.
Assessment
Results of both CDM and FDG-PET were reported at a multidisciplinary oncology 
meeting by surgical oncologists, radiologists and nuclear medicine physicians. A joint 
assessment of all available data was performed to review clinical information and 
diagnostic imaging on a case-by-case basis.
Surgical Technique
Surgery was performed through a right subcostal incision. Upon the abdomen being 
entered, an initial exploration was performed to preclude the presence of 
extrahepatic disease. Biopsy specimens and fresh frozen sections were taken in 
case of suspicious lymph nodes or peritoneal deposits. Intraoperative ultrasound was 
then performed to identify, count and characterise the nature, number and 
localisation of lesions relative to major biliary and vascular structures, and 
resectability was assessed. Resection was always considered to be the treatment of 
choice. The majority of resections were anatomical or segmental in both groups. 
Wedge resections accounted for 25% of procedures. When complete resection with
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negative resection margins was deemed not possible, local tumour destruction by 
radiofrequency ablation (RFA) or cryosurgery was considered.
In case of intraabdominal extrahepatic disease or if liver lesions were too extensive 
to be treated completely, further hepatic surgery was abandoned. The reason for 
unresectable disease was recorded prospectively. After hepatic surgery, patients did 
not receive any standard chemotherapy. Chemotherapy was only started in case of 
tumour recurrence that was not amenable for surgical reintervention.
Follow-up
After surgical intervention, all patients were followed prospectively at regular 
predetermined intervals. Standard follow-up in the first 3 years after hepatic surgery 
consisted of abdominal CT and serum CEA levels every 3 months and chest CT or 
chest X-ray every 6 months. After 3 years, imaging and serum CEA were reduced to 
twice yearly until 5 years after surgery. Colonoscopy or barium enema were 
performed regularly every 3 years. When one of the tests results indicated possible 
recurrent disease, further investigations were performed to confirm recurrence. 
Recurrence was defined as one or more new lesions on CT or, in case of 
inconclusive imaging, cytological or histological proof of recurrent disease was 
utilised. An isolated rise in serum CEA level was not considered sufficient evidence 
for recurrence. Median follow-up was 53 (range 13-116) months for all patients, 87 
(range 72-116) months for group A and 43 (range 13-72) months for group B.
Statistic Analysis
The time from date of surgery to date of death was used as the end point in overall 
survival (OS); patients alive at the end of study were censored. The time interval 
between hepatic surgery and the first relapse, irrespective of its localisation, was 
taken as the period for disease-free survival (DFS). No secondary DFS was taken 
into account. Overall survival and DFS analyses were performed by the Kaplan­
Meier method. All statistical analyses were performed with the SPSS programme 
(version 12.0.1). For comparison of differences in quantitative and ordinal variables 
between the groups, a chi-square test was used; for other comparisons, a t test was 
used. Group differences for survival analyses were analysed with the log-rank test; P 
values of less than .05 were considered statistically significant.
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RESULTS 
Analysis at Laparotomy
After diagnostic workup, 203 patients underwent laparotomy: 100 in group A and 103 
in group B. For group comparison, tumour and patient characteristics were analysed 
according to the prognostic scoring system of Fong12. The distribution of Fong criteria 
between groups was comparable (Table 1).
Table 1. Prognostic score according to Fong for patients analysed without FDG-PET (group A) and 
with FDG-PET (group B).
Score: Fong criteria, total group (n = 203)* Group A, n = 100 Group B, n = 103
0-1 32 (32.0) 42 (40.8)
2-3 65 (65.0) 60 (58.2)
4-5 3 (3.0) 1 (1.0)
Score: Fong criteria, surgical treated group (n =155)* Group A, n = 72 Group B, n = 83
0-1 21 (29.2) 35 (42.2)
2-3 48 (66.7) 47 (56.6)
4-5 3 (4.2) 1 (12)
Fong criteria : positive nodal status primary tumour, disease-free interval of 12 months or more, number of 
tumour(s) more than one, size of tumour > 5 cm and carcinoembryonic antigen (CEA) > 200. If an item is present, 
this results in 1 point. Minimum score is 0, maximum score is 5.
* Total group: for difference between groups A and B (t test. P = .28).
** Surgical treatment group: for difference between groups A and B (t test, P = .40).
Also, the yield of intraoperative ultrasound was similar in both groups. At laparotomy, 
28 patients (28.0%) in group A (n = 100) and 20 (19.4%) in group B (n = 103) were 
considered ineligible for surgical treatment at laparotomy, and further treatment 
consisted of chemotherapy only (Table 2). Remarkably, futile laparotomy was due to 
extrahepatic disease in only two (1.9%) patients in group B compared with 10 (10%) 
in group A (P = .017).
In the other irresectable patients, metastases were considered too extensive or too 
close to main vasculare structures in group A in 18 patients (18.0%) and in group B 
in 18 patients (17.4%) to permit resection or local tumour ablation.
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Table 2. Summary of findings at laparotomy
Variable Group A n = 100 (%) Group B n = 103 (%) P -value
Total laparotomies without further surgical 28 (28.0) 20 (19.4) .186
treatment
Hepatic disease too extensive 18 (17.0) 18 (17.4) 1.000
Extrahepatic disease 10 (10.0) 2 (1.9) .017*
Omentum metastases 3
Truncal lymph nodes 5
Metastasis gallbladder 1
Adrenal metastasis 1
Peritoneal metastasis 1
Hilar lymph nodes 1
* Significance: P < .05.
Treatment Analysis
At laparotomy, 155 patients (76%) ultimately underwent surgical treatment of liver 
metastases. One group of 72 patients (January 1995 to December 1998) had been 
selected by standard CDM and laparotomy (group A) and a second group consisting 
of 83 patients (January 1999 up to November 2003) had been selected by CDM and 
additionally FDG-PET and laparotomy (group B).
Patient and tumour characteristics of the patients who underwent surgical treatment 
within both groups are given in detail in Table 3. No significant differences could be 
observed. Also, prognostic score according to the Fong criteria12 was comparable 
between both subgroups (Table 1).
In group A (CDM), 49 patients (68.1%) were treated by resection, 16 (22.2%) by 
resection plus local tumour ablation and seven (9.7%) by local tumour ablation alone. 
For group B (CDM plus FDG-PET), these figures were 47 (56.6%), 25 (30.1%), and 
11 (13.3%), respectively.
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Table 3. Demographics and tumour characteristics of patients undergoing surgical treatment without 
(group A) or with (group B) fluorine-18-deoxyglucose positron emission tomography (FDG-PET).
Variable Group A Group B P value
Number of patients 72 83
Gender: male:female 44:28 45:38 .39
Median Age at time of surgery (range) 59.8 (24.2-83.5) 62.2 (32.8-80.0) .12
Median number of liver metastases (range) 2.6 (1-10) 2.4 (1-13) .59
Location primary tumour .87
Cecum 8 5
Colon ascending 4 6
Colon transverse 3 2
Colon descending 1 3
Sigmoid 30 35
Rectum 24 31
Double tumour 2 1
Stage primary tumour .61
pT1 - 2
pT2 7 8
pT3 57 65
pT4 8 8
Nodal stage primary tumour .24
pN0 31 40
pN1 32 29
pN2 9 13
pN3 - 1
Preoperative carcinoembryonic antigen (CEA) .34
<200 68 82
>200 3 1
Unknown 1 -
Tumour size .93
<5 cm 54 61
>5 cm 18 21
Unknown - 1
Median disease-free interval (range) 11.2 (0-69) 8.9 (0-77) .65
Overall Survival
Survival analysis of the patients who underwent surgical treatment of metastases is 
given in Figure 1. For patients in group A (without FDG-PET, n = 72), 1- and 3-year
OS was 86.1% and 57.1%, respectively. For patients in group B (with FDG-PET, n = 
83), these figures were 94.0% and 60.1%, respectively. No significant difference was 
observed in OS between groups (log rank, P value = .678). Perioperative mortality in 
both groups was similar; three patients (3%) in group A and three (3%) in group B.
For those patients who underwent resection only (and no local tumour ablation), OS 
at 1 and 3 years was 93.8% and 69.2% in group A (n = 49) and 93.6% and 63.7% in 
group B (n = 47). Again, survival curves between groups were not statistically 
significant (log rank, P value = .840). Subgroup analysis based on tumour
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characteristics (number of liver lesions, size of liver tumours and synchronous or 
metachronous occurrence) showed no significant differences in survival between the 
two groups.
Figure 1. Overall survival for patients who underwent surgical treatment selected either without (group 
A) or with (group B) fluorine-18-deoxyglucose positron emission tomography (FDG-PET).
Disease-free Survival
DFS at 1 and 3 years for patients who underwent surgical treatment was 54.4% and 
23.0%, respectively, in group A (without FDG-PET) and 56.9% and 31.4%, 
respectively, in group B (with FDG-PET) (Figure 2). For those patients who 
underwent resection only, DFS at 1 and 3 years was 62.6% and 29.9%, respectively, 
in group A (n = 49) and 67.4% and 29.2%, respectively, in group B (n = 47). DFS 
curves did not show any significant difference between groups (log rank, P value = 
.656).
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Figure 2. Disease-free survival for patients who underwent surgical treatment selected either without 
(group A) or with (group B) fluorine-18-deoxyglucose positron emission tomography (FDG-PET).
Site of Recurrence
Recurrence rate for the first site of recurrence in both groups is depicted in Figure 3. 
Recurrence in the liver was found in 25/72 patients in group A (34.7%) and in 21/83 
(25.3%) in group B. Extrahepatic recurrence was the first site of recurrence in 19 
patients from group A (26.3%) and in 21 from group B (25.3%). Combined recurrence 
was observed in six patients (8.3%) from group A and 11 patients (13.3%) from 
group B. No significant differences were observed between groups.
Figure 3. Site of first recurrence for patients who underwent surgical treatment selected either without 
(group A, n = 72) or with (group B, n = 83) fluorine-18-deoxyglucose positron emission tomography 
(FDG-PET). Percentages indicate patients within one group (A or B) who developed recurrence at the 
indicated site. Actual numbers are noted above the bars.
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DISCUSSION
It has been recognised that FDG-PET may have a role in the selection of patient who 
would benefit from surgical resection of colorectal liver metastases. Previous studies 
demonstrate that FDG-PET may, in particular, detect additional extrahepatic lesions 
missed by conventional CT. It is generally assumed that, except for isolated lung 
lesions, these extrahepatic lesions indicate poor prognosis and preclude further liver 
resection. The present study shows that FDG-PET decreases the number of futile 
laparotomies for resection of colorectal liver metastases by better detection of 
extrahepatic abdominal disease. The number of patients in which resection was 
refrained from during laparotomy because of extrahepatic intraabdominal disease 
was significantly lower in patients screened by FDG-PET. However, when surgical 
exploration of the abdomen did result in resection or local ablation of liver 
metastases, in this subgroup of the population, no significant differences between 
patients selected with or without FDG-PET were observed for both DFS and OS. 
Although many studies have evaluated the additional diagnostic accuracy of FDG- 
PET, data on the effect of FDG-PET on OS after liver resection of colorectal 
metastases are limited. Strasberg et al.22 reported a 3-year survival rate of 77% after 
resection in patients selected for liver surgery by conventional CT plus additional 
FDG-PET. The authors concluded an improved survival rate in comparison with 
previous published series, showing 3-year survival rates between 30% and 58% 
without the use of FDG-PET23-35. When identifying a comparable group of patients in 
our series— patients who underwent resection without local ablative procedures— the 
3-year survival rate in the FDG-PET group was 63.4% versus 69.9% in the group 
without FDG-PET. Since we included a well-matched control group of patients 
without FDG-PET, our series differs significantly from the study by Strasberg et al.22 
In particular because resection criteria, diagnostic protocols and CT readings were 
identical in both arms of our study. When using a well-balanced control group, the 
effect of FDG-PET on OS seems lower than reported in several other studies. Even 
more clearly, in patients who indeed underwent resection, we could not identify any 
significant difference in survival between patients selected for surgery with or without 
FDG-PET. This at least suggests that the intraoperative surgical approach to disease 
control and postoperative care were similar. Moreover, it shows that the determinants 
of survival remain primarily the biology of the tumour, its resectability and its 
response to chemotherapy, none of which apparently was altered by imaging 
techniques used primarily for lesion detection.
Similarly, technical advances in CT scanning implemented during the study do not 
seem to have had an impact on survival data. It may well be that, except for the well-
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matched control group, the identical quality of radiological reading in both groups is 
of overriding importance. It seems inevitable that a high accuracy of conventional 
radiological workup will influence the beneficial effect of additional FDG-PET 
scanning. As CT techniques improved concurrent with the use of FDG-PET, it would 
be a reasonable assumption that some patients with extrahepatic disease who may 
have been missed using older CT technology were now detected, therefore reducing 
the potential incremental yield of FDG-PET imaging.
Although FDG-PET significantly reduced the number of patients who could not be 
resected at laparotomy because of extrahepatic intraabdominal disease, FDG-PET 
had no influence on the number of patients who did not proceed to resection because 
of more extensive liver disease than estimated before surgery. In these cases, 
unexpected additional small liver lesions not detected by imaging methods before 
surgery precluded resection. As noted by various other studies, the sensitivity of 
FDG-PET for liver lesions smaller than 1 cm is relatively low, and for these cases, 
FDG-PET did not show any added value compared with CT or MRI20’22’36. The finding 
that FDG-PET mainly influences resection rates by detecting additional extrahepatic 
disease is in accordance with earlier observation by others and our own 
group13,15,19’20’37-39. Several studies9’10’12’13’15-18’20’37’40-46 show that additional FDG- 
PET may change clinical management in up to 30% of patients analysed by 
conventional workup, mainly because of additional extrahepatic lesions detected by 
FDG-PET.
In conclusion, in this study the introduction of FDG-PET reduced the number of futile 
laparotomies in patients with extrahepatic disease due to better detection of these 
tumour laesions. However, after surgical treatment, both OS and DFS were similar, 
irrespective whether or not FDG-PET was used.
The main shortcoming of the present study is that only patients were analysed who 
were already selected for explorative laparotomy either with or without additional 
FDG-PET. Thus, the precise impact and relevance of FDG-PET on clinical 
management decisions during the diagnostic workup is not taken into account. 
However, any major benefit from the addition of FDG-PET in the preoperative workup 
would have been noted in our data by improved survival in the FDG-PET group. 
Moreover, patients were not randomised, and results may have been influenced by 
the improved performance and interpretation of CT. Such issues can only be 
overcome in a randomised controlled clinical trial. To date, data from such a trial are 
not available, which means that the role of FDG-PET in patients with colorectal liver 
metastases can only be defined from well-controlled, case-mixed, cohort studies, 
such as presented here.
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Our study indicates that screening of patients with FDG-PET who are considered for 
resection of colorectal liver metastases remains appropriate. As newer modalities 
such as PET-CT become more widely available, reevaluation may be considered.
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Abstract
Background. For patients with colorectal liver metastases, resection is the treatment 
of choice. Careful selection of these patients is crucial in order to reduce the chance 
of unexpected findings at laparotomy and abandoning further surgical intervention. 
Here, we evaluate the predictive value of CT and FDG-PET of the liver and 
extrahepatic findings compared to findings during laparotomy and 6 months follow- 
up.
Methods. 131 consecutive patients, selected for hepatic surgery for colorectal liver 
metastases by CT and FDG-PET, were evaluated prospectively. During surgery, the 
liver was assessed by intra-operative ultrasound, palpation and histology.
Results. In 127 patients (97%), CT was true-positive for liver metastases. In 3 
patients, CT was false-positive and in 1 patient false-negative. In 126 patients (96%), 
FDG-PET was true-positive for liver metastases, in 2 patients FDG-PET was false- 
negative, in 3 patients true-negative (negative FDG-PET, false-positive CT). At 
laparotomy a total of 363 liver metastases was identified: 63 lesions <10 mm [10 
(16%) detected by both CT and FDG-PET], 172 lesions of 10-20 mm [123 (72%) CT- 
positive, 129 (75%) by FDG-PET-positive], and 28 lesions >20 mm [124 (97%) CT- 
positive, 121 (95%) FDG-PET-positive].
CT and FDG-PET missed approximately 30% of the smaller liver lesions, resulting in 
a significant change in clinical management during surgery in only nine patients. 
Conclusions. CT and FDG-PET have a similar diagnostic yield for the identification of 
liver metastases; both modalities being adequate on a patient-basis but inadequate 
to detect the smallest of liver lesions. However, the clinical relevance of the latter is 
limited.
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Survival in colorectal cancer is strongly associated with the stage of the disease1’2. 
Approximately 50-60%  of the patients with primary colorectal tumour develop hepatic 
metastases. These metastases are either identified at the time of diagnosis and 
treatment of the primary tumour (synchronic metastases) or during follow-up 
(metachronous metastases)3-5. Surgery is the only potentially curative treatment in a 
select group of patients with colorectal liver metastases. Data in the literature 
suggest that only 20% of the patients with colorectal liver metastases qualify for 
curative treatment6’7. After resection, 5-year survival rates between 35 and 45% have 
been reported8-11. However, in up to 50% of the patients who undergo curative liver 
resection, recurrent disease is detected in the first year after surgery. These figures 
strongly suggest that both before and during surgery minimal hepatic and 
extrahepatic metastatic disease remains undiagnosed. Therefore, a critical 
evaluation of preoperative and intra-operative diagnostic modalities is necessary.
In the last two decades, both computed tomography (CT) and magnetic resonance 
imaging (MRI) in the preoperative setting for colorectal hepatic metastases have 
been proven superior to preoperative abdominal ultrasound12’13. These techniques 
are essential to obtain information on the anatomical location of the lesions and the 
possibilities for curative surgical treatment, although recently these modalities have 
shown more and more functional imaging potential.
Positron emission tomography (PET) with 18[F]-fluorodeoxyglucose (FDG) is a 
promising and upcoming modality for evaluation of recurrent colorectal disease14-19. 
FDG-PET imaging is based on metabolic changes, instead of anatomic and structural 
changes as is the case in conventional imaging by CT or MRI. As such, FDG-PET 
has the potential of demonstrating tumour activity ahead of CT.
Most studies report on the diagnostic accuracy of FDG-PET in recurrent colorectal 
disease in general 15,19,20; only a few focus on liver involvement14’16-18. In patients 
with colorectal liver metastases FDG-PET is considered particularly important to 
identify extrahepatic disease, which is generally considered a contraindication for 
surgical treatment of colorectal liver metastases7’10’21-24. As described previously, 
approximately 25% of patients who are eligible for surgery on the basis of CT of the 
chest and abdomen are excluded from surgery by PET due to the identification of 
previously unknown extrahepatic disease18. The combination of FDG-PET with CT 
and/or MRI could allow better patient selection before hepatic surgery is performed, 
due to the fusion of functional and anatomical imaging. In patients with too extensive 
liver involvement or extrahepatic disease, futile laparotomy can thus be 
prevented11,14-20,25,26. However, the relative contribution of each technique is still not
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well defined, and this often results in either suboptimal or inappropriate use of both 
techniques.
In the present study, we evaluated the accuracy of preoperative and intra-operative 
imaging in a subgroup of patients with colorectal liver metastases, who were selected 
for liver resection by both preoperative CT of the chest and abdomen and 
preoperative FDG-PET.
MATERIALS AND METHODS 
Patients and Study Design
Between January 1999 and November 2004, 132 consecutive patients were 
identified in our prospective database of patients operated for colorectal liver 
metastases. All patients were selected for resection of colorectal liver metastases 
with a standardized diagnostic protocol consisting of diagnostic imaging by CT of 
liver, abdomen and chest, FDG-PET, and colon visualization (either colonoscopy or 
colonography with barium enema). In all patients, surgical treatment of the liver was 
considered feasible on CT, i.e. favourable localization of the liver metastases in 
relation to the main vascular and biliary structures and absence of extrahepatic 
disease except for less than three lung metastases27-30. Local recurrence had to be 
absent on colonoscopy or barium enema. FDG-PET was predominantly used to 
exclude extrahepatic disease and as an adjunct to CT to evaluate disease activity in 
the liver.
None of the patients had a history of previous liver surgery; thus excluding false 
positive findings on CT, FDG-PET and intra-operative ultrasound, due to 
postoperative fibrosis, inflammation, or altered liver architecture.
Patient and tumour characteristics were analysed according to the prognostic scoring 
system of Fong et al.22, in which the combination of five criteria (a disease-free 
interval of less than 12 months after resection of the primary tumour, number of 
tumours more than one, size of tumour more than 5 cm, node-positive primary 
tumour, and CEA >200 ng/ml) in a preoperative scoring system was highly predictive 
of poor outcome. As the Fong score proved to be highly prognostic for long-term 
outcome, it can be used to compare groups of patients for baseline prognostic 
variables between different studies22.
Postoperative follow-up after liver surgery was performed according to a stringent 
protocol: the first 3 years patients underwent a CT scan of the abdomen every 3 
months and a CT scan of the chest every 6 months, and in case CT was inconclusive 
(e.g. indiscriminant results to whether the found lesion was malignant or benign), an
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additional FDG-PET scan, an ultrasound and/or MR scan of the liver were performed. 
Disease-free survival for at least 6 months after surgery was set as the criterion that 
justified laparotomy for curative liver surgery. In case of a relapse within 6 months or 
surgery for unexpected benign disease, the laparotomy was considered not 
appropriate. This time frame was chosen because FDG-PET generally shows lesions 
6 month prior to CT and hence in this way FDG-PET could possibly have predicted 
these cases17. Furthermore, laparotomy has a profound impact on the quality of life in 
the first months after surgery31. Such negative effect on HRQoL hardly outweighs the 
benefit of resection when disease recurs within 6 months time.
CT Scanning
Multislice CT scan of the abdomen and chest was performed with a 4-slice scanner 
(Somatom Volume Zoom, Siemens, Erlangen, Germany). All patients received 900 
ml diluted ionic oral contrast (Telebrix gastro, 30 g/3 l) 1 h before the CT 
examination. A noncontrast liver scan was followed by three distinct enhancement 
phases (arterial, portal and late venous phase). In combination with the portal phase 
the whole chest and abdomen were scanned. For multislice CT in the portal venous 
phase, initially 100 ml of contrast medium was administered [100 ml Omnipaque 
(iodine 350 mg/ml; Nycomed)], from January 2003 150 ml Xenetix (iodine 300 mg/ml; 
Guerbet). In all patients an Envision CT injector (Medrad, Pittsburgh, PA, USA) was 
used, with an injection rate of 4 ml/s. The scan parameters were 120 kV and 150­
200 mAs. The detector configuration used was initially 4 x 5 mm2 (slice width 8 mm) 
and from April 2004 4 x 2.5 mm2 (slice width 3 mm). The timing of the venous phase 
was 70 s. Contiguous reconstructed sections were obtained. A Picture Archiving 
Communication System (PACS) was introduced in our hospital in April 2003. All 
images were evaluated by a radiologist with special experience in hepatic imaging.
FDG-PET
All PET scans were acquired using a full-ring dedicated PET scanner (Siemens 
ECAT Exact 47, Siemens AG, Germany). Patients fasted for at least 6 h prior to the 
study. Then all the patients had a serum glucose evaluated to interpretate potential 
poor imaging due to high glucose levels. One hour after injection of 250 MBq FDG 
(Tyco-Mallinckrodt, Petten, The Netherlands), emission images were acquired in 3D 
mode. Germanium-68 based transmission imaging was performed for attenuation 
correction. Acquisition time per bed position was 5 min for emission and 3 min for 
transmission. All PET scans were reconstructed using an iterative 2D Ordered 
Subset Expectation Maximization (OSEM) algorithm32 using default settings (two 
iterations, eight subsets, and a three-dimensional Gaussian filter of 6 mm).
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Attenuation correction was based on segmented transmission images. All images 
were evaluated by a nuclear medicine physician with more than 5 years experience 
in hepatic imaging.
Surgical Technique
Nearly all surgical procedures were performed by one experienced surgical 
oncologist (TJMR) with more than 5 years experience in hepatic surgery. Surgery 
was performed through a right subcostal incision. Upon entering the abdomen, an 
initial exploration was performed to identify any previously undetected extrahepatic 
disease. Biopsy specimens and fresh frozen sections were taken in case of 
suspicious lymph nodes or peritoneal deposits. Intra-operative ultrasound was then 
performed (see subsequently). Resection was always considered to be the treatment 
of choice. Histopathological examination was performed on all resected tissues.
When complete resection with negative resection margins was considered 
impossible, local tumour destruction by radio-frequency ablation (RFA) or 
cryosurgery (in the first 2 years of our study) was considered. Ablative techniques 
were performed in those cases in which complete tumour clearance of the liver could 
still be obtained, either by local tumour destruction alone or in combination with 
resection. Both techniques were monitored by intra-operative ultrasound. In principle, 
hepatic surgery was abandoned in case of intra-abdominal extrahepatic disease or in 
case liver lesions were too extensive to be treated completely by resection or local 
ablation. The findings at a laparotomy and any reason for unresectable disease were 
recorded prospectively (e.g. too much tumour load or an involvement of the greater 
biliary or vascular structures). After curative hepatic surgery patients did not receive 
any standard chemotherapy. Chemotherapy was only initiated in case of tumour 
recurrence that was not amenable for surgical re-intervention.
Intra-Operative Ultrasound
Intra-operative ultrasound was performed using a Toshiba Diagnostic Ultrasound 
(SSA-340 with a PVF-738H Microprobe, Toshiba/Tustin, CA, USA) to detect, 
delineate, and characterize liver lesions relative to major biliary and vascular 
structures to assess resectability. All ultrasounds were performed by a radiologist 
with more than 5 years experience in hepatic imaging.
Assessment
All CT images were reviewed by a radiologist with special expertise in hepatic and 
abdominal imaging. All FDG-PET imaging was evaluated by a nuclear medicine 
physician with expertise in FDG-PET in colorectal cancer. First, CT and FDG-PET
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were reported independently. Subsequently, results of all preoperative diagnostic 
procedures, including verification of the imaging procedures by reviewing the images, 
were evaluated in a multidisciplinary oncology meeting by surgical oncologists, 
radiologists and nuclear medicine physicians. A joint assessment of all available data 
was performed to review clinical information and diagnostic imaging on a case-by- 
case basis, in order to decide which patients qualified for surgical treatment. Also if 
treatment consisted of liver resection, tumour ablation, or a combination of both. To 
avoid a too stringent patient selection for liver resection, which could deny patients a 
potentially curative intervention, laparotomy was performed in case of conflicting or 
equivocal diagnostic results in both CT and PET (intention to treat). However, CT 
was always considered the dominant technique for clinical decision making. The gold 
standard for intra-operative lesions was considered histopathology and if this was not 
possible, the intra-operative ultrasound.
RESULTS
Patients
Table 1 shows the characteristics of the study population. A total of 131 of 132 
patients were included for evaluation.
One patient with poorly regulated diabetes mellitus and high blood glucose levels 
was excluded, as his FDG-PET scan was of poor quality and noninterpretable. No 
patients were lost to follow-up in the first 6 months after laparotomy. The interval 
between CT and FDG-PET was in most cases less than 2 weeks (mean 10.4 days, 
range 0 -32  days), and the interval between completion of the diagnostic procedures 
and surgical intervention was always less than 6 weeks, except in one patient (mean 
31.0 days, range 1-54 days).
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Table 1. Patients characteristics
Mean age at laparotomy (years) 62.8 (range 32-80)
Gender M:F 73 (56%): 58 (44%)
Localisation primary tumour
Cecum 9 (7%)
Ascending colon 11 (8%)
T ransverse colon 4 (3%)
Descending colon 6 (5%)
Sigmoid 57 (44%)
Rectum 42 (32%)
Double tumour 2 (2%)
Stage primary tumour
pT1 4 (3%)
pT2 13 (10%)
pT3 105 (80%)
pT4 9 (7%)
Nodal stage primary tumour
pN0 62 (47%)
pN1 47 (36%)
pN2 20 (15%)
pN3 2 (2%)
Fong-criteria
0 9 (7%)
1 30 (23%)
2 49 (37%)
3 38 (29%)
4 5 (4%)
5 0 (0%)
Mean disease free interval after resection of primary tumour (months) 8.8 (range 0-77)
Mean number of hepatic lesions 2.8 (range 1-13)
Mean size of hepatic lesions (mm) 42 (range 3-180)
Notes: None of the patients received neo-adjuvant chemotherapy before or adjuvant chemotherapy after liver 
resection. After resection of the primary tumour, 44 of the patients who had positive lymph nodes had received 
adjuvant chemotherapy for a period of 6 months. In none of these 44 patients, FDG-PET was performed within 
6 months after the end of chemotherapy.
Liver Metastases
As shown in Table 2, in a patient-based analyses CT detected liver metastases in 
127 patients (true-positive CT results) as compared to the findings at laparotomy, 
with intra-operative ultrasound. In three patients, the CT lesions proved to be benign 
(false-positive CT) and in one patient a liver metastasis was missed (false-negative 
CT). FDG-PET was true-positive in 126 patients, false-negative in 2 patients, and 
true-negative in the 3 patients with benign liver lesions.
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Table 2. Patient-based analysis of preoperative imaging results in 131 patients as compared 
to the histologically proven metastases at laparotomy.
Liver Extrahepatic intra-abdominal
metastases metastases
Patients with metastases, identified at 128 (98%) 10 (8%)
laparotomy
CT
True positive 127 2 a
False positive 3 3 b
True negative 0 1
FDG-PET
True positive 126 6 a
False positive 0 6 c
True negative 3 1 d
False negative 2 4
a Number of patients with lesions identified on preoperative CT or FDG-PET, but not considered unequivocally positive. The 
lesions proved to be metastases during surgery. On FDG-PET in two patients and/or on CT in six patients. 
b Two of these three patients had equivocal lesions on preoperative CT. Lesions could not be identified at laparotomy and 
initially scored as false-positive CT. Follow-up proved metastases. Thus, only one patient ultimately had a false-positive CT for 
extrahepatic intra-abdominal disease (FDG-PET was true-negative).
c Five of these six patients had lesions identified on preoperative FDG-PET, but not (or not unequivocally) identified on CT 
(considered the dominant technique). Lesions could not be identified at laparotomy and initially scored as false-positive FDG- 
PET. Follow-up however proved metastases. Thus, only one patient ultimately had a false-positive FDG-PET for extrahepatic 
intra-abdominal disease (CT was true-negative) after 6 months of follow-up.
d This patient had a false positive CT and a true negative FDG-PET, as no evidence of extrahepatic disease was found during 
surgery or follow-up.
At laparotomy, 363 histologically proven liver metastases were found with intra­
operative ultrasound and palpation. As shown in Table 3, both CT and FDG-PET 
missed most lesions smaller than 10 mm, many of which were only a few millimeters. 
Approximately 25% of lesions between 10 and 20 mm were missed by both CT and 
FDG-PET, while both techniques adequately detected lesions larger than 20 mm. 
More specifically, of the 63 lesions smaller than 10 mm, 10 were found with CT and 
10 with FDG-PET (both 16%). Of the 172 lesions between 10 and 20 mm, 123 (71%) 
were seen on CT and 129 (75%) on FDG-PET. Of the 128 lesions greater than 20 
mm, 124 (97%) were found on CT and 121 (95%) on FDG-PET.
Table 3. Detection rate of histologically proven liver metastases
Lesion size Intra-operative ultrasound and palpation CT FDG-PET CT and/or FDG-PET
<10 mm 63 10 (16%) 10 (16%) 12 (19%)
10-20 mm 172 123 (72%) 129 (75%) 142 (83%)
>20 mm 128 124 (97%) 121 (95%) 125 (98%)
All 363 257 (71%) 260 (72%) 279 (77%)
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Figure 1. Two liver metastases identified on CT (left panel), one of which was FDG-PET negative 
(right panel).
Figure 2. Liver metastasis missed on CT (left panel), but detected on FDG-PET (rightpanel).
Figures 1 and 2 show that FDG-PET and CT may be discongruent and 
complementary for detection of metastases.
During laparotomy, it proved to be technically impossible to perform a liver resection 
in 21 (16%) of the 131 patients. This was caused by too close proximity of the 
metastases to major biliary or vascular structures in 12 patients or by too extensive 
liver involvement in 9 patients; the latter being predicted by FDG-PET in 5 patients. 
Furthermore, 75 patients had hepatic resection alone, 13 patients had RFA only and 
15 had resection in combination with ablative therapy. Three patients had benign
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liver disease, not requiring any further treatment. The remaining four patients were 
not treated surgically due to irresectable extrahepatic disease.
In the first 6 months of follow-up after laparotomy 42 new liver lesions developed in 
15 patients, found by both CT and PET, suggesting that approximately 10% of liver 
metastases are too small to be detected during laparotomy, by either palpation or 
intra-operative ultrasound. Only one of these patients had a local recurrence (at the 
margin of a previous liver resection) in the liver, 14 patients had a recurrence 
elsewhere in the liver, including 1 patient with a recurrence in both the liver and the 
lung, and 1 patient with recurrence in both the liver and the lower abdomen. None of 
the three patients with benign liver lesions developed hepatic metastases in the first
6 months after surgery.
Intra-abdominal Extrahepatic Disease
As shown in Table 2, intra-abdominal extrahepatic disease was found in 10 patients 
(8%) during laparotomy. Although not unequivocally, CT had predicted extrahepatic 
disease in 2 of these patients, so it was missed in 8. In contrast, FDG-PET had 
predicted extrahepatic disease in 6 of these patients, so missed 4. In 6 patients, the 
liver metastases and the extrahepatic deposits were resected, while in 4 the 
laparotomy was terminated.
In one patient, an equivocal extrahepatic lesion on CT was considered false-positive 
as laparotomy was negative and no recurrence occurred in the first 6 months after 
laparotomy; in this case FDG-PET was negative for extrahepatic disease. In another 
patient with a no extrahepatic abnormalities on CT, FDG-PET was false-positive in a 
biopsy-proven inflammatory deposit in the abdomen. During follow-up, no metastatic 
disease occurred in this patient. In case of any discrepancies between CT and FDG- 
PET, CT was always considered the dominant technique for clinical decision making. 
Extrahepatic disease in the abdomen not identified during laparotomy was 
unequivocally diagnosed at follow-up in seven additional patients (5%). Preoperative 
CT scan showed very small abnormalities in two of these patients. FDG-PET was 
positive in five of these patients, including the two patients with abnormal CT.
Pulmonary Disease
At the time of laparotomy, eight patients (6%) were known with pulmonary disease 
(14 lesions); all had curative resections of these lesions shortly after liver resection. 
Both CT and FDG-PET predicted these pulmonary lesions. Nine patients with 
pulmonary lesions on preoperative CT had to be classified as false-positive (no 
progression during follow-up), whereas FDG-PET had no false-positive 
intrapulmonary results.
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However, in the first 6 months after the liver surgery an additional 10 patients (8%) 
unequivocally developed pulmonary lesions. None of these patients were correctly 
diagnosed on the preoperative CT, but 6 patients already had small pulmonary 
lesions on the preoperative FDG-PET. These lesions were always located in the 
perihilar regions of the lungs.
Overall Disease Activity
Figure 3 summarizes the overall results of the study. Immediately after resection of 
liver and lung metastases, 106 (81%) of the 131 patients were considered to be free 
of disease, so in 25 patients (19%) curative treatment was not possible. As indicated 
above, in 21 of these patients liver lesions could technically not be resected, and in 4 
cases laparotomy was terminated because of unresectable extrahepatic disease. 
However, in the first 6 months after surgery, 24 (23%) of the 106 patients who were 
initially considered free of disease after surgery had developed new lesions in liver, 
abdomen, lungs or multiple sites. Of these patients, 6 were eligible for a curative 
surgical re-intervention and in 18 patients surgery was considered impossible and 
systemic therapy was started. These 24 patients who developed an early recurrence 
did not differ from the rest of the surgically treated patients with respect to the 
histological grade of the primary tumour, histological grade of the metastases, or 
according to prognostic variables of the Fong classification.
6 pts: curative surgery 
Figure 3. Flowchart of patients and outcome.
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Both CT and FDG-PET contribute to the selection of patients with colorectal liver 
metastases, potentially eligible for surgical treatment. It is clear that those patients 
who are eventually taken to surgery represent a fraction of the total population of 
patients with colorectal liver metastases, which also includes those who do not 
qualify for surgery on the basis of diagnostic imaging. Nevertheless, the present 
study shows that both CT and FDG-PET have a number of limitations when 
comparing the CT and FDG-PET results to the findings during surgery and at follow- 
up. The majority of lesions smaller than 10 mm were missed by both modalities. 
However, the presence of unexpected additional small metastases did not have a 
major impact on surgical management. In only 9 of 131 (6.8%) patients, liver 
involvement was considered to be too extensive to achieve a curative resection. 
Unexpected technical issues due to close proximity of liver metastases to vessels or 
bile ducts are a relevant cause for unsuccessful surgery in 12 of 131 patients (9.2%). 
Although integrated PET-CT does have superior accuracy in patients with a history of 
prior liver surgery, it is unlikely that FDG-PET will play a major role to solve this issue 
in patients without prior liver surgery33. Nevertheless, when FDG-PET indicates more 
extensive liver disease than CT (5 of 131 patients), the impact of this finding needs to 
be evaluated carefully as it may predict irresectability during laparotomy. 
Furthermore, technical issues may become less important by improvements in CT 
and contrast-enhanced MRI33’34. In most of the patients with new liver metastases in 
the first 6 months after surgery, the CT scan was performed according the first 
protocol (i.e. 8 mm slices, 100 ml contract medium) and nearly all were read from 
film. With further optimalization of the CT liver protocol and the use of PACS, more 
adequate identification of metastases should be feasible, due to the possibility for 
peer reviewing and cataloguing of images. The same holds true for intra-operative 
ultrasound. Although it is currently considered to be the best technique to evaluate 
the liver during surgery35-37. 10% of patients develop new metastases in the first 6 
months after surgery. Although speculative, these lesions may have been present 
during laparotomy, but too small for detection. Improvement of the sensitivity of 
ultrasound e.g. by using ultrasound contrast agents38-40 may result in identification of 
more lesions, better surgical treatment and thus improving disease-free survival.
As expected in a patient population selected for surgery on the basis of CT of the 
chest and abdomen and FDG-PET, the number of patients with extrahepatic disease 
at laparotomy was low (10 patients, 8%). FDG-PET was superior to CT in predicting 
these findings, which is in line with reports that evaluate the added value of FDG- 
PET when added to the staging procedure with CT alone11,16,25. FDG-PET only
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missed four patients with extrahepatic abdominal disease, established during 
surgery. Although FDG-PET was false-positive in one patient with an inflammatory 
focus, the present study shows that positive extrahepatic intra-abdominal lesions on 
FDG-PET require very careful inspection during laparotomy. In five of six patients, 
FDG-PET findings were initially classified as false-positive during surgery, but 
metastases developed at these locations in the first 6 months thereafter. This finding 
suggests that it may be very difficult in a subgroup of patients to identify intra­
abdominal lesions at laparotomy, even if the surgeon is aware of abnormalities on 
FDG-PET and/or CT.
CT of the chest is considered the gold standard to identify lung metastases41-44. Data 
in literature suggest that small pulmonary metastases are better detected with CT 
than with FDG-PET45-47. However, the present study shows that patients with a 
negative chest-CT but FDG-positive lesions in the perihilar region of lungs should be 
monitored carefully as the FDG-PET findings are strongly suggestive of metastases.
In the present study, a curative resection could not be achieved in 25 of 131 patients 
(19%). These patients require postoperative systemic therapy. Furthermore, 24 of the 
106 patients (23%) in whom surgery was considered curative developed new 
metastases during the first 6 months of follow-up. This subgroup of patients might 
benefit from surgical re-intervention or from (initially adjuvant) systemic therapy after 
initial resection of the liver and lung metastases. In the present study, such adjuvant 
chemotherapy was not administered after hepatic resection.
In conclusion, the present study shows that in patients with colorectal liver 
metastases the frequency of unexpected findings at laparotomy is relatively low when 
using CT and FDG-PET in the preoperative work-up. The main challenge for 
improvement of diagnostic techniques is a more adequate assessment of the liver 
itself, as the liver often proves to be more involved than expected with regard to both 
the number of lesions and the exact localization. Unexpected extrahepatic FDG-PET 
findings require careful evaluation because these findings could potentially alter 
surgical patient management. FDG-PET may reveal occult disease both in the 
abdomen and chest earlier than CT. Furthermore, even at explorative laparotomy it 
appears to be very difficult to identify all metastases detected by FDG-PET.
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Abstract
Background. The current study focuses on the prognostic value of pretreatment 
metabolic activity in metastases as measured with [18F]fluorodeoxyglucose positron 
emission tomography (FDG-PET), as an indicator of survival in colorectal cancer. 
Methods. In a prospective series of 152 patients with metastatic colorectal cancer, of 
whom 67 were treated with resection of metastases and 85 with chemotherapy, 
standardized uptake values (SUV) as measured with FDG-PET, were calculated prior 
to treatment. Survival probabilities were estimated by Cox proportional regression 
analysis. For Kaplan-M eier analysis SUV was stratified by the median value. 
Survival differences were assessed using the log-rank test.
Results. SUV in metastases was a significant predictor for overall survival (hazard 
ratio 1.17, 95% confidence interval 1.06-1.30, P = 0.002), independent of the 
subsequent treatment. According to the median value of the patient population a low 
(SUV <4.26) and high uptake group (SUV >4.26) was defined. The median survival 
and the 2- and 3-year survival rates were 32 months, 59% and 45%, respectively, in 
the low-uptake group and 19 months, 37% and 28%, respectively, in the high-uptake 
group (P = 0.017).
Conclusion. A significant survival benefit was observed in patients with low FDG 
uptake in metastases of colorectal cancer.
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In Europe and in the United States, each year more than 150 000 people develop 
metastases from colorectal carcinoma1. The prognosis has improved substantially 
with the introduction of hepatic resection for treatment of isolated liver involvement 
and of effective chemotherapeutic agents. Over the past 10 years, median survival 
times for patients with advanced colorectal carcinoma have almost doubled, ranging 
from 20 months for patients with less favorable prognostic factors up to 50 months in 
patients with the most favorable prognostic factors2-4. Several chemotherapeutic 
agents can be combined, such as fluoropyrimidines, irinotecan and oxaliplatin, 
chemotherapy can be given alone or in combination with molecular-targeted agents 
such as cetuximab or bevacizumab, and one can vary in duration and sequence of 
therapy4. Furthermore, in the past two decades remarkable progress was made 
regarding the surgical techniques and postoperative management of major hepatic 
surgery5,6. Consequently, the indications for hepatectomy have been extended. As 
individualized treatment strategies become more relevant, there is a need for 
identification of novel biologic pretreatment factors that potentially predict outcome, to 
ensure that patients benefit from hepatic surgery, novel anticancer therapies and 
intensive treatment combinations. These pretreatment factors may be of particular 
value in stratifying patients for clinical trials. Therefore, there is growing interest in 
metabolic imaging of cancers.
Many malignancies, including colorectal carcinoma, have increased glucose 
metabolism. They accumulate the positron-emitting glucose analog 
[18F]fluorodeoxyglucose (FDG) and can thus be visualized using positron emission 
tomography (PET). Previous studies clearly indicated that FDG-PET is of value in the 
diagnostic work-up of patients with colorectal liver metastases and that FDG-PET as 
a complementary staging method improves the therapeutic management, especially 
by detecting unsuspected extrahepatic disease7-9. A recent study reported on 
therapy response monitoring with FDG-PET and the biologic basis of the change of 
tumor FDG uptake in patients treated with neo-adjuvant chemotherapy1. Several 
investigators have speculated that the amount of FDG uptake correlated with biologic 
factors such as Ki-67, proliferating cell nuclear antigen, Glut-1 and hexokinase1, and 
that FDG uptake resembles the biological behavior of the tumor and might be 
associated with intrinsic biologic characteristics, like hypoxia10, low apoptosis rate11, 
cell viability12, proliferative activity13 and p53 overexpression14. These characteristics 
are all potentially adverse factors in patients treated with radiotherapy or 
chemotherapy, while some of them may also impact negatively in patients treated 
surgically.
INTRODUCTION
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The advantage of FDG-PET is that it is a non-invasive, in vivo method that cannot 
only visualize, but can also quantify FDG uptake to distinguish metabolically active 
from less active tumor. This quantitative analysis of FDG uptake can be done before 
any treatment has been performed. In the current study, the predictive value of 
quantitative pretreatment FDG uptake for patient prognosis in metastatic colorectal 
carcinoma was investigated. If the amount of FDG uptake in metastases of colorectal 
carcinoma is of prognostic significance, this diagnostic modality could be an 
important adjunct to traditional staging and could improve appropriate selection of 
high-risk candidates for aggressive therapies and treatment combinations and could 
be useful as an early indicator of tumor chemosensitivity, which could help to refine 
therapeutic strategies.
PATIENTS AND METHODS 
Patients
From 2000 to 2005, a prospective series of 152 patients with histologically proven 
metastatic colorectal cancer (64 female, 88 male patients; mean age 61.6 years, 
range 33-86  years) underwent FDG-PET in the diagnostic work-up before a decision 
was made between surgical resection of metastases or treatment with 
chemotherapy. Exclusion criteria were poorly regulated diabetes mellitus and 
pregnancy. Follow-up closed on 1 December 2005.
FDG-PET
A dedicated PET scanner (ECAT-EXACT, Siemens/CTI, Knoxville, TN, USA) was 
used for data acquisition. Prior to FDG injection, patients fasted for at least 6 h. One 
hour after intravenous injection of 200-220 MBq FDG (Mallinckrodt Medical, Petten, 
The Netherlands), emission and transmission images were acquired. The images 
were corrected for attenuation and reconstructed using the ordered-subsets 
expectation maximization (OSEM) algorithm.
FDG-PET analysis
All patients underwent FDG-PET within 6 weeks prior to treatment. Two experienced 
nuclear medicine physicians primarily interpreted FDG-PET images for staging on 
the basis of a visual inspection. For this study, all studies were reanalyzed to acquire 
semiquantitative data. For that purpose volumes of interest were drawn around all 
metastases using an automatic 50% isocontour (ECAT software tool), which 
enclosed pixels with 50% or more of the maximum radioactivity within the volume of
98
Prediction of Survival
interest. Standardized uptake values (SUV) were calculated using the concentration 
of FDG in the volume of interest as measured by PET, divided by the injected dose 
and multiplied by body weight as a normalization factor. A volume weighted mean 
value of each PET scan was derived from all lesions to give one average SUV 
(SUVavg, hereafter SUV) for each PET scan. Survival data served as a reference for 
the FDG-PET data.
Treatment
Surgical decision-making, as well as the decision for chemotherapy, was made by a 
multi-disciplinary team including surgeons, medical oncologists, radiation oncologists, 
pathologists, radiologists and nuclear medicine physicians for all patients. Resection 
of metastases was considered the treatment of choice in case CT and FDG-PET 
indicated resectable liver metastases and/or less than three resectable lung 
metastases in the absence of other extrahepatic disease. Hepatic causes for 
irresectability included involvement of major blood vessels or extensive bilobar liver 
disease, which would either preclude negative resection margins or would result in 
inadequate hepatic reserve. After curative surgery, patients were considered to be 
free of disease. Curative liver resection was defined as any procedure (resection, 
radiofrequency ablation or the combination of both) that rendered the patient free of 
all hepatic disease. Patients not eligible for surgery were treated with 5-fluorouracil 
(5-FU) based chemotherapy in combination with leucovorin (LV), capecitabine, 
irinotecan or combination therapy (capecitabine with irinotecan or 5-FU with 
oxaliplatin and LV) as first-line treatment. Irinotecan or capecitabine in combination 
with oxaliplatin was given as second-line treatment.
Clinical follow-up
Overall survival was defined as the time interval from date of FDG-PET until death 
related to malignancy or date of last follow-up. In the surgically treated patient group, 
disease-free survival was also estimated. Disease-free survival was defined as the 
time interval between FDG-PET and the first recurrence of the disease (local-regional 
or distant recurrence). Follow-up was performed according to a stringent protocol for 
3 years. Apart from clinical examinations, routine laboratory tests and 
carcinoembryonic antigen (CEA) measurement, patients underwent a CT scan of the 
abdomen every 3 months and a CT scan of the chest every 6 months and, in cases 
of inconclusive findings on CT, an additional FDG-PET scan, an ultrasound and/or 
MR scan was performed. For the surgically treated group the variables that form the 
prognostic scoring system according to Fong et al.15 (node-positive primary, disease- 
free interval from primary to metastases, number of liver metastases, diameter of the
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largest liver lesion, and the preoperative CEA level) were also recorded 
prospectively. These five variables were dichotomized into a low- and a high-risk 
category. A patient variable was assigned to the high-risk category if the disease-free 
interval was 12 months or more after resection of the primary tumor, if the number of 
liver lesions was more than one, if the largest liver lesion was more than 5 cm, if the 
primary tumor was node-positive and if the preoperative CEA level exceeded 200 
ng/ml. The clinical risk score according to Fong et al. assigns each of the five criteria 
one point if it is part of the high-risk category, resulting in a score of zero to five.
Statistical analysis
The predictive value of SUV for overall and disease-free survival was determined. 
The main end point was overall survival. Overall and disease-free survival 
probabilities were estimated by the univariate Cox regression analysis and the 
estimated hazard ratio and 95% confidence interval (CI) were reported. SUV, 
disease-free interval from the primary to discovery of the liver metastases (months), 
number of liver metastases, diameter of the largest liver lesion (cm) and the 
preoperative CEA level (ng/ml) were analyzed as continuous variables. Invasiveness 
of the primary tumor (pT), nodal status of the primary (pN) and the histologic grade of 
the primary were analyzed as categorical variables. The overall survival curve with 
respect to SUV was generated using Kaplan-M eier estimates. SUVs were stratified 
by the median value to avoid data-driven significance for the cut-off level. 
Significance of the differences between the low and high SUV group was assessed 
using the log-rank test. Spearman's rho correlations were used to determine 
associations between the SUV and the degree of tumor cell differentiation of the liver 
metastases and the SUV and the Fong's score. Statistical analyses were performed 
using the SPSS 12.0.1 package. Statistical tests were based on a two-sided 
significance level and the level of significance was set at 0.05.
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RESULTS 
Patients
The median follow-up was 17 months (range 2-61 months) for surviving patients. At 
the closeout date 71 of the 152 patients had died. No patients were lost to follow-up. 
Assessment of preoperative CT and FDG-PET revealed that most patients had 
metastatic involvement of the liver (n = 149). Lung metastases were found in 14 
patients. The histological tumor type was adenocarcinoma in 134 patients, mucinous 
adenocarcinoma in three patients, adenocarcinoma with some mucinous 
components in 13 patients, adeno-acanthoma in one patient and adenocarcinoma 
with neuroendocrine morphology in one patient. In 67 patients, liver surgery with 
curative intent was performed, using resection (n = 42), radiofrequency ablation (n = 
9) or resection combined with radiofrequency ablation (n = 16). Four out of these 67 
patients received chemotherapy postoperatively. In 85 patients, metastases were not 
resectable. In first-line treatment these patients received capecitabine, irinotecan or 
combinations of capecitabine and irinotecan or 5-FU (with or without oxaliplatin) and 
LV (n = 72). In second-line treatment patients received irinotecan or capecitabine in 
combination with oxaliplatin (n = 13).
Survival
In the surgically treated patients disease-free survival was estimated using the Fong- 
criteria as an independent variable (Table 1). During follow-up 35 out of the 67 
surgically treated patients presented with recurrent disease and 32 remained 
disease-free. The aggregated Fong-criteria proved to be a predictor for disease-free 
survival (hazard ratio 1.75, 95% CI 1.24-2.47, P = 0.002) as shown in Table 1. The 
individual variables that are assessed in the prognostic scoring system of Fong were 
not predictive for recurrence or survival (Table 1). There was no association between 
SUV and Fong's score (r = -0.006, P = 0.96) or between SUV and the degree of 
tumor cell differentiation of the liver metastases (r = 0.04, P = 0.66). Median overall 
survival in the whole group was 15.5 months (range 1-61 months). Median overall 
survival in the surgery group was 22 months (range 2-61 months), which was 
significantly longer than the median survival in the chemotherapy group (12 months, 
range 1-54 months, P < 0.001).
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Table 1. Results of univariate Cox proportional regression analysis for predicting overall survival and 
disease-free survival in the surgically treated group (n = 67)
Variable
Overall survival P value Disease-free survival P value
Hazard ratio 95% CI Hazard ratio 95% CI
pT 1.34 0.47-3.78 0.59 1.87 0.69-5.10 0.22
pN (dichotomized N0 versus N1-3)a 0.93 0.47-1.84 0.82 1.01 0.65-1.58 0.95
CEA preoperative (ng/ml)a 1.11 0.81-1.52 0.51 1.13 0.93-1.36 0.23
Disease-free interval (month)a 0.99 0.94-1.04 0.62 1.00 0.97-1.03 0.88
Number of liver metastases3 0.97 0.78-1.20 0.76 1.03 0.91-1.17 0.65
Largest liver lesion (mm)a 1.25 0.54-2.90 0.60 0.88 0.51-1.53 0.66
Histologic grade of primary tumor 0.85 0.52-1.36 0.49 1.12 0.79-1.58 0.52
Fong criteria 1.34 0.80-2.22 0.27 1.75 1.24-2.47 0.002
‘ Variables that are assessed in the prognostic scoring system according to Fong et al.
FDG uptake
For the whole study population, the mean and median of the SUV were 4.33 and 
4.26, respectively (range 0.5-12.14). In the group of patients who underwent curative 
liver surgery (n = 67), the mean and median of the SUV were 3.65 and 3.60 (range 
0.80-9.60). In the chemotherapy group (n = 85), the mean and median of the SUV 
were 4.86 and 4.66 (range 0.50-12.14), being significantly higher than in the surgery 
group (P < 0.03). The mean SUV in the group of patients, who remained free of 
disease after hepatic resection, was not significantly different from the mean SUV in 
the group of patients with recurrent disease after hepatic resection (3.47 ± 1.69, n = 
35 versus 3.84 ± 1.96, n = 32, respectively).
Prediction of survival by FDG-PET
Although median SUV proved to be higher in the group of patients treated with 
chemotherapy compared with patients treated by surgery, the SUV of individual 
patients proved to be highly variable and largely overlapping in both groups. 
Therefore, SUV of metastatic lesions was evaluated for the whole group. SUV of the 
metastases proved to be an independent and significant predictor for overall survival 
(hazard ratio 1.17, 95% CI 1.06-1.30, P = 0.002), irrespective of the subsequent 
choice of therapy (i.e. surgery or chemotherapy). A one-unit increase in SUV
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corresponded to a 17% increase in the risk of death. To generate Kaplan-M eier 
survival curves, SUV values were dichotomized at 4.26, being the median value of 
the study cohort. The Kaplan-M eier survival analysis further confirmed the value of 
SUV to predict survival, as the difference in survival was highly significant (P = 0.017, 
log-rank test, Figure 1). The 2-year survival rates according to Kaplan-M eier were 
59% in the low-uptake group (SUV <4.26) and 37% in the high-uptake group (SUV 
>4.26); the 3-year survival rates were 45% in the low-uptake group and 28% in the 
high-uptake group. Median survival in the low-uptake group was 32 months and 19 
months in the high-uptake group. At the closeout date, 32 of 76 patients in the low- 
uptake group and 39 of 76 patients in the high-uptake group died of their disease. 
There was no difference in age or gender when comparing the low-uptake group 
(mean age 62.0 years, 31 females, 45 males) with the high-uptake group (mean age 
61.2 years, 33 females, 43 males). The hazard ratio did not change significantly 
when analyzing the SUV of just one lesion per PET-scan, i.e. the SUV of the most 
FDG avid lesion of the patient (hazard ratio 1.19, 95% CI 1.08-1.31, P <0.0001). 
Also the median survival and the 2- and 3-year survival rates were comparable, 
being 32 months, 59% and 45%, respectively, for the low-uptake group (SUV <4.53) 
and 19 months, 36% and 28%, respectively for the high-uptake group (SUV >4.53).
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Figure 1. Kaplan-Meier analysis of the relationship between SUV (dichotomized using median value 
of 4.26) and overall survival.
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DISCUSSION
Compared with the tumors of patients with colorectal liver metastases who were 
taken to surgery, the tumors of patients who underwent chemotherapy were on 
average metabolically somewhat more active, which may reflect enhanced tumor 
aggressiveness. However, uptake of FDG in tumors proved to be highly variable 
within the two treatment groups with considerable overlap between the groups. 
However, when analyzing SUV for the whole group, the metabolic activity of the 
metastatic colorectal carcinoma as depicted by FDG uptake, proved to be a 
significant independent predictor for overall survival, regardless of whether patients 
subsequently underwent curative surgery or chemotherapy. A one-unit increase in 
SUV corresponded to a significant increase in the risk of death with 17%. When 
dichotomizing SUV values at the median value of the patient population, there was a 
highly significant difference in survival, as patients in the low-uptake group had a 
median survival of 32 months, compared with 19 months in the high uptake group. 
Comparable survival rates and hazard ratio were observed when analyzing all 
metastases or only the most FDG avid (i.e. the most aggressive) lesion.
It is well established that patients with unresectable disease have a much poorer 
outcome than patients with resectable disease. The 5-year survival for hepatic 
metastasectomy now approaches 30% -40% , with a median survival up to 50 months 
in patients with the most favorable prognostic factors. Unresectable patients who are 
treated with current state-of-the-art multidrug systemic therapy have a median 
survival of 18-20 months3. However, many of the patients treated with systemic 
therapy have more advanced disease than patients who are selected for liver 
metastasectomy, which may contribute to the difference in survival observed 
between these groups4. Nevertheless, the present study suggests that metabolic 
activity of the metastases is also an important factor, since SUV proved to be an 
independent predictive factor for survival, no matter if the patient had resectable or 
irresectable, more widespread disease. Thus, our data indicate that intense glucose 
metabolism in metastases of colorectal cancer is a negative marker of prognosis.
To the best of our knowledge, there are no studies addressing the predictive value of 
FDG uptake for survival in metastatic colorectal carcinoma. However, our results are 
in line with the results of previous reports on the prognostic information of FDG 
uptake in patients with primary tumors such as non-small-cell lung cancer 
(NSCLC)16-22, head and neck squamous cell carcinoma (HNSCC)23-29, breast 
cancer14, 30, 31, glioma32, esophageal carcinoma33, 34, pancreatic cancer35-38 and 
hepatocellular carcinoma39.
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As early as 1985, Patronas et al.32 already reported a significant correlation between 
FDG uptake and survival in patients with gliomas. Several studies in patients with 
NSCLC treated with complete resection reported that SUV and pathologic tumor size, 
provided excellent independent prognostic information16, 17, 19. The combination of 
SUV and pathologic tumor size identified a subgroup of patients at highest risk of 
death as a result of recurrent disease after resection. Other studies in NSCLC found 
that staging of tumor-node-metastasis and SUV were independent prognostic 
variables20-22. However, the SUV for the primary tumor was the strongest prognostic 
factor, whereas the prognostic ability of the SUV for the regional lymph nodes 
remained uncertain. There was an indication that primary tumors showing high SUVs 
have the potential to be resistant to therapy and to metastasize22. Jeong et al. found 
that the SUV of squamous cell carcinoma was higher than that of 
adenocarcinomas20.
Previous clinical series in HNSCC23-29 also suggested that highly elevated primary 
tumor FDG uptake predicted worse prognosis. It was shown that patients with an 
advanced clinical stage26 or tumors of lesser differentiation25, 26 display higher FDG 
uptake and that higher baseline SUV predicted inferior response to radiotherapy, 
local disease control, and survival27, 29.
In pancreatic cancer SUVs were also introduced as a new metabolic predictor of 
prognosis35-38. Most previous studies in this tumor type demonstrated that tumor- 
associated histologic characteristics are important in defining prognosis. However, 
most of them were available only after a resection procedure has been performed36. 
In another series of pancreatic cancer, the SUV was not able to predict survival in a 
subgroup of patients with resectable tumors35. In the subgroup with unresectable 
tumors, however, SUV proved to be an independent prognostic indicator for overall 
survival. In breast tumors FDG uptake was also a significant predictor of prognosis30 
and some investigators14, 31 examined the possible association between FDG uptake 
and several histopathological and immunohistochemical factors. The results of the 
present study also support the hypothesis that FDG uptake reflects biological
23aggressiveness23.
In conclusion, pretreatment FDG uptake in metastatic colorectal cancer predicts 
outcome, irrespective of the subsequent treatment modality, as patients with FDG 
avid disease show reduced overall survival. FDG-PET could become an important 
adjunct to traditional staging to improve appropriate selection of high-risk candidates 
for aggressive multimodality treatments and could be helpful in stratifying patients for 
prospective studies when different therapeutic options are to be compared.
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Abstract
Background. With the increasing possibilities for surgical treatment of colorectal liver 
metastases, careful selection of patients who may benefit from surgical treatment 
becomes critical. Staging by positron emission tomography (PET) with 18- 
fluorodeoxyglucose (18FDG) is thought to improve conventional staging by CT. Up to 
now, however, evidence that the addition of FDG-PET leads to superior clinical 
results and improved clinical management in these patients is lacking. In this 
randomized controlled trial in patients with colorectal liver metastases we 
investigated whether the addition of FDG-PET is beneficial and reduces the number 
of futile laparotomies.
Methods. 150 patients with colorectal liver metastases selected for surgical treatment 
by imaging with CT scan were randomly assigned to CT imaging only (n=75) or CT 
imaging plus FDG-PET (n=75). Follow up was performed for at least 3 years. 
Outcome measures were the number of futile laparotomies, disease free and overall 
survival. Futile laparotomy was defined as any laparotomy that did not result in 
complete tumour treatment, that revealed benign disease or that did not result in a 
disease free survival period longer than 6 months.
Results. Demographics, patient and tumour characteristics were similar for both 
groups. The number of futile laparotomies was 34 (45%) in the control arm without 
FDG-PET and 21 (28%) in the experimental arm with FDG-PET, the relative risk 
reduction for futile laparotomy was 38% (95% CI = 4-60, P= 0.042). Thee year overall 
and disease-free survival were comparable between both groups 
Conclusion. The addition of FDG-PET to the work-up for surgical resection of 
colorectal liver metastases prevents unnecessary surgery in one out of six patients. 
In the group randomized for FDG-PET, this improved selection was not 
counterbalanced by a decrease of overall or disease-free survival.
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INTRODUCTION
Liver metastases are an important issue in the treatment of colorectal cancer. After 
apparently curative resection of the primary tumour, the liver is often the first site of 
metastatic disease and may be the only site of spread in as many as 30% of the 
patients1, 2. Hepatic resection is the only potentially curative treatment in a subset of 
patients with colorectal liver metastases. Eligibility for hepatic surgery depends on 
the possibility to completely resect all metastases while maintaining adequate liver 
reserve. There should be no extrahepatic disease, with the possible exception of one 
or few resectable lung metastases3.
To assess whether these strict criteria are met, conventional staging consists of 
contrast enhanced CT or MRI of the liver with additional abdominal and chest CT to 
exclude extrahepatic disease. Despite current diagnostic work-up, up to 40% of 
patients prove to have unresectable liver metastases at the time of surgery4-7. 
Moreover, within one year after potentially curative resection up to 50% of patients 
show metastatic disease elsewhere, suggesting unrecognized tumour foci at the time 
of hepatic resection despite extensive radiological imaging8-11. Therefore, more 
accurate staging of patients with colorectal liver metastases is needed to restrict 
surgical treatment to those who will potentially benefit.
Recently, positron emission tomography (PET) with fluorine-18-deoxyglucose (FDG) 
has been introduced as an additional staging modality in patients with colorectal liver 
metastases. Being a functional imaging modality, FDG-PET may be of value in the 
characterization of liver lesions or the detection extrahepatic disease. Descriptive 
studies on the use of FDG-PET have shown an average sensitivity in detecting 
hepatic metastases of approximately 75% 12, 13. Moreover, FDG-PET imaging 
improved detection of extrahepatic disease and changed the treatment plan in 25­
30% of the patients14-17.
These studies were generally aimed at the assessment of accuracy. Such studies 
are subject to bias and may lead to overestimation of the added value of FDG-PET. 
Consequently, in the absence of randomized data it remains unclear whether the 
introduction of FDG-PET to the work-up of patients with potentially resectable liver 
metastases may indeed prevent unnecessary surgery, being surgery not resulting in 
a complete tumour clearance. As in the assessment of new treatments, a 
randomized study that compares the standard of care with the new diagnostic 
strategy is required to comply with the ever-increasing need for evidence based 
practice. In the present prospective randomized trial, we investigated the value of the 
addition of FDG-PET to conventional CT-based diagnostic imaging in patients
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considered eligible for hepatic surgery of colorectal liver metastases. Outcome 
measures were the number of futile laparotomies, disease free and overall survival.
PATIENTS AND METHODS
Study design, eligibility and randomization
Patients were enrolled in a phase III randomized, multicentre trial between May 2002 
and February 2006. Eligible patients were required to have a history of histologically 
documented colorectal cancer treated by R0 surgical resection (tumour-free 
resection margins), suspicion of one to four potentially resectable colorectal liver 
metastases without evidence of extrahepatic metastatic disease (with exception of a 
maximum of two resectable lung metastases) on contrast enhanced CT scan of the 
abdomen, pelvis and chest, no signs of recurrent or second colorectal carcinoma on 
barium enema or colonoscopy, age 18-75 years and WHO performance status 0-2. 
Exclusion criteria included other previous malignancies other than in situ carcinoma 
of the cervix or non-melanoma skin cancer unless a disease free interval of at least 
10 years, signs of liver dysfunction (bilirubin, alkaline phosphatase > 3 times the 
upper limit of normal), active infection and poorly regulated diabetes mellitus. The 
study was approved by the institutional review boards of all participating centres, and 
all patients provided written informed consent. Four surgical departments 
experienced in liver surgery and three centres for nuclear medicine experienced in 
FDG-PET participated in this trial.
After standard work-up by CT imaging, all patients were evaluated for eligibility by a 
multidisciplinary oncology team, including a surgeon and a radiologist specialized in 
hepatobiliary oncology. Resectable disease was defined as the possibility to obtain 
negative resection margins with sufficient future liver remnant, after meticulous 
assessment of CT chest and abdomen by the multidisciplinary team. When 
considered eligible for potentially curative hepatic resection, patients were randomly 
assigned to the conventional arm (control arm) using no further imaging beyond CT 
scan or to the experimental arm using additional FDG-PET.
Randomization was performed at the central trial office (by central telephone) and 
was based on permuted blocks of four, with stratification according to centre. When 
randomized to the experimental arm, additional whole body FDG-PET was 
performed, generally within 2 weeks (range 1-5 weeks), and results of both CT 
imaging and FDG-PET scan were again reported at a multidisciplinary oncology 
meeting. A joint assessment of all available data was performed to review clinical 
information and diagnostic imaging on a case-by-case basis. In case of discordance
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between CT and FDG-PET, it was at the referring surgeon’s discretion to refrain from 
surgical resection, opt for additional imaging (e.g. another CT-scan or MRI-scan) or 
additional diagnostic procedures (e.g. ultrasound guided biopsy), or to still attempt 
surgical resection of the liver metastases.
IMAGING, SURGICAL PROCEDURE AND QUALITY CONTROL
CT imaging
During the study period all CT examinations of the abdomen (including pelvis) and 
chest were performed with multi detector CT scanners. A non contrast liver scan was 
followed by three distinct enhancement phases (arterial, portal and late venous 
phase). In combination with the portal phase the whole chest and abdomen were 
scanned. Intravenous contrast agent containing 35 -  45 g iodine was injected. The 
timing of the venous phase was 70 s. All patients received about 1 litre diluted ionic 
oral contrast 1 hour before the CT examination. The scan parameters were 120 kV 
and 150-200 mAs. Reconstructed section thickness was 3-5 mm using a lung and 
soft tissue reconstruction kernel. All examination results were stored on an optical 
disc for further review and were evaluated by two radiologists with special experience 
in hepatic imaging.
FDG-PET
Patients were referred to one of the 3 participating PET-centres. Patients were fasted 
for at least 6 hours. Patients were hydrated with sugar-free liquids. Patients received 
a dose of approximately 4 MBq of FDG per kilogram bodyweight. Scans were 
acquired 60-90 minutes after FDG injection on either ECAT Exact HR+ or ECAT 
Exact PET-scanners (Siemens CTI, Knoxville TN). All scans were visually analyzed 
by experienced nuclear medicine physicians. Standardized uptake values (SUV) 
were not calculated. At the time of the study integrated PET-CT scanners were not 
available in the participating centres.
Surgical procedures
Laparotomy was performed generally within 4 weeks after randomization (range 1-7). 
At laparotomy, careful examination of the abdominal cavity was performed for extra­
hepatic disease. In case of any suspicion of extra-hepatic disease, biopsies were 
taken for frozen sections. When positive, further surgical treatment was at the 
surgeon’s discretion, as long as complete tumour clearance could be obtained, 
otherwise further surgical treatment was abandoned by protocol.
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Intra-operative ultrasound was performed to detect and localize all metastatic liver 
lesions. In case intra-operative examination showed more than four lesions, surgical 
treatment was still performed when possible. Surgery was aimed at obtaining tumour 
negative resection margins, when possible with a safety margin of more than 1cm. 
The type of liver resection (anatomical, wedge or combination) as well as the 
additional use of radiofrequency ablation was at the surgeon’s discretion. After 
hepatic surgery, patients did not receive any standard (adjuvant) chemotherapy. 
Chemotherapy was only started in case of unresectable disease or tumour 
recurrence that was not amenable for surgical re-intervention. During the study 
period systemic chemotherapy consisted of 5-fluorouracil (5-FU), leucovorin and 
oxaliplatin in the first line and irinotecan in the second line. Since 2005, bevacizumab 
was added to the standard chemotherapy regimen.
Follow-up
All patients were followed prospectively at regular predetermined intervals. After 
hepatic resection standard follow up during the first 9 months consisted of 3 monthly 
serum CEA levels and abdominal and chest contrast enhanced CT. Thereafter, 
patients with normal CEA levels before hepatic resection continued this regimen for 
the next 3 years, while patients with elevated CEA levels before hepatic resection 
were followed up by 3 monthly CEA levels, abdominal ultrasound and chest X-ray for 
the next 3 years. In case of inconclusive findings additional imaging (e.g. MRI or 
FDG-PET) or diagnostic procedures (e.g. biopsy) were used to determine a 
recurrence of disease.
Statistical analysis
The primary outcome measure of the study was the number of futile laparotomies. 
Futile laparotomy was defined as any laparotomy that did not result in complete 
tumour clearance either intrahepatic or extrahepatic, that revealed benign disease at 
laparotomy or histopathological examination, or that did not result in a disease-free 
survival period longer than 6 months. The time frame of 6 months was chosen 
because of the apparent lead time FDG-PET as compared to CT18.
At the time of study design, data in literature suggested that 60% of the patients who 
undergo laparotomy for colorectal liver metastases would have curative hepatic 
resection by intention4, 6’ 7. The study was designed to detect a 15% reduction in the 
number of futile laparotomies. To detect such a difference 75 patients were needed 
in each study arm.
For testing differences in clinical outcome measures, p-values of 0.05 or less were 
considered to be statistical significant. Disease-free and overall survival was
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assessed from the day of randomization. Data on patients who were alive or free of 
recurrence were censored at the time of last follow-up. The rate of recurrence was 
calculated on the basis of all eligible patients undergoing laparotomy.
Disease-free and overall survival analyses were performed by the Kaplan-Meier 
method. All statistical analyses were performed with SPSS statistical software 
(version 15.0). For the membership of groups, Fisher's exact test was used and t- 
tests for the quantitative measures. Group differences for survival were analysed with 
the logrank test.
RESULTS
Characteristics of patients
A total of 150 eligible patients were randomly assigned to one of the two diagnostic 
strategies. All 150 patients were evaluable and met the inclusion criteria for 
considering hepatic resection of colorectal liver metastases. No patients were lost to 
follow up. Patient and tumour characteristics were similar between the two strategy 
groups (Table 1). None of these patients received pre-operative chemotherapy. For 
further comparison, both strategy groups were analyzed according to the prognostic 
scoring system for hepatic resection of colorectal liver metastases according to Fong 
et al.19. The distribution of the various prognostic scores was identical in both groups.
Futile laparotomies
Additional FDG-PET findings resulted in cancellation of planned resection of the 
suspected liver metastases in 5 patients. Follow up learned that FDG-PET correctly 
predicted benign disease in 2 patients and unresectable extrahepatic disease in 3. 
So, in total 75 patients in the conventional arm without FDG-PET and 70 patients in 
the experimental arm with FDG-PET underwent laparotomy (Table 2). Potentially 
curative treatment (R0 resection) could be performed in 58 (77%) patients in the 
conventional arm and in 63 (84%) patients in the experimental arm.
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Table 1. Demographics.
Control arm Experimental arm P-values
(CT) (CT+PET)
N=75 N=75
Age in years (range) 62.9 (37.9-79.9) 62.6 (32.8-78.1) 0.94
Gender (female:male) 19:56 27:48 0.21
Primary tumour 
pN0 
pN >1
34
41
32
43
0.87
Disease free survival 
<12 months 
>12 months
29
46
35
40
0.40
Number of hepatic tumours*
1 41
>1 34
42
33
1.0
Size of greatest hep. tumour*
<50mm 60
>50mm 15
58
17
0.84
CEA preoperatively 
<200 
>200
75 75
1.0
Fong criteria 0.76
0 9 7
1 17 24
2 29 24
3 19 19
4 1 1
5 - -
* As preoperatively predicted on CT, at time of randomization. No significant statistical differences 
were found between the groups.
116
Selection of Patients in a Randomized Clinical Trial
Table 2. Primary outcome measure.
Control arm Experimental arm (PET)
N=75 N=75
No laparotomy 0 5
Confirmed benign disease - 2
Confirmed extra-hepatic disease - 3
Laparotomy 75 (100%) 70 (93%)
Non-futile laparotomy 41 (55%) 49 (65%)
Futile laparotomy 34 (45%) 21 (28%)
Extra-hepatic disease* 6 2
Too extensive liver disease* 8 3
Benign disease at laparotomy 3 2
Benign disease after resection 1 1
Disease recurrence < 6 months 16 13
* not resectable or too extensive to perform potentially curative resection
At laparotomy, 17 (23%) patients in the conventional arm and 7 (9%) patients in the 
experimental arm either showed significant additional findings precluding any further 
curative surgical treatment or showed benign disease, both of which leading to futile 
laparotomy (p = 0.043). In both groups one additional patient underwent futile 
resection because of benign disease shown at definite histopathological examination. 
In addition, follow-up showed disease recurrence within 6 months after surgical 
treatment in 16 and 13 patients in the conventional and experimental group, 
respectively.
As a result a significant greater proportion of patients underwent futile laparotomy in 
the control arm without FDG-PET (45%) than in the experimental arm with FDG-PET 
(28%) (P= 0.042). The relative risk reduction was 38% (95% CI: 4-60). The absolute 
difference of 17% means that 6 patients need to undergo FDG-PET scan to avoid 
one futile laparotomy. Futile laparotomy was not related to other prognostic factors as 
measured by the Fong score (P = 0.539).
Survival
All patients were follow up at least three years after randomization. For all patients 
randomized, three year overall and disease free survival in the experimental group 
was 41,3% and 24,0%, respectively. In the control group these figures were 45,3%
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and 24,0%, respectively. Both overall and disease-free survival were not statistically 
different, respectively P=0.310 and P= 0.375 (Figures 1 and 2).
Figure 1. Kaplan Meyer analysis for disease-free survival. Numbers at risk mentioned at 
corresponding months. CT = computed tomography, PET = positron emission tomography
Figure 2. Kaplan Meyer analysis for overall survival. Numbers at risk mentioned at corresponding 
months. CT = computed tomography, PET = positron emission tomography
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FDG-PET findings
In 7 patients, FDG- PET detected additional extrahepatic disease initially missed on 
CT scan. Lung or mediastinal metastases in 5 patients and extensive abdominal 
lymph node metastases in 2 cases. Re-assessment of CT scan confirmed 
extrahepatic disease in one patient with multiple mediastinal and pulmonary 
metastases and in both patients with abdominal extrahepatic (i.c. nodal) disease. In 
these patients futile laparotomy was avoided. In the other 4 patients, chest lesions 
predicted on FDG-PET did not result in any change of strategy and hepatic resection 
was performed. In all 4 patients mediastinal and or lung metastases were confirmed 
by chest CT within 6 months after hepatic resection.
In 5 patients, FDG- PET showed benign liver disease. Laparotomy was cancelled in
2 cases, in whom additional follow-up in the first year of randomisation confirmed 
benign lesions. The multidisciplinary team disregarded the FDG-PET result in 3 
cases after assessment of all available data, which all 3 proved to be benign at 
laparotomy. In two of these patients, laparotomy showed haemangioma or multiple 
cysts, not requiring any surgical intervention. One patient underwent resection of a 
deep seeded lesion not recognised as a benign fibrotic lesion at laparotomy.
In 18 patients, FDG-PET showed additional liver findings discordant with CT. In 15 
patients, additional liver lesions were observed (1 in 11 pts, 2 in 3 pts and 6 in 1 pt). 
In all these fifteen patients the clinical team decided that hepatic resection was still 
possible and FDG-PET did not influence the treatment decision for hepatic surgery. 
Indeed, all patients eventually underwent potentially curative resection. In the other 3 
patients, however, FDG-PET predicted extensive central liver involvement judged 
resectable on CT but most likely unresectable on FDG-PET, due to greater size of 
the metastases than anticipated after CT. In all three patients resection was judged 
impossible at laparotomy and further surgical treatment was cancelled.
Thus, FDG-PET predicted futile laparotomy in at least 15 patients. However, the 
clinical team disregarded the FDG-PET result in 10 of these cases and proceeded to 
laparotomy.
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DISCUSSION
Futile laparotomy is a significant issue in patients taken to surgery for potentially 
resectable colorectal liver metastases. In the present randomized study we show that 
the addition of whole body FDG-PET to a full CT-based conventional work-up of 
patients with potentially resectable liver metastases from colorectal cancer actually 
reduces the number of futile laparotomies by 38%. Furthermore, this study also 
shows that disregarding FDG-PET findings by the multidisciplinary team was 
responsible for 10 (48%) futile laparatomies in the FDG-PET group. Thus, a 
retrospective scenario analysis indicated that if the correct clinical decision was made 
by accepting FDG-PET findings, the number of futile laparatomies would have been 
reduced even further to more than 65%.
For disease free and overall survival (OS), no differences were found in the first three 
years of follow-up. Any difference in OS is expected to appear after a longer follow- 
up. So, although less laparotomies were performed in the experimental group as 
compared to the conventional group, this was not at the expense of a decrease in 
DFS or OS.
The results we observed in our study could differ from the hypothesis when designing 
the study due to the fact that all CT scans were more extensively reviewed than 
standard by an expert panel before patient was assessed for randomization. This 
means that in daily practice the value of additional FDG-PET may even be higher 
than observed in the present study. Moreover, the most favorable category of 
patients with liver metastases were included being patients with a maximum of 4 liver 
lesions. There is, however, an increasing trend to consider also patients with more 
significant liver involvement for surgical resection of the liver metastases. It is very 
well feasible that the clinical impact of the addition of FDG-PET in patients with more 
extensive liver disease may even be higher.
The results of the current study confirm the results of previous retrospective and non­
randomized studies, which were recently summarized in two meta-analyses12, 16. 
Bipat et al. showed that FDG-PET had a significantly higher sensitivity on a per 
patient basis for detection of liver metastases, compared with that of the other 
modalities12. However, on a per lesion basis, sensitivity of CT, MR imaging and FDG- 
PET was similar. In earlier studies we concluded that the combined sensitivity and 
specificity of FDG-PET has added value in the diagnostic work-up of patients with 
colorectal liver metastases in preoperative staging, especially for excluding or 
detecting extrahepatic disease16. Sahani et al. also reported that FDG-PET provided 
additional information about extra-hepatic disease as compared to MRI, which itself 
proved more useful in detecting smaller liver metastases20.
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The current study was performed using stand-alone PET scanners, as integrated 
PET-CT scanners were not available at the time of the study. Comparison with CT 
was done by side-by-side viewing. At present, integrated PET-CT scanning is 
considered state-of-the-art for oncological staging. For clinical implementation of the 
results of the present study, this means that most probably the number of clinically 
significant FDG-PET findings that is disregarded by multidisciplinary teams will 
decrease, as integrated FDG-PET-CT provides immediate and direct correlation of 
functional changes depicted by FDG-PET with anatomical abnormalities shown on 
CT21. Thus, it can be envisioned that the actual reduction of futile laparotomies will be 
larger than 38%, especially due to the reduction of disregarded FDG-PET findings. 
Besides the recent introduction of PET-CT, MR imaging of the liver is now 
considered part of the standard of care in CRC with hepatic involvement. Liver MR 
may decrease a major source of futile surgery, i.e. underestimation of the degree of 
liver involvement.
In conclusion, the introduction of FDG-PET in the preoperative work-up of patients 
with colorectal liver metastases who are considered resectable on CT significantly 
reduces the number of futile laparotomies due to unexpected unresectable disease. 
Therefore, FDG-PET should be implemented in the diagnostic algorithm before 
laparotomy for resection of colorectal liver metastases is performed.
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Abstract
Background.FDG-PET is used increasingly in the work-up to surgery for patients with 
potentially resectable colorectal liver metastases. This study evaluates clinical 
effectiveness, impact on health care resources and cost-effectiveness of adding 
FDG-PET to the diagnostic algorithm alongside a RCT from a health care 
perspective.
Methods.ln a RCT, the net monetary benefit (NMB) of FDG-PET added to 
conventional diagnostic work-up (CWU) was determined in patients with colorectal 
liver metastases. Seventy-five patients were included in each arm. Change in clinical 
management, futile laparotomies, preoperative findings, and all relevant health care 
consumption were prospectively documented during three years. To assess health- 
related quality of life (HRQoL) EuroQol-5D was administered at time of 
randomization, 3 and 6 weeks post-operatively, and every 3 months post-operatively 
for 3 years. Quality-adjusted life years (QALYs) were calculated based on EuroQol- 
5D outcomes.
Results.In adding FDG-PET, diagnostic performance increased and futile 
laparotomies were reduced by 38%. Both HRQoL and QALYs showed no significant 
difference between CWU and PET group. For CWU and PET group costs were € 
92,836 and €  81,776 respectively, accumulated in three years after randomization. 
NMB ranged from €1,004 to €11,060 depending on the monetary value given to a 
QALY. When costs for chemotherapy were disregarded, costs amounted to €  15,874 
for CWU and €  18,664 for PET group.
Conclusion.Additional costs of FDG-PET in the diagnostic work-up of patients with 
potentially resectable colorectal liver metastases were compensated by a reduction 
of futile laparotomies. The NMB analysis showed savings over a relevant range of 
willingness to pay for a QALY.
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Survival of patients with colorectal cancer strongly depends on the development of 
distant metastases. Approximately 50-60%  of the patients with primary colorectal 
tumour develop hepatic metastases 12. These metastases are either identified at the 
time of diagnosis of the primary tumour (synchronous metastases) or during follow- 
up (metachronous metastases). Hepatic resection is the only curative therapy for a 
selected group of patients with colorectal liver metastases. For surgical treatment 
stringent selection criteria apply, because no survival benefit is found if residual 
disease should remain after hepatectomy. After resection, 5-year survival rates have 
been reported between 35 and 45% 3-6, compared to less than 15% in patients with 
unresectable colorectal liver metastases 78. In up to 50% of the patients who undergo 
curative liver resection, recurrent disease is detected in the first year after surgery 9­
12. These figures strongly suggest that both before and during surgery minimal 
residual metastatic disease remains undetected. Therefore, a critical evaluation of 
preoperative and intra-operative diagnostic modalities is necessary with regard to 
both efficacy and cost-effectiveness.
Positron emission tomography (PET) with [F-18]-fluorodeoxyglucose (FDG) is a 
sensitive diagnostic tool to display both primary colorectal cancer and its metastases 
13,14. As a promising and upcoming modality for evaluation of recurrent colorectal 
disease, FDG-PET imaging is based on metabolic changes instead of anatomic and 
structural changes as is the case for CT (Computed Tomography) or MRI (Magnetic 
Resonance Imaging). As such, FDG-PET has the potential of demonstrating tumour 
activity ahead of CT or MRI [15]. Furthermore, data suggest that additional FDG-PET 
results in a change in clinical management of up to 30% during the diagnostic work­
up of patients eligible for surgical treatment metastatic colorectal cancer 16-18.
The added value of the integration of FDG-PET in the diagnostic algorithm for 
surgical treatment of colorectal liver metastases has yet to be determined, despite 
increased sensitivity and specificity of FDG-PET as reported in the literature. Several 
studies have examined the cost-effectiveness of the FDG-PET in a number of 
diagnostic scenarios through modelling 19-21, whereas others have emphasized cost- 
effectiveness of hepatic resection 22,23. These studies attempt to show that FDG-PET 
is cost-effective in colorectal metastatic disease when added to conventional work­
up, although strong data has yet to emerge. To increase the level of evidence of the 
value of adding FDG-PET to the conventional diagnostic work-up, a randomized 
controlled study was conducted 24. Alongside this study the costs from a healthcare 
perspective of the conventional work-up versus conventional work-up supplemented 
by FDG-PET was evaluated.
INTRODUCTION
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MATERIALS AND METHODS 
Study design
Patients were enrolled in a randomized, controlled, multicentre trial between May 
2002 and February 2006. Eligible patients were required to have a history of 
histologically documented colorectal cancer treated by adequate surgical resection 
(tumor-free resection margins), suspicion of up to four potentially resectable 
colorectal liver metastases without evidence of extrahepatic metastatic disease (with 
exception of a maximum of two resectable lung metastases) on contrast enhanced 
CT scan of the abdomen, pelvis and chest, no signs of recurrent or second colorectal 
carcinoma.
Randomization was performed at the central trial office. When randomized to the 
conventional arm patients were scheduled for hepatic surgery without any further 
diagnostic procedures. When randomized to the experimental arm, additional whole 
body FDG-PET was performed, generally within 2 weeks, and results of both CT 
imaging and FDG-PET scan were again reported at a multidisciplinary oncology 
meeting. A joint assessment of all available data was performed to review clinical 
information and diagnostic imaging on a case-by-case basis.
For more details about study protocol, eligibility, and standardized follow up we refer 
to a recent paper by this group 24. All patients were followed prospectively at regular 
predetermined intervals of 3 months for the first 3 years after intervention. The study 
was approved by the institutional ethical review boards of all participating centres and 
all patients provided written informed consent.
OUTCOME MEASURES AND DATA COLLECTION 
Clinical outcomes
Case record forms were used to collect data during the trial period. The standardized 
forms were used to record preoperative and demographic data, all diagnostic and 
per-operative information, essential costs during hospital stay, and all follow-up data, 
including additional diagnostics for 3 years after hepatic resection.
Futile laparotomies were defined as any laparotomy that did not result in complete 
tumour removal, hepatic or extra-hepatic, that revealed benign disease at laparotomy 
or at histopathology, or that did not result in a disease free survival period longer than 
6 months. Disease-free and overall survival were assessed from the day of 
randomization.
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Health-state values
Overall health-related quality of life (HRQoL) appraisals in different states of health 
can be expressed as a single metric number, often referred to as values or utilities. 
These health-state values are combined with survival data to compute quality- 
adjusted life years (QALYs). One QALY equals one year in full health.
HRQoL during the first 3 years of follow-up was measured with the EQ-5D (European 
Quality of Life-5 Dimensions) 25-27. Health status on the EQ-5D was described 
according to five attributes: mobility, self-care, usual activities, pain/discomfort and 
anxiety/depression, each of these attributes consists of three levels: no problems, 
some problems, or severe problems. HRQoL of both groups was evaluated at time of 
randomization, 3 and 6 weeks after surgery, and subsequently every 3 months for 3 
years.
Case record forms were used to collect data during the trial period. Futile 
laparotomies were defined as any laparotomy that did not result in complete tumour 
clearance, hepatic or extra-hepatic, that revealed benign disease at laparotomy or at 
histopathology, or that did not result in a disease free survival period longer than 6 
months. Disease-free and overall survival were assessed from the day of 
randomization.
Treatment costs
All direct health-care related costs during the first three years after inclusion were 
prospectively documented in the case record forms, including inpatient and 
outpatient costs, such as: the surgical technique used, the amount of blood loss, total 
operation time, chemotherapy, secondary operations, complications (e.g., ileus, 
wound infection, biloma, pneumonia), outpatient visits, diagnostic tests. For prices, 
the actual, true unit-cost were used. Unit-cost were build up out of personnel, 
material and capacity cost. For standard units of care, like intensive care unit (ICU)- 
days, in hospital days, out-patient visits etc., standard cost-prices as stated in the 
Dutch Manual for costing research by Oosterbrink et al. 28 indexed using the 
consumer price index (CPI) to 2007 prices, were used 29. Overhead was defined as 
35% of the accumulated direct costs in line with the Dutch guidelines for costing 
research (Oostenbrink, 2004) 28.
Excluding chemotherapy costs seems obvious when dealing with a diagnostic driven 
trial, but given the influence on outcomes in disease-free and overall survival, both 
evaluations were taken into account. This underlines the fact that considering only 
the diagnostic channel provides in intermediate outcomes with potentially biased 
results and potentially different policy decisions about adding the FDG-PET 
technology to the benefit package. Whether and under what conditions FDG-PET is
129
Chapter 7
an efficient modality for patients adhering to the inclusion criteria of this trial is 
therefore described in a transparent way presenting both scenarios, the diagnostic 
channel only and the diagnostic channel plus the clinical pathway up to three years. 
Costs and effectiveness have been discounted at a 3% rate for the duration of the 
study, i.e. three years. The perspective of accumulated costs in this study is that of 
the Dutch national health system.
Efficiency analysis
Cost-utility analysis was conducted from a health-care perspective. Efficiency of 
FDG-PET compared to CWU is expressed as the net monetary benefit (NMB). The 
NMB is an outcome presented in money terms that subtracts the net cost from the 
net effect between FDG-PET and CWU. The net cost are measured as the difference 
in costs between FDG-PET and CWU. The net effect is measured as the difference 
in QALYs between FDG-PET and CWU multiplied by a monetary value given to a 
QALY. The decision rule states when the NMB is positive, FDG-PET is cost-effective 
compared to CWU. For the Netherlands the range for "Willingness to pay for a 
QALY” is based on a report by the RVZ (Raad voor Volksgezondheid en Zorg = 
Council for Public Health and Health Care), an advisory board to the ministry of 
health, titled “Duurzame en Zinnige zorg, 2006” and ranges from €10,000 to €80,000 
depending on burden of illness 30.
Further, a bootstrap procedure was performed to provide an estimate of the 
uncertainty surrounding the incremental cost-effectiveness ratio (ICER) 31. 
Bootstrapping is a statistical procedure that for example 1,000 times re-samples with 
replacement from the original sample. This method reduces the chance that outliers 
significantly influence the cost-utility analysis with extra health care consumption in 
the nominator and QALYs gained in the denominator. The cost-effectiveness plane 
visualizes the results of the bootstrap procedure with effects on the X-axis and costs 
on the Y-axis. This is presented in a cost-effectiveness plane in which FDG-PET can 
be placed, where every point represents an estimated ICER. An ICER is the ratio of 
the change in costs of a therapeutic intervention (compared to the alternative) to the 
change in effects of the intervention.
Sensitivity analysis
To demonstrate the influence of a more intensive use, i.e., a higher occupancy rate, 
of the PET, possibly resulting in a lower unit cost per scan, a sensitivity analysis 
varying the occupancy rate of the PET scanner was performed.
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Statistical analysis
For the difference between groups in costs and clinical outcomes Fisher's exact test 
(2-sided) was used for categorical data and t-tests for continuous data. Differences in 
survival were analyzed with the log rank test. All statistical analyses were performed 
with SPSS statistical software (version 16.0) and all data analyses in Excel 2007 
(Microsoft).
RESULTS 
Clinical outcomes
There were no baseline differences between both diagnostic work-up modalities 
(Table 1). Additional FDG-PET findings resulted in cancellation of planned resection 
of the suspected liver metastases in 5 patients. Follow up of these cases showed that 
FDG-PET correctly predicted benign disease in 2 patients and unresectable 
extrahepatic disease in 3.
Table 1. Demographic data
Control arm 
N=75
Experimental arm 
N=70
Age in years (range) 62.9 (37.9-79.9) 61.8 (32.8-78.1)
Gender (female:male) 19:56 25:45
Primary tumor
pN0 34 30
pN >1 41 40
Disease free survival 
<12 months
>12 months 29 32
46 38
Number of hepatic tumors* 
i
>1 41 40
34 30
Size of greatest hepatic 
tumor*
<50 mm 60 54
>50 mm 15 16
CEA preoperatively
<200 ng/ml 75 70
>200 ng/ml - -
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So, in total 75 patients in the conventional arm without FDG-PET and 70 patients in 
the experimental arm with FDG-PET underwent laparotomy (Table 2). At laparotomy, 
17 (23%) patients in the conventional arm and 7 (9%) patients in the experimental 
arm either showed significant additional metastatic disease precluding any further 
curative surgical treatment or showed benign disease, both of which leading to futile 
laparotomy (p = 0.043).
Table 2. Means of the costs (€) and difference of the mean and the QALYs in first 3 years after 
randomization for the two treatment arms:
conventional work-up (CWU) and conventional work-up with additional FDG-PET (PET)
CWU
(range)
PET
(range)
Mean difference 
(95%-CI interval)
Total cost 92,836 81,776 11,060
(7,516 -  290,308) (6,087 -  341,012) (-16,830 / 38,949)
Cost without chemotherapy 15,874 18,664 -2,790
(5,974 -  34,143) (1,984 -  87,930) (-6,343 / 762)
Total cost first hospital stay 10,429 11,770 -1,341
(3,671-24,420) (401-64,982) (-4,006 / 1,322)
Total cost diagnostics 1,929 2,529 -600
(253-4,827) (401-64,982) (-925 / -276)
Total cost outpatient visits 1,061 984 77
(83-2,008) (84-1,841) (-61 / 215)
Total cost additional hospital 2,455 3,380 -925
stay(s) (196-5,544) (335-21,037) (-1,755 / -95)
QALYs in 3 years 1.78 1.68 0.10
(0.30-2.76) (0.10-2.76) (-0.19 / 0.39)
In addition, follow-up showed disease recurrence within 6 months after surgical 
treatment in 16 and 13 patients in the conventional and experimental group, 
respectively. As a result a significant greater proportion of patients underwent futile
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laparotomy in the control arm without FDG-PET (45%) than in the experimental arm 
with FDG-PET (28%) (P= 0.042). The relative risk reduction was 38% (95% CI: 4%- 
60%). Futile laparotomy was not related to demoghraphic differences or prognostic 
factors, as reported elsewhere 24
Health-state values and QALYs
The calculated health-state values were based on 73 patients in the CWU group (2 
patients did not return any EQ-5D form) and 75 patients in the FDG-PET group. 
During the follow-up in the first 3 years the health-state values were not different for 
the two study groups (Figure 1). As 3 year overall survival appeared to be almost 
identical for the two groups (65.8% for CWU and 61.3% for PET group), QALYs 
accumulated over the 3 years follow-up period were not significantly different. For the 
CWU group 1.78 QALYs were generated, whereas for the PET group 1.67 QALYs 
(mean difference 0.10, 95%-CI: -0.19 to 0.39).
Figure 1. Overall value of patients’ health in the first 3 years after randomization, as calculated by the 
EQ-5D values. Area under the curve can be interpreted as number of QALYs = Quality-Adjusted Life 
Years
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Cost Analysis
The different costs over several diagnostic and treatment options are presented in 
Table 3. The cost for surgery were standardized to the cost for a 3 hour OR 
(operation room) session, without radiofrequency ablation (which would raise costs 
with 1,950 Euros). Overall, after comparing the diagnostic strategies, the average 
total costs were lower in the PET group (Table 2). Three years after randomization 
the mean costs for CWU and PET-group were €  92,836 (range: €  7,516 -  €  290,308) 
and €  81,776 (range: €  6,087 -  €  341,012) respectively. When the costs for 
chemotherapy were not taken into account, the mean costs in the CWU group were € 
15,874 (range: €  5,974 -  €  34,143) versus €  18,664 (range: €  1,984 -  €  87,930) in 
the PET group.
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Table 3 a-c. actual cost of diagnostic, therapy, and hospital stay
Table 3a, Costs of diagnostics, hospital days, Intensive care treatment, outpatients v is its (In euros)
* based on “Oosterhuis et al”
CT
scan
MR Ultrasound Chest
X-ray
PET
scan
Colono
scopy
Outpatient* Normal
Care*
Intensive
Care*
Capacity 67.55 143.41 3.33 1.78 663.26 28.72
Personnel 56.51 60.10 41.82 16.49 67.98 100.52
Overhead 43.42 71.23 15.80 6.40 255.93 45.24
Total 167.48 274.74 60.95 24.67 987.17 174.48 107.28 490.12 1,692.91
Table 3b, Costs operation (in euros)
Operation Additional costs: RFA
OR, utilities & 
Personnel
855.00 1,500.00
Diagnostics & personnel 37.99 -
Overhead 313.89 450.00
Total 1,206.88 1,950.00
Table 2c, Costs chemotherapy (in euros)
5FU/LV Oxaliplatin 5FU/LV 
Scheme A
Oxaliplatin 5FU/LV 
Scheme B
irinotecan Oxaliplatin
Capacetabine
Per therapy 1,393.12 13,267.52 13,087.48 1,820.45 5,828.59
Per week 1,393.12 1,895.36 1,869.64 606.82 1,942.86
Overhead 487.60 663.38 654.37 312.38 680.11
Total/week 1,880.72 2,558.74 2,524.01 819.20 2,622.87
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Economic Analysis
The NMB (with 95% confidence intervals) shows a decline (Figure 2). This decline 
can be explained by the fact that as the willingness to pay for a QALY increases, 
more weight is given to the slightly (insignificant) negative QALY effect in the FDG- 
PET group.
Results of the bootstrap procedure are shown in the cost-effectiveness plane (Figure 
3), where most outcomes lie beneath the X-axis, meaning that additional FDG-PET is 
more likely to save money than to lose money over a period of 3 years (given the 
indecisive effect). In a second scenario when the bootstrap procedure was performed 
over the data generated without chemotherapy, it is demonstrated that the inclusion 
of FDG-PET results in a less favorable, more costly strategy (Figure 4). Every point in 
this cost-effectiveness plane represents an estimated ICER derived from the 
bootstrap procedure expressed as cost per QALY gained.
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Figure 4. Cost-effectiveness plane of additional PET (positron emission tomography) scan from a 
health care perspective, without costs for chemotherapy.
Sensitivity analysis
Sensitivity analysis varying the occupancy rate of the PET scanner (Table 3) 
demonstrated that 1200 PET scans per scanner per year (with 260 days for clinical 
use, thus 4.6 PETs per day) would result in a unit-cost of € 987 per PET. In case the 
PET scanner can be used at a higher occupancy rate these costs will decrease. For 
instance with 10 scans a day, the unit-costs would become € 759. However, this 
strategy does not result into a statistically significant advantage in costs nor NMB for 
the PET group.
Table 3. Sensitivity analysis with number of PET scans per day in one centre
Sensitivity analysis
Number of PET scans per day Costs per PET scan
3 € 1,214.92
4.6* € 987.27*
10 € 759.42
12 € 726.88
*scenario during the trial
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DISCUSSION
This study shows that the addition of FDG-PET to CWU in the diagnostic work-up for 
patients with potentially resectable colorectal liver metastases results in a better 
selection of patients for surgical intervention, and thus in avoiding futile laparotomies. 
When considering a follow-up period of three years and including all health care 
costs accumulated in these years, addition of FDG-PET remained favourable, and 
resulted in an expected net monetary benefit of up to €  11,060, depending the 
willingness to pay for a QALY gained. However, conclusions about these findings 
should be made with caution as statistical significance could not be established. This 
leads to the conclusion that the introduction of FDG-PET might be a potentially cost- 
efficient diagnostic modality in the diagnostic work-up of these patients.
Our findings are in line with previous non-randomised studies on the use of FDG- 
PET in patients with colorectal liver metastases 13,15,17,18. Bipat et al showed that 
FDG-PET had a higher sensitivity for the detection of liver metastases compared to 
other imaging modalities 13. Identical observations were made for the detection of 
extrahepatic disease 18.
In the present study, 14 patients (18.7%) in the control arm underwent futile 
laparotomy because of too extensive liver disease at laparotomy or detection of 
extrahepatic disease (data not shown). The outcome is comparable to an EORTC 
(European Organisation for Research and Treatment of Cancer) study investigating 
the role of adjuvant peri-operative chemotherapy in patients undergoing hepatic 
resection for colorectal liver metastases. In this study, 16.4% of the randomized 
patients in the control arm (without chemotherapy) did not undergo planned hepatic 
resection 32. The present study emphasises the fact that chemotherapy is a 
significant cost driver.
This cost-effectiveness analysis was based on a conservative approach meaning that 
not all beneficial effects were included in the analysis. Additional FDG-PET findings 
were divided in extrahepatic disease, evidence of benign disease, and addition liver 
disease. In 7 patients, FDG- PET detected additional extrahepatic disease initially 
missed on CT scan (lung or mediastinal metastases in 5  patients and extensive 
abdominal lymph node metastases in 2 cases). In 5 patients, FDG- PET did not show 
uptake in focal liver lesions, indicating benign liver disease, additional diagnostics 
confirmed this. In 18 patients, FDG-PET showed additional liver findings discordant 
with CT. In 3 of these patients, FDG-PET predicted extensive central liver 
involvement judged resectable on CT. In all three patients resection was judged 
impossible at laparotomy and further surgical treatment was cancelled. In this last 
group, FDG-PET correctly predicted futile laparotomies in 10 patients who were
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operated on, due to discordances compared to CT (the leading diagnostic in our 
study). Those ten operations could have increased the non-chemotherapy costs of 
the PET group.
The results in the present study showed that futile laparotomies were avoided, so the 
main economical benefits of adding FDG-PET to the diagnostic work-up would be 
logistical, as hospital performance and quality of care improves, due to more effective 
planning of operation room (OR) capacity and because unnecessary operations are 
avoided. This "quality benefit” is not represented in the outcome of our cost-utility 
analysis. Overall this could imply that the hospital performance and management 
improves, because unnecessary operations are avoided and the use of OR capacity 
is optimised.
The results of the sensitivity analyses indicate that the costs of PET could benefit 
from a better use of occupancy and suggests that PET-scanning should be 
concentrated in high volume centres that are better able to exploit economies of 
scale. When the capacity of PET scanners is optimally exploited, this results in a 
more efficient use of hardware and trained personnel, providing a solid argument for 
centralization of this modality.
Contrary to other studies, no improvement in HRQoL due to the decrease of futile 
laparotomies could be observed in this study. A possible explanation for the fact that 
77% of the treated patients in the CWU group and the 84% patients in the PET group 
showed almost identical HRQoL outcomes could be the timing of the start of 
chemotherapy. Patients in whom laparotomy is avoided due to the addition of FDG- 
PET are scheduled early for chemotherapy. This could lead to a relatively early 
decrease in HRQoL compared to the patients who receive chemotherapy later 
because of disease recurrence after initial hepatic resection, as reported earlier 24. 
The main limitations of this paper is that the RCT (Randomized Clinical Trial) was 
performed in the dawning of the hybrid PET/CT scanner, so this technology was not 
taken into account for the cost calculation. When data on this hybrid scanning 
becomes available, the added value of the application of PET/CT scanners should 
become more evident. The next challenge will be to develop imaging methods for 
better assessment of liver involvement e.g. with hybrid PET/MR, thus further 
exploiting innovations in hybrid scanner technology.
In conclusion, the addition of FDG-PET to the diagnostic work-up in patients with 
potentially resectable colorectal liver metastases results in better patient selection 
without leading to additional costs and with the potential for savings.
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Abstract
Background. Surgical treatment of colorectal liver metastases has become 
increasingly aggressive. However, the influence of this more active surgical approach 
on the patients’ Health-Related Quality of Life (HRQoL) has hardly been evaluated. 
This study evaluates the impact of surgical and systemic treatment on HRQoL in 
patients undergoing hepatic resection.
Methods. In total 145 patients with colorectal liver metastases prospectively entered 
this study. Based on HRQoL values derived with the EuroQol-5D, health summary 
measures were calculated to express the overall impact on four distinctive clinical 
states. The HRQoL instrument was used at baseline, 3 and 6 weeks post-operatively, 
and every 3 months post-operatively for up to 3 years.
Results. Patients showed a clear deterioration in HRQoL in the first weeks after 
surgery, followed by a recovery to baseline levels at 3 months after potentially 
curative surgery. In contrast, a sustained decline was observed when initial surgery 
for colorectal liver metastases was considered futile and palliative chemotherapy was 
started immediately. Three years after initial surgery, there were distinct differences 
in HRQoL between patients with or without recurrence. The latter group still showed 
HRQoL scores at baseline levels, while patients with tumor recurrence showed a 
significant deterioration in HRQoL. Remarkably, patients with recurrent disease that 
could be treated by secondary surgical intervention did not notice a decline in 
HRQoL.
Conclusion. Superior overall HRQoL in the first 3 years after initial successful 
surgical intervention merits an aggressive surgical approach and intensive follow-up 
to detect recurrences early.
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Colorectal cancer is the third most common cancer and the second most frequent 
cause of death related to cancer. Worldwide, approximately half a million people die 
from colorectal cancer every y e a r1. Liver metastases develop in 40 percent of all 
patients with colorectal cancer 2; if their metastatic disease is limited to the liver, 
resection is the curative treatment of choice. Survival rates of 40-50 percent for the 
first 5 years after initial treatment have been reported 3,4.
For many years outcomes of medical treatments in cancer were primarily expressed 
in terms of survival and disease-free status. Changes in health policy shifted the 
emphasis of health evaluation from traditional, easy-to-measure clinical indicators to 
more complex patient-based outcomes such as quality of life. Today, it is increasingly 
acknowledged that quality of life, or rather Health-Related Quality of Life (HRQoL), is 
an important additional outcome measure in the assessment of oncologic surgery 
and systemic treatment 5-7.
In current literature there are several studies addressing long-term HRQoL in primary 
colorectal cancer 8-11. However, very limited data are available on HRQoL after 
surgery for metastatic colorectal cancer 12. As contraindications for surgical treatment 
of metastatic disease are increasingly abandoned and local ablative techniques are 
upcoming treatment modalities, an increasing number of patients qualify for 
aggressive treatment 13. While considered important in this context, data on HRQoL 
in this patient category is scarce in current literature.
Most HRQoL instruments measure multiple domains (e.g., EORTC QLQ-C30) and 
are therefore commonly indicated as descriptive profile measures. In contrast, a 
distinguishing feature of a value-based HRQoL instrument is its potential to assign a 
single metric figure to a specific health status (i.e., HRQoL). Such value-based 
HRQoL instruments produce outcomes that can be incorporated in health summary 
measures such as Quality-Adjusted Life Years (QALYs) and the Quality-adjusted 
Time Without Symptoms of disease and Toxicity of treatment (Q-TWiST). Health 
summary frameworks produce an outcome measure that combines the effects of 
health interventions on mortality and morbidity into a composite measure of health 
benefit 14.
The aim of this prospective study is to comprehensively describe long-term HRQOL 
in patients undergoing surgical treatment of colorectal liver metastases by the use of 
health summary frameworks.
INTRODUCTION
145
Chapter 8
PATIENTS AND METHODS 
Enrolment & data collection
Patients were enrolled in a prospective multicenter trial between May 2002 and 
February 2006. Four surgical departments with experience in liver surgery 
participated in this trial. Patients were required to have a history of proven colorectal 
cancer treated by surgical resection and the suspicion of up to four potentially 
resectable colorectal liver metastases without evidence of extra-hepatic metastatic 
disease on contrast-enhanced CT and/or FDG-PET. The study was approved by the 
ethical committees of all participating centers, and all patients provided written 
informed consent.
Laparotomy for hepatic resection was performed generally within 4 weeks after 
inclusion (1-7 weeks). Surgical treatment was only performed if it was deemed that 
all liver lesions could be removed adequately. In case any extra-hepatic disease was 
discovered during laparotomy, further surgical treatment was done at the surgeon’s 
discretion. By exception, resection of an isolated extra-hepatic intra-abdominal lesion 
was performed. After hepatic surgery, patients did not receive any standard 
(adjuvant) chemotherapy. The follow-up lasted 3 years after initial intervention.
None of the patients received pre-operative chemotherapy. Chemotherapy was only 
started in case of non-resectable disease or tumor recurrence that was not amenable 
to surgical re-intervention. During the study period systemic chemotherapy consisted 
of 5-fluorouracil (5-FU), leucovorin, and oxaliplatin in the first line and irinotecan in 
the second line. Since 2005, bevacizumab had been added to the standard 
chemotherapy regimen.
Clinical management and peri-operative findings were prospectively documented in 
standardized case record forms. For measurement of HRQoL, futile laparotomy was 
defined as any laparotomy that did not result in surgical treatment of the liver 
metastases, either because of extra-hepatic disease or because of liver involvement 
was too extensive and resection would lead to an insufficient liver remnant. Hence, 
patients were categorized in two groups: one in which surgery was considered 
curative (curative surgery group); the other in which surgery was considered futile 
(non-curative group) because during laparotomy complete resection of all tumor 
lesions was not considered possible.
Health summary frameworks
The quality-adjusted life year (QALY) is a health summary measure 15,16. It comprises 
two key elements that together express health, namely the quantity and the quality 
(HRQoL) of life lived. Apart from the QALY, the Quality-adjusted Time Without
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Symptoms of disease and Toxicity of treatment (Q-TWiST) method was used as a 
particularly promising alternative approach to express the overall impact of medical 
interventions in the setting of cancer treatment 17,18. The objective of the Q-TWiST 
method, similar to that of the QALY method, is to include patient mortality (survival) 
and HRQoL in a single analysis. However, in the Q-TWiST method HRQoL is 
expressed for a limited number of distinct clinical health states (for computational 
strategy: see Statistical Analysis).
HRQoL instrument
The EuroQol-5D (EQ-5D), a widely applied and validated instrument, was used as a 
generic value-based HRQoL instrument. The EQ-5D encompasses five different 
domains: mobility; self-care; usual activities; pain and discomfort; and anxiety and 
depression 19. Each attribute is rated at three levels: no problems; some problems; or 
severe problems. The EQ-5D index or value is obtained by applying predetermined 
weights to the five domains derived from the general public. This results in a society- 
based quantification of the responders’ health status or HRQoL on a scale of 0 
(dead) to 1 (perfect health) 20. Furthermore, the responders were asked to rate their 
overall HRQoL on a visual analogue scale (EQ-5D VAS) consisting of a vertical line 
ranging from 0 (worst imaginable health status) to 100 (best imaginable health 
status), representing the patients’ perspective. As these two measures (society- 
based and patient-based) are expressed on an absolute scale capturing the whole 
continuum of HRQoL, differences of 1-2% can already be considered as clinical 
significant. Baseline EQ-5D forms were completed in hospital, and subsequent forms
3 and 6 weeks and after that every 3 months for the next 3 years were sent to the 
patient’s postal address. If forms were not returned within 2 weeks, a telephone or 
written reminder was sent.
Statistical analysis
For the Q-TWiST analyses all patients were distributed over four categories, 
representing the main clinical states of patients with colorectal cancer after initial 
treatment of liver metastases: death; the state after non-curative surgery; the state 
after curative surgery with recurrent disease; and the disease-free state after curative 
surgery. For each state, the proportion of patients was computed for the entire follow- 
up period (3 years). Patients could shift between states in a certain order (Figure 1). 
Next, for each of the four clinical states the mean HRQoL values were determined 
based on the EQ-5D measures. In the Q-TWiST, the element of time was expressed 
as the interval between two measurements. Finally, for each clinical state the mean 
durations were multiplied by the corresponding mean HRQoL values and the
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proportion of patients. This resulted in the number of QALYs accumulated for each 
clinical state during 3 years of follow-up. One-way analysis of variance was applied to 
test for differences between the groups at the various measurement occasions (ad 
hoc multiple comparison test: Scheffe test). All statistical analyses were performed 
with SPSS statistical software (version 17.0, Chicago, Illinois, USA).
Figure 1. State transition diagram for patients in possible clinical health states
RESULTS
Patients
In total 145 patients were included in the study. Seven patients were excluded from 
further analysis because final histology after laparotomy demonstrated the presence 
of benign liver lesions without any evidence of metastatic CRC. Thus, 138 patients 
underwent laparotomy for potentially curative resection of proven liver metastases. 
The general demographics (gender, mean age) and tumor characteristics (primary 
cancer site, T status, N status) of this group are described in Table 1. Before 
intervention, 136 of the 138 patients completed the EQ-5D instrument (98.6%). In the 
end, this group was prospectively analyzed. After 3 years the overall response rate 
was 90.8% (1852 forms out of 2040 possible responses).
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Table 1. Demographics and tumor characteristics
Mean age (range) 62.9 (33-80)
Gender (female: male) 44:94
Nodal stage primary tumor
- NO 60
- N+ 78
Disease-free interval (months)*
- < 12 57
- > 12 81
Number of hepatic tumor(s)**
- 1 82
- 2-4 56
Median size largest lesions in mm 35.0 (6-160)
* time interval between primary tumor and hepatic metastases 
** as seen on preoperative CT-scan
Q-TWiST: distribution of the four clinical states
The four clinical groups representing the main optional clinical status of patients 
(death, non-curative surgery, curative surgery with recurrent disease, and curative 
surgery with disease-free status) and their distribution over time are depicted in 
Figure 2, representing the Q-TWiST. The states ‘disease-free’ and ‘non-curative’ are 
the main groups in the first few months. In the course of the study, obviously the 
percentage of patients with ‘recurrence’ and ‘death’ increased. In total, 117 patients 
(86%) underwent successful surgical intervention (curative group), while 19 patients 
(14%) underwent non-curative laparotomy because of inoperable disease at the time 
of surgery. Disease-free survival of all 136 patients at 2 and 3 years was 32.5% 
(44/136) and 27.9% (38/136) respectively. The median time to disease recurrence 
was 8.5 months (range: 0-75). For patients with recurrent disease and no option for 
surgical re-intervention, chemotherapy was started at a median time of 12.0 months 
(range: 1-36) after hepatic resection.
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0 6 12 18 24  30  36
D u ra tion  (m on ths )
T im e 0 3 6 9 12 15 18 21 24 27 30 33 36
D eath 0 7 9 14 20 21 23 29 36 39 43 48 53
R ecurrence 0 16 35 44 45 53 55 52 49 47 45 44 41
D isease-free 117 95 75 63 59 50 48 56 44 43 40 38 38
N on-cura tive 19 18 17 15 12 12 10 9 7 7 7 6 4
Figure 2. The four clinical states of patients (death, after noncurative surgery, recurrent disease, 
disease-free) and their proportions over time in the first 3 years (patients may have been moved from 
one state to another over the course of the study)
HRQoL of the four clinical states
Three weeks after surgery, all patient groups showed a clear decrease in HRQoL, as 
expressed in the EQ-5D utilities. Afterwards, the HRQoL values for the three (death 
is 0 by definition) clinical groups showed distinct patterns over time. In general, 
disease-free patients had the best HRQoL, whereas patients after non-curative 
surgery were doing worse than patients with recurrent disease (Figure 3). Statistically 
significant overall effects (all differences > 2% are considered as clinical significant) 
were observed between the disease-free and the non-curative groups from week 12 
onwards (P < 0.05). Between the disease-free and the recurrence group, a significant 
difference was observed at the end of follow-up (144 weeks, p=0.024). An identical 
pattern was observed for differences between the non-curative surgery and the 
recurrence groups. The HRQoL of the group with recurrent disease was intermediate 
between the non-curative and the curative surgery groups. Separate analyses were 
performed within this group concerning patients treated for their recurrence either by 
repeated surgical intervention or by chemotherapy (Figure 4). The HRQoL in patients 
treated by repeated surgical resection was significantly better after 52 weeks than in 
the group receiving chemotherapy. EQ-5D VAS scores (patients’ perception) showed 
a pattern for all clinical groups similar to that of the society-based EQ-5D values (not 
shown).
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R ecurrence - 2 5 16 34 37 41 45 44 44 43 39 37 33 36 
N on-cura tive  19 17 17 16 15 13 12 10 10 6 7 6 5 5 4
Figure 3. Mean index value (with standard errors, asterisks indicating statistically significant effects, 
only reported if number of observations > 10) of patients’ health in the first 3 years after inclusion for 
each clinical health state as calculated by the EQ-5D (area under the curve correlates with number of 
quality-adjusted life years)
1.0
0.6
0.8
0.4
0.2  - •  recu rrence  w ith ou t chem o
— o —  recu rrence  w ith  chem o
0.0  -1----------1----------- 1----------- 1----------- 1----------- 1----------- 1----------- 1----------- 1------------
0 20 40  60 80 100 120 140
W e e ks  a fte r  in te rve n tio n
W ithout chem o 12 21 19 21 20 20 19 17 16 13 10 15
W ith chem o 0 13 18 20 25 24 25 26 23 24 23 21
Figure 4. Overall index value (with standard errors, asterisks indicating statistically significant effects, 
only reported if number of observations > 10) of patients’ health in the first 3 years after inclusion for 
the subgroups in recurrent disease treated by (repeated) surgery or chemotherapy, as calculated by 
the EQ-5D (area under the curve correlates with number of quality-adjusted life years)
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QALYs
In view of the mean HRQoL values for each different clinical state, it is clear that the 
group in the disease-free state did better than the group in the state after non­
curative surgery or those in the state with recurrent disease. Furthermore, whenever 
surgical re-intervention in the recurrence group seemed feasible, the HRQoL was 
comparable to that of the group in which no recurrence occurred. Separate analyses 
were performed to express the number of QALYs contributed for each clinical state. 
These analyses revealed that the group with a disease-free state accumulated 0.78 
QALYs annual over 3 years, the non-curative group 0.67 annual, and the recurrence 
state 0.74 annual (Table 2). A total of 2.18 QALYs were collected in 3 years, where 
theoretically a total of 3.0 QALYs could have been achieved if all patients had been 
in perfect health for the 3-year duration of follow-up. Additionally, table 2 shows a 
difference of 13,4% between both recurrence groups, one treated with chemotherapy 
(0.68) and the second surgically, without additional chemotherapy (0.82).
Table 2. Mean HRQoL values (EQ-5D) per clinical state
State Mean (SD) Observations Maximum Minimum
Death G (G) 349 G G
Disease-free G.78 (0.23) 891 G.92 -G.59
Non-curative G.67 (0.31) 162 G.92 -G.59
Recurrence G.74 (0.25) 45G G.92 -G.59
-Without chemotherapy G.82 (G.17) 2G5 G.92 -G.43
-With chemotherapy 0.68 (G.28) 245 G.92 -G.59
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This paper presents the results of 3 years of global HRQoL measurement in patients 
selected for surgical treatment of colorectal liver metastases and subjected to 
different subsequent treatment modalities after initial surgical intervention. Initially the 
patients showed a clear overall deterioration in HRQoL during the first weeks after 
intervention, which was in line with previous observations 12.
Thereafter, four distinct clinical health states were distinguished and described. The 
corresponding HRQoL outcomes for the patients in these clinical states showed 
distinct patterns. Disease-free patients performed significantly better than patients 
who underwent non-curative surgery or patients with recurrent disease. The inferior 
HRQoL in patients with recurrent disease may be attributed to the knowledge of 
progressive disease as well as to the disease burden or the administration of 
palliative chemotherapy. HRQoL outcomes combined with survival data (expressed 
as QALYs) showed that the patients who were surgically treated, had on average 
13% more QALYs gained during the study period of 3 years, which can be 
considered as a substantial and clinically significant health gain.
The current data show a superior overall HRQoL in the first 3 years after surgical 
treatment of metastatic colorectal cancer, which supports an aggressive surgical 
approach to colorectal liver metastases, when feasible. Furthermore, when recurrent 
disease was diagnosed, patients who were subjected to a second surgical 
intervention had a better HRQoL than patients who were treated with chemotherapy. 
This supports an intensive follow-up scheme to detect recurrent metastatic disease at 
an early stage, thus maximizing the chances for resectability.
Aditionally, it was observed that patients undergoing non-curative (futile) laparotomy 
show a significant deterioration of HRQoL, not recovering to baseline. These data 
confirm earlier observations that non-curative laparotomy had a more severe impact 
on patients’ well-being than primary denial of surgical treatment 12. In the present 
study, the number of non-curative -  i.e., futile, because the disease was too 
extensive at surgery -  laparotomies (14%) is similar to the percentage reported in a 
recent multicenter study in an comparable patient group. In the latter study, 16.4% of 
the patients did not undergo planned hepatic resection 21.
In the present study, no standard adjuvant chemotherapy was given after hepatic 
surgery. The data on overall and disease-free survival found here are similar to the 
standard arm in most recent studies comparing adjuvant chemotherapy with no 
additional treatment (standard arm) 21,22. Hence, data on HRQoL as presented in this 
series may be applicable to other studies as well.
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The most commonly applied HRQoL instruments, such as the EORTC QLQ C-30 
and the FACT-G (and the modules of these two), produce descriptive profile 
measures encompassing multiple health domains 23. The same holds for 
supplementary modules of the EORTC QLQ-C30 24. Instruments in this class are 
predominantly based on the classical test theory measurement model, which 
estimates the level of a health domain as the sum of responses to individual items 25. 
Preferably, HRQoL measures should allow computational procedures and 
parametrical statistical testing. This is facilitated when outcome measures are at least 
at the interval level 26, meaning that the metric of the HRQoL scale is continuous. In 
fact, the underlying rationale for the value-based HRQoL approach used in this 
studywas to derive such qualified HRQoL measures. From a theoretical point of view 
the value-based approach is more in line with measurement theories 27. Until now it 
is rarely applied as an HRQoL measure in clinical studies, but predominantly used by 
health economists in the context of cost-effectiveness analysis. Yet the value-based 
HRQoL approach is conceptually identical to the index approach advocated by 
clinimetrics 28,29. A serious drawback of the generic value-based HRQoL instruments 
is that these are all based on a limited set of health domains and often lacking 
relevant domains for specific diseases. This may explain the recent interest in 
developing disease-specific value-based HRQoL instruments 5,30. AT present, it 
seems that generic value-based instruments and descriptive (profile) HRQoL 
measures are both necessary to discern the overall impact and the disease-specific 
domains that contribute to this.
The present study can be regarded as an example how these HRQoL instruments 
can identify the value of specific interventions in surgical oncology.
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Summary and General Discussion
The aim of this thesis was to study several clinical aspects of the implementation of 
[18F]-2-deoxy-2-fluoro-D-glucose positron emission tomography (FDG-PET) in the 
management of patients with colorectal liver metastases and the effect of 
consecutive treatment.
In chapter 1, an overview of the literature is presented. FDG-PET, Computed 
Tomography (CT) and Magnetic Resonance Imaging (MRI) are complimentary 
techniques in staging patients with disseminated colorectal cancer. A combination of 
FDG-PET and CT scanning characteristics seems promising, and integrated PET/CT 
scanners are becoming more widely available, although the exact clinical value and 
efficacy is not yet fully established. In addition, assessment of these modalities in 
joint reading sessions with radiologist, nuclear medicine physician, medical and 
surgical oncologists significantly impacts upon patient management. This review 
evaluates the potential of FDG-PET and combined PET/CT in patients with colorectal 
liver metastases and discusses potential future possibilities.
Chapter 2  describes the results of a meta-analysis, clearly indicating that FDG-PET 
is useful in the diagnostic workup of patients with potentially resectable hepatic 
metastases from colorectal carcinoma, despite the apparent omissions in the 
literature. Most evident is the detection of extrahepatic disease, in which FDG-PET 
demonstrated superior sensitivity and specificity compared to CT scanning. A clear 
influence of FDG-PET on clinical management was observed in the majority of 
studies. Nevertheless, randomized controlled clinical trials should be performed to 
investigate the role played by FDG-PET scanning in patients with colorectal liver 
metastases and its actual impact (e.g. on survival parameters). An additional 
assessment of the cost-effectiveness of FDG-PET may serve to strengthen its role 
further.
Chapter 3 describes data from 203 patients, concluding that introduction of FDG-PET 
reduced the number of futile laparotomies in patients with extrahepatic disease due 
to better detection of these tumor lesions. However, after surgical treatment, both 
overall and disease-free survival were similar, irrespective whether or not FDG-PET 
was used. The main shortcoming of this study is that only patients were analyzed
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who were already selected for explorative laparotomy either with or without additional 
FDG-PET. Thus, the precise impact and relevance of FDG-PET on clinical 
management decisions during the diagnostic workup is not taken into account. 
However, any major benefit from the addition of FDG-PET in the preoperative workup 
would have been noted in our data by improved survival in the FDG-PET group. 
Moreover, patients were not randomized, and results may have been influenced by 
the improved performance and interpretation of CT. Such issues can only be 
overcome in a randomized controlled clinical trial (RCT). The study indicates that 
screening of patients with FDG-PET who are considered for resection of colorectal 
liver metastases remains appropriate.
In chapter 4, a study of 131 consecutive patients shows that in patients with 
colorectal liver metastases the frequency of unexpected findings at laparotomy is 
relatively low when using CT and FDG-PET in the preoperative work-up. The main 
challenge for improvement of diagnostic techniques seems better assessment of liver 
involvement itself, as the liver often proves to be more affected than expected with 
regard to both the tumor load and the exact localization of metastases. Unexpected 
extrahepatic FDG-PET findings demand careful evaluation because these findings 
could potentially alter surgical patient management. FDG-PET may reveal occult 
disease both in the abdomen and chest earlier than CT. Furthermore, even at 
explorative laparotomy it appears to be very difficult to identify all metastases 
detected by FDG-PET.
Chapter 5 describes a series of 152 patients, which shows that the degree of FDG 
uptake in colorectal cancer metastases (expressed as SUV) can predict outcome, 
irrespective of the subsequent treatment modality, as patients with more FDG-avid 
disease show reduced overall survival. Therefore, FDG-PET could become an 
important adjunct to traditional staging to improve appropriate selection of high-risk 
candidates for aggressive multimodality treatments and could be helpful in stratifying 
patients for prospective studies when different therapeutic options are to be 
compared.
In chapter 6, the results of a RCT of 150 patients are presented, in which the 
introduction of FDG-PET in the preoperative work-up of patients with colorectal liver 
metastases who are considered resectable on CT significantly reduces the number of 
futile laparotomies, due to unexpected unresectable disease. It is concluded that 
FDG-PET should be implemented in the diagnostic algorithm before laparotomy for 
resection of colorectal liver metastases is performed.
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Chapter 7 shows that additional PET to conventional work-up in patients with 
potentially resectable colorectal liver metastases resulted in better test performance 
and in avoiding futile laparotomies. This increase in diagnostic accuracy did not result 
in additional costs. When considering a follow-up period of three years and including 
all health care costs accumulated in these years, addition of FDG-PET remained 
cost-neutral, and may even result in an expected financial benefit. Thus, the addition 
of FDG-PET to the diagnostic work-up results in less laparotomies without generating 
additional costs and potentially better use of OR capacity.
Chapter 8 describes the results of Health Related Quality of Life (HRQoL) in patients 
with colorectal liver metastases. A better overall HRQoL for patients after successful 
primary and additional surgical treatment in the first three years after initial 
intervention is found. When recurrent disease is present, patients who are subjected 
to secondary curative surgical intervention fare better than patients who were treated 
with chemotherapy. This merits an aggressive surgical approach. Additionally, an 
intensive follow-up scheme seems justified, to find recurrent metastatic disease in 
possibly still resectable stage. Computed health measures show the patient group 
with disease-free health state in a favorable way compared to the patients with 
recurrent disease, even after repeated surgery their health state fare better than 
patients who had initial futile surgical intervention or irresectable recurrent disease.
At this moment, promising new PET tracers are met with enthusiasm. Besides 
visualization of glucose metabolism with FDG-PET scanning may be applied for non­
invasive in vivo evaluation of other tissue characteristics using tracers other than 
FDG. Studies using O-15-water for flow determination are reported. DNA synthesis 
activity may be quantitatively assessed using [F-18]fluoro-deoxy-L-thymidine (FLT) 
as a reflection of cell proliferation and tumor growth, but is disappointing so far in liver 
metastases, even though it seems promising in differentiation with inflammatory 
lesions in other anatomical regions. The exact clinical applicability of these and other 
tracers is currently under investigation, but at present more uncertain than the utility 
of FDG-PET.
Other PET radiopharmaceuticals depict specific receptors on the tumor cell 
membrane, which is not only important for staging patients with tumors that express 
a particular receptor, but also for characterization of these tumors’ receptor status in 
vivo. For example, somatostatin derivatives radiolabeled with F-18, Y-86 or Ga-68 
are extensively studied in patients with neuro-endocrine tumors.
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Current choices for implementation of FDG-PET in diagnostic strategies appear 
rather random, and large variations exist among institutes. This theses emphasizes 
that PET/CT should be a standard imaging modality when surgical treatment of 
colorectal liver metastases is considered. In the near future, the value of FDG-PET in 
day-to-day clinical practice, and the added value of the application of PET/CT 
scanners should become more evident. The next challenge will be to develop 
imaging methods for better assessment of liver involvement e.g. with hybrid PET/MR, 
thus further exploiting innovations in hybrid scanner technology.
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NEDERLANDSE SAMENVATTING EN DISCUSSIE
Dit proefschrift beschrijft verschillende klinische aspecten van [18F]-2-deoxy-2-fluoro- 
D-glucose positron emissie tomografie (FDG-PET) bij de diagnostiek van colorectale 
levermetastasen en de effecten van de behandeling.
In hoofdstuk 1 wordt een overzicht van de bestaande literatuur gegeven. FDG-PET, 
computertomografie (CT) en Magnetic Resonance Imaging (MRI) zijn 
beeldvormende technieken die gebruikt worden bij patiënten met gemetastaseerde 
colorectale kanker. Een combinatie van FDG-PET en CT-scans lijkt veelbelovend en 
geïntegreerde PET / CT-scanners zijn op een steeds grotere schaal beschikbaar, 
hoewel de exacte klinische waarde en de effectiviteit nog niet volledig is vastgesteld. 
Bovendien blijkt gezamenlijke beoordeling door radioloog, nucleair geneeskundige, 
medische en chirurgische oncologen een aanzienlijke impact op de keuzes voor de 
behandelingsstrategie van patiëntente hebben. Dit hoofdstuk evalueert de 
mogelijkheden van FDG-PET en gecombineerde PET / CT bij patiënten met 
colorectale levermetastasen en bespreekt toekomstige mogelijkheden.
Hoofdstuk 2 beschrijft de resultaten van een meta-analyse, waaruit duidelijk blijkt dat 
FDG-PET van waarde is voor de diagnostiek bij patiënten met potentieel resectabele 
levermetastasen van colorectaal carcinoom, ondanks dat beschikbare literatuur nog 
omissies vertoont. Het meest evident is het belang voor de detectie van 
extrahepatische ziekte (buiten de lever), waarbij voor FDG-PET een superieure 
sensitiviteit en specificiteit aangetoond wordt in vergelijking met CT-scan. In de 
meerderheid van de beoordeelde studies wordt een duidelijk positief effect van FDG- 
PET op de klinische besluitvorming waargenomen. Om de rol van FDG-PET scan bij 
patiënten met colorectale levermetastasen en de daadwerkelijke impact (bijvoorbeeld 
op de overlevingsparameters) aan te tonen zijn echter gerandomiseerde klinische 
studies nodig. Aanvullend onderzoek naar de kosteneffectiviteit van FDG-PET kan 
het belang van deze techniek verder onderbouwen.
Hoofdstuk 3 beschrijft de gegevens van 203 patiënten en concludeert dat invoering 
van de FDG-PET resulteert in een vermindering van het aantal onnodige 
laparotomiëen bij patiënten met extrahepatische ziekte, door een betere opsporing 
van deze laesies. Toch zijn na chirurgische behandeling zowel de overleving als de 
ziektevrije overleving vergelijkbaar, ongeacht of FDG-PET werd gebruikt. De
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belangrijkste beperking van deze studie is dat alleen patiënten werden geanalyseerd 
die al waren geselecteerd voor de exploratieve laparotomie, hetzij met of zonder 
additionele FDG-PET. Daarom is de precieze impact en relevantie van FDG-PET op 
veranderingen in klinisch beleid tijdens de diagnostische fase is niet goed te 
beoordelen. Verdere nadelen van een retrospectieve analyse zijn het ontbreken van 
randomisatie en de mogelijke invloed van verbeterde prestaties en de interpretatie 
van CT. Dergelijke vragen kunnen alleen worden beantwoord in een 
gerandomiseerde gecontroleerde klinische trial (RCT). De studie toont wel aan dat 
screening van patiënten met FDG-PET die in aanmerking komen voor resectie van 
colorectale levermetastasen toegevoegde waarde heeft.
In hoofdstuk 4 wordt een studie van 131 opeenvolgende patiënten beschreven. 
Hierin wordt bij patiënten met colorectale levermetastasen aangetoond dat de 
frequentie van onverwachte bevindingen bij laparotomie relatief laag is als zowel CT 
als FDG-PET bij de preoperatieve diagnostiek zijn gebruikt. De belangrijkste 
uitdaging voor verbetering de diagnostiek lijkt een betere beoordeling van de lever 
zelf, omdat de lever zelf vaak meer betrokken blijkt dan voor de operatie werd 
verwacht, zowel wat betreft de hoeveelheid tumor als de exacte lokalisatie van 
metastasen. Onverwachte extrahepatische bevindingen middels FDG-PET vragen 
om zorgvuldige evaluatie, omdat deze bevindingen de chirurgische behandeling van 
de patiënt kunnen veranderen. FDG-PET kan occulte ziekte zowel in de buik als in 
de borst eerder aantonen dan CT. Het viel op dat zelfs bij exploratieve laparotomie 
het zeer moeilijk kan zijn om alle door FDG-PET gedetecteerd metastasen te 
identificeren.
Hoofdstuk 5 beschrijft in een serie van 152 patiënten, dat de mate van FDG opname 
in colorectale kanker met uitzaaiingen, uitgedrukt als “Standardized Uptake Value” 
(SUV), de uitkomst van behandeling kan voorspellen, ongeacht de aard van de 
behandeling. Patiënten met afwijkingen met een sterk verhoogde FDG uptake bleken 
een verminderde overleving te hebben. FDG-PET kan daarom een belangrijke 
aanvulling zijn op de traditionele screening door patiënten met een hoog risico te 
identificeren om vervolgens middels agressievere behandelingen de prognose 
proberen te verbeteren. Ook zou kwantitatieve FDG-PET nuttig kunnen zijn voor de 
stratificatie van patiënten in prospectief onderzoek waarbij verschillende 
therapeutische opties worden vergeleken.
In hoofdstuk 6 worden de resultaten van een RCT bij 150 patiënten gepresenteerd. 
Door de invoering van de FDG-PET bij de preoperatieve work-up van patiënten met
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op CT resectabele colorectale levermetastasen werd een aanzienlijke vermindering 
van het aantal onnodige laparotomieën gezien, omdat preoperatief onverwachte 
inoperabele ziekte werd vastgesteld. Geconcludeerd wordt dat FDG-PET moet 
worden toegevoegd in het diagnostisch algoritme voordat laparotomie voor resectie 
van de colorectale levermetastasen wordt uitgevoerd.
Hoofdstuk 7 laat zien dat toevoeging van FDG-PET aan de conventionele work-up bij 
patiënten met potentieel resectabele colorectale levermetastasen resulteerde in 
betere diagnostische prestaties en bij het voorkomen van zinloze laparotomieën. 
Deze betere diagnostiek resulteert niet in extra kosten. Bij een follow-up periode van 
drie jaar, waarin alle medische kosten gemaakt in deze jaren zijn meegenomen, blijkt 
de toevoeging van FDG-PET kostenneutraal en zelfs kan leiden tot een te 
verwachten financieel voordeel. Zo leidt de toevoeging van FDG-PET tot minder 
onnodige laparotomieën zonder dat het extra kosten genereert en dus mogelijk 
resulteert in een beter gebruik van de medische capaciteit geeft.
Hoofdstuk 8 beschrijft de kwaliteit van leven (Health Related Quality of Life - HRQoL) 
bij patiënten met colorectale levermetastasen. Er werd een betere algemene HRQoL 
gevonden voor patiënten na een succesvolle eerste en eventuele aanvullende 
chirurgische behandeling in de eerste drie jaar na de eerste interventie. Als er sprake 
is van recidiverende ziekte zijn patiënten ook na een secundaire curatieve 
chirurgische ingreep beter af dan de patiënten die worden behandeld met 
chemotherapie. Dit vraagt echter om een agressieve chirurgische aanpak. Daarnaast 
lijkt een intensieve follow-up gerechtvaardigd om de gemetastaseerde ziekte in een 
eventueel nog resectabel stadium vast te stellen.
Op dit moment worden er veelbelovende nieuwe PET-tracers ontwikkeld en getest, 
waarmee specifieke weefselkenmerken in beeld kunnen worden gebracht, zoals 
bijvoorbeeld tracers waarmee de mate van DNA synthese en proliferatie van 
tumorcellen kan worden beoordeeld. Daarnaast lijkt het onderscheid maken tussen 
tumor en ontstekingshaarden ook beter mogelijk. De klinische relevantie van deze 
nieuwe tracers moeten nog worden onderzocht.
De huidige keuzes voor de implementatie van FDG-PET in de verschillen 
diagnostische strategieën lijken nogal willekeurig en er bestaan grote verschillen 
tussen medische instellingen. Dit proefschrift benadrukt dat PET / CT als een 
standaard beeldvormende modaliteit bij de chirurgische behandeling van colorectale 
levermetastasen moet worden beschouwd. In de nabije toekomst, zal zowel de
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waarde van FDG-PET in de dagelijkse klinische praktijk, als de toegevoegde waarde 
van geïntegreerde PET / CT-scanners duidelijker moeten worden. De volgende 
uitdaging zal zijn om beeldvormende modaliteiten te ontwikkelen voor een betere 
beoordeling van de betrokkenheid van de lever in colorectale kanker, bijvoorbeeld 
met hybride PET / MR, gebruikmakend van de steeds vorderende innovaties in 
hybride scanner technologie.
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